Updated on 2024/11/28

Information

 

写真a

 
ITOH SHINJI
 
Organization
Kyushu University Hospital Liver Surgery Lecturer
School of Medicine Department of Medicine(Concurrent)
Title
Lecturer
Profile
【略歴】平成12年に九州大学第二外科に入局。2年間の一般外科の研修後、九州大学第二外科医員として臨床・研究に従事。肝細胞癌に関する基礎的および臨床的研究を行い、学位を習得した。九州大学病院および関連病院にて消化器癌の診療に従事した。特に肝胆膵悪性腫瘍に対する外科手術および化学療法について専門的に取り組んでいる。平成26年からは九州大学大学院消化器・総合外科の助教、平成29年より助教講師、令和3年より講師、令和5年より診療准教授として肝胆膵疾患領域の外科治療および薬物療法、肝移植の臨床・研究、および学生、研修医、大学院生の教育を行っている。 【学会活動】日本外科学会、日本消化器外科学会(評議員)、日本肝胆膵外科学会(評議員)、日本肝臓学会(代議員、支部評議員)、日本胆道学会、日本膵臓学会、日本移植学会(代議員)、日本消化器病学会(学会評議員、支部評議員)、日本癌治療学会(代議員)、日本癌学会(評議員)、日本内視鏡外科学会(評議員)、日本臨床外科学会(評議員)、日本消化器癌発生学会(評議員)、日本がん分子標的治療学会(評議員)、日本がん転移学会(評議員)、日本外科感染症学会、日本腹部救急医学会(評議員)、日本酸化ストレス学会(評議員)、日本門脈圧亢進症学会(評議員)、日本肝癌研究会、日本肝がん分子標的治療研究会(世話人)、手術手技研究会、九州外科学会(評議員)
External link

Degree

  • PhD

Research Interests・Research Keywords

  • Research theme:Intratumoral heterogeneity in HBP malignancy

    Keyword:heterogeneity

    Research period: 2020.4

  • Research theme:Immunooncology in HBP malignancy

    Keyword:immunooncology, biomarker

    Research period: 2017.4

  • Research theme:Role of stress response in HBP malignancy

    Keyword:liver cancer, biliary cancer, pancreatic cancer, stress response、nrf2、ferroptosis

    Research period: 2016.4

  • Research theme:Cancer metabolism of HBP surgery

    Keyword:cancer metabolism

    Research period: 2016.4

  • Research theme:Role of microRNA on tumor progression in HBP surgery

    Keyword:micro RNA

    Research period: 2015.4

  • Research theme:Functional Remnant Liver Assessment Predicts Liver-Related Morbidity after Hepatic Resection in Patients with Hepatocellular Carcinoma

    Keyword:Functional remnant liver assessment, morbidity, hepatic resection

    Research period: 2015.4

  • Research theme:Role of Sarcopenia and frailty in patients with liver disease or HBP malignancy

    Keyword:sarcopenia, frailty, physical performance

    Research period: 2015.4

  • Research theme:Efficacy of liver resection

    Keyword:liver resection

    Research period: 2014.4

  • Research theme:Impact of liver transplantation on outcome

    Keyword:liver transplantation

    Research period: 2014.4

Awards

  • 第3回 IJCO Best Reviewer賞

    2023.10   日本癌治療学会  

  • 第2回 IJCO Best Reviewer賞

    2022.11   日本癌治療学会  

  • 福岡県医学会賞奨励賞

    2022.3  

  • 日本消化癌発生学会大原毅賞

    2020.11   日本消化器癌発生学会  

  • 日本肝臓学会冠Award

    2019.11   日本肝臓学会  

  • 日本医師会医学研究奨励賞

    2019.11   日本医師会  

  • 福岡医学会総会一般演題優秀賞

    2019.2   福岡県医師会  

  • 日本肝臓学会研究奨励賞

    2018.6   日本肝臓学会  

  • 日本外科学会研究奨励賞

    2013.4   日本外科学会  

▼display all

Papers

  • Impact of ACSL4 on the prognosis of hepatocellular carcinoma: Association with cancer-associated fibroblasts and the tumour immune microenvironment Reviewed International journal

    Toshida, K; Itoh, S; Iseda, N; Tomiyama, T; Yoshiya, S; Toshima, T; Liu, YC; Iwasaki, T; Okuzaki, D; Taniguchi, K; Oda, Y; Mori, M; Yoshizumi, T

    LIVER INTERNATIONAL   44 ( 4 )   1011 - 1023   2024.4   ISSN:1478-3223 eISSN:1478-3231

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Liver International  

    Background & Aims: Recently, the association between hepatocellular carcinoma (HCC) and ferroptosis has been the focus of much attention. The expression of long chain fatty acyl-CoA ligase 4 (ACSL4), a marker of ferroptosis, in tumour tissue is related to better prognosis in various cancers. In HCC, ACSL4 expression indicates poor prognosis and is related to high malignancy. However, the mechanism remains to be fully understood. Methods: We retrospectively enrolled 358 patients with HCC who had undergone hepatic resection. Immunohistochemistry (IHC) for ACSL4 was performed. Factors associated with ASCL4 expression were investigated by spatial transcriptome analysis, and the relationships were investigated by IHC. The association between ACSL4 and the tumour immune microenvironment was examined in a public dataset and investigated by IHC. Results: Patients were divided into ACSL4-positive (n = 72, 20.1%) and ACSL4-negative (n = 286, 79.9%) groups. ACSL4 positivity was significantly correlated with higher α-fetoprotein (p =.0180) and more histological liver fibrosis (p =.0014). In multivariate analysis, ACSL4 positivity was an independent prognostic factor (p <.0001). Spatial transcriptome analysis showed a positive correlation between ACSL4 and cancer-associated fibroblasts; this relationship was confirmed by IHC. Evaluation of a public dataset showed the correlation between ACSL4 and exhausted tumour immune microenvironment; this relationship was also confirmed by IHC. Conclusion: ACSL4 is a prognostic factor in HCC patients and its expression was associated with cancer-associated fibroblasts and anti-tumour immunity.

    DOI: 10.1111/liv.15839

    Web of Science

    Scopus

    PubMed

  • Clinical Outcomes and Histologic Findings of Patients with Hepatocellular Carcinoma with Durable Partial Response or Durable Stable Disease after Receiving Atezolizumab Plus Bevacizumab Reviewed International coauthorship International journal

    Shen Y.C., Liu T.H., Nicholas A., Soyama A., Yuan C.T., Chen T.C., Eguchi S., Yoshizumi T., Itoh S., Nakamura N., Kosaka H., Kaibori M., Ishii T., Hatano E., Ogawa C., Naganuma A., Kakizaki S., Cheng C.H., Lin P.T., Su Y.Y., Chuang C.H., Lu L.C., Wu C.J., Wang H.W., Rau K.M., Hsu C.H., Lin S.M., Huang Y.H., Hernandez S., Finn R.S., Kudo M., Cheng A.L.

    Journal of Clinical Oncology   JCO2400645   2024   ISSN:0732183X

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Clinical Oncology  

    PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors. PATIENTS AND METHODS The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated. RESULTSIn the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev. Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% v 16.7%, P =.034). PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150. We found no reliable radiologic features to predict PCR of the residual tumors. CONCLUSION Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision.

    DOI: 10.1200/JCO.24.00645

    Scopus

    PubMed

  • Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. Invited Reviewed International journal

    Itoh S, Toshida K, Morita K, Kurihara T, Nagao Y, Tomino T, Toshima T, Harada N, Mori M, Yoshizumi T.

    Int J Clin Oncol.   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation Reviewed International journal

    Itoh, Shinji; Yoshizumi, Tomoharu; Kitamura, Yoshiyuki; Yugawa, Kyohei; Iseda, Norifumi; Shimagaki, Tomonari; Nagao, Yoshihiro; Toshima, Takeo; Harada, Noboru; Kohashi, Kenichi; Baba, Shingo; Ishigami, Kousei; Oda, Yoshinao; Mori, Masaki

    HEPATOLOGY COMMUNICATIONS   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep4.1715

  • Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation Reviewed International journal

    Itoh, Shinji; Yoshizumi, Tomoharu; Yugawa, Kyohei; Imai, Daisuke; Yoshiya, Shohei; Takeishi, Kazuki; Toshima, Takeo; Harada, Noboru; Ikegami, Toru; Soejima, Yuji; Kohashi, Kenichi; Oda, Yoshinao; Mori, Masaki

    HEPATOLOGY   72 ( 6 )   1987 - 1999   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep.31206

  • Robot-assisted laparoscopic hepatectomy for liver metastasis from clitoral malignant melanoma: a case report Reviewed International journal

    Iwasaki, H; Itoh, S; Iseda, N; Tsutsui, Y; Izumi, T; Bekki, Y; Yoshiya, S; Ito, T; Toshima, T; Nakahara, T; Yoshizumi, T

    SURGICAL CASE REPORTS   10 ( 1 )   258   2024.11   ISSN:2198-7793

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s40792-024-02058-7

    Web of Science

    PubMed

  • 特集 肝胆膵外科領域のロボット支援下・腹腔鏡下手術 I. 肝臓 6.再肝切除のコツと注意点

    伊藤 心二, 湯川 恭平, 別城 悠樹, 本村 貴志, 戸島 剛男, 吉住 朋晴

    外科   86 ( 12 )   1288 - 1295   2024.11   ISSN:0016593X eISSN:24329428

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka86_1288

    CiNii Research

  • Clinical utility of <i>BRCA</i> and <i>ATM</i> mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer Reviewed International journal

    Sudo, K; Nakamura, Y; Ueno, M; Furukawa, M; Mizuno, N; Kawamoto, Y; Okano, N; Umemoto, K; Asagi, A; Ozaka, M; Ohtsubo, K; Shimizu, S; Matsuhashi, N; Itoh, S; Matsumoto, T; Satoh, T; Okuyama, H; Goto, M; Hasegawa, H; Yamamoto, Y; Odegaard, JI; Bando, H; Yoshino, T; Ikeda, M; Morizane, C

    BRITISH JOURNAL OF CANCER   131 ( 7 )   1158 - 1168   2024.10   ISSN:0007-0920 eISSN:1532-1827

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:British Journal of Cancer  

    Background: Identification of homologous recombination deficiency (HRD) remains a challenge in advanced pancreatic cancer (APC). We investigated the utility of circulating tumour DNA (ctDNA) profiling in the assessment of BRCA1/2 and ATM mutation status and treatment selection in APC. Methods: We analysed clinical and ctDNA data of 702 patients with APC enroled in GOZILA, a ctDNA profiling study using Guardant360. Results: Inactivating BRCA1/2 and ATM mutations were detected in 4.8% (putative germline, 3.7%) and 4.4% (putative germline, 0.9%) of patients, respectively. Objective response (63.2% vs. 16.2%) and PFS (HR 0.55, 95% CI 0.32–0.93) on platinum-containing chemotherapy were significantly better in patients with putative germline BRCA1/2 (gBRCA) mutation than those without. In contrast, putative gBRCA mutation had no impact on the efficacy of gemcitabine plus nab-paclitaxel. In 2 patients treated with platinum-containing therapy, putative BRCA2 reversion mutations were detected. Three of seven patients with somatic BRCA mutations responded to platinum-containing therapy, while only one of four with putative germline ATM mutations did. One-third of somatic ATM mutations were in genomic loci associated with clonal haematopoiesis. Conclusion: Comprehensive ctDNA profiling provides clinically relevant information regarding HRD status. It can be a practical, convenient option for HRD screening in APC.

    DOI: 10.1038/s41416-024-02834-0

    Web of Science

    Scopus

    PubMed

  • RAS mutant transverse colon cancer with multiple liver metastases achieving long-term disease-free survival with postoperative maintenance therapy with aflibercept plus FOLFIRI and four repeated radical resections: a case report Reviewed International journal

    Tanaka, Y; Nakanishi, R; Sato, S; Otake, A; Ryujin, K; Ikeda, S; Ebata, Y; Harima, T; Natsugoe, K; Yoshiyama, T; Shin, Y; Kawazoe, T; Kudo, K; Zaitsu, Y; Hisamatsu, Y; Ando, K; Nakashima, Y; Itoh, S; Oki, E; Oda, Y; Yoshizumi, T

    SURGICAL CASE REPORTS   10 ( 1 )   231   2024.10   ISSN:2198-7793

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s40792-024-02033-2

    Web of Science

    PubMed

  • Clinical validation of preoperative serum markers for liver fibrosis in living donor liver transplantation recipients Reviewed International journal

    Tomino, T; Itoh, S; Toshima, T; Yoshiya, S; Bekki, Y; Iseda, N; Izumi, T; Tsutsui, Y; Toshida, K; Yoshizumi, T

    SURGERY TODAY   2024.9   ISSN:0941-1291 eISSN:1436-2813

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Purpose: To validate the reliability of fibrosis markers as predictors of graft survival in living donor liver transplantation (LDLT) recipients. Methods: We reviewed data retrospectively, from 163 patients who underwent adult LDLT with preoperative measurements of type IV collagen (CIV), Mac-2 binding protein glycosylation isomer (M2BPGi), and hyaluronic acid (HA). Patients were divided into high and low groups for each biomarker, based on optimal cutoff values, and graft loss within 6 months was evaluated in each group. Results: The high CIV level group showed significantly lower 6-month graft survival rates and significantly higher rates of postoperative sepsis and sepsis from pneumonia. However, the groups with high and low M2BPGi levels and those with high and low HA levels did not show significant differences in 6-month graft survival rates or rates of postoperative sepsis. Multivariate analysis revealed that a CIV level ≥ 590 was a significant predictor of graft loss within 6 months, postoperative sepsis, and sepsis from pneumonia. Conclusion: Unlike other fibrosis markers, preoperative CIV levels can predict graft survival, postoperative sepsis, and sepsis from pneumonia after LDLT.

    DOI: 10.1007/s00595-024-02941-8

    Web of Science

    Scopus

    PubMed

  • Novel protocol for prevention from hepatitis B reactivation following living-donor liver transplantation Reviewed International journal

    Izumi, T; Toshima, T; Itoh, S; Yoshiya, S; Bekki, Y; Iseda, N; Tsutsui, Y; Toshida, K; Nakayama, Y; Ishikawa, T; Yoshizumi, T

    HEPATOLOGY RESEARCH   2024.9   ISSN:1386-6346 eISSN:1872-034X

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aim: Reactivation of hepatitis B virus (HBV) after liver transplantation (LT) remains a problem; thus, development of more effective HBV reactivation prophylaxis is desirable. We evaluated the efficacy of a combination of a long-term nucleotide analog (NA), such as entecavir (ETV) or tenofovir alafenamide (TAF), and short-term hepatitis B immunoglobulin (HBIG) in preventing HBV reactivation and compared it with conventional HBV prophylaxis. Methods: Between February 1999 and August 2023, 135 patients underwent living-donor liver transplantation for liver cirrhosis or acute liver failure caused by HBV infection or received an LT from a hepatitis B core antibody-positive donor. Recipients who had undergone LT were classified as being in the first or second era (namely until September 2017 and from October 2017), respectively, and outcomes of prophylaxis against HBV reactivation were compared between the two eras. Results: In the second era, recipients with HBV-related disease or who had received hepatitis B core antibody-positive liver received combination therapy with short-term HBIG and an NA such as TAF and ETV long-term. The duration of HBIG treatment was markedly shorter than in the first era in both categories of patients and HBIG could be discontinued in all cases. Surprisingly, we observed HBV reactivation in the first era, but not in the second era, in both groups. Conclusions: We have established a protocol for prophylaxis against HBV reactivation using a combination of short-term HBIG and long-term NA. This protocol was found to be sufficient to prevent HBV reactivation after LT.

    DOI: 10.1111/hepr.14110

    Web of Science

    Scopus

    PubMed

  • Recurrence of hepatocellular carcinoma following liver transplantation

    ITOH Shinji, TOSHIMA Takeo, YOSHIZUMI Tomoharu

    Nippon Shokakibyo Gakkai Zasshi   121 ( 9 )   729 - 736   2024.9   ISSN:04466586 eISSN:13497693

     More details

    Authorship:Corresponding author   Language:Japanese   Publisher:The Japanese Society of Gastroenterology  

    DOI: 10.11405/nisshoshi.121.729

    Scopus

    PubMed

    CiNii Research

  • Robot-assisted laparoscopic hepatectomy for hepatocellular carcinoma with Fontan-associated liver disease: a world-first case report Reviewed International journal

    Ishikawa, T; Itoh, S; Toshima, T; Yoshiya, S; Bekki, Y; Iseda, N; Tsutsui, Y; Sakamoto, I; Abe, K; Yoshizumi, T

    SURGICAL CASE REPORTS   10 ( 1 )   210   2024.9   ISSN:2198-7793

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s40792-024-02014-5

    Web of Science

    PubMed

  • Impact of portal-phase signal intensity of dynamic gadoxetic acid-enhanced magnetic resonance imaging in hepatocellular carcinoma Reviewed International journal

    Tomino T, Itoh S*, Okamoto D, Yoshiya S, Nagao Y, Harada N, Fujita N, Ushijima Y, Ishigami K, Yoshizumi T

    J Hepatobiliary Pancreat Sci.   30 ( 9 )   1089 - 1097   2024.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1002/jhbp.1345

  • Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living-donor liver transplantation: Single-center controlled trial Reviewed International journal

    Tsutsui, Y; Itoh, S; Toshima, T; Yoshio, S; Yoshiya, S; Izumi, T; Iseda, N; Toshida, K; Nakayama, Y; Ishikawa, T; Kosai-Fujimoto, Y; Takeishi, K; Yoshizumi, T

    HEPATOLOGY RESEARCH   54 ( 9 )   827 - 837   2024.9   ISSN:1386-6346 eISSN:1872-034X

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aim: Sarcopenia is reportedly associated with a poor prognosis in patients who undergo living-donor liver transplantation (LDLT), most of whom are not able to tolerate muscle strengthening exercise training. Myostatin is one of the myokines and a negative regulator of skeletal muscle growth. The clinical feasibility of an electrical muscle stimulation (EMS) system, which exercises muscle automatically by direct electrical stimulation, has been reported. In this study, we aimed to determine the effect of perioperative application of SIXPAD, which is a type of EMS system, with reference to the serum myostatin and sarcopenia in LDLT patients. Method: Thirty patients scheduled for LDLT were divided into a SIXPAD group (n = 16) and a control group (n = 14). In the SIXPAD group, EMS was applied to the thighs twice daily. The serum myostatin was measured in samples obtained before use of SIXPAD and immediately before LDLT. The psoas muscle index (PMI) at the level of the third lumbar vertebra and the quadriceps muscle area were compared on computed tomography images before use of SIXPAD and 1 month after LDLT. Results: The preoperative serum myostatin was found to be higher in LDLT patients than in healthy volunteers and EMS significantly reduced the serum myostatin. Electrical muscle stimulation prevented a postoperative reduction not only in the area of the quadriceps muscles but also in the PMI despite direct stimulation of the thigh muscles. Conclusion: Stimulation of muscles by EMS decreases the serum myostatin and helps to maintain skeletal muscle in patients who have undergone LDLT.

    DOI: 10.1111/hepr.14027

    Web of Science

    Scopus

    PubMed

  • Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study Reviewed International journal

    Iseda, N; Itoh, S; Toshima, T; Yoshiya, S; Bekki, Y; Tsutsui, Y; Toshida, K; Inokuchi, S; Utsunomiya, T; Tomino, T; Sugimachi, K; Morita, K; Ninomiya, M; Harada, N; Minagawa, R; Yoshizumi, T

    SURGERY TODAY   2024.8   ISSN:0941-1291 eISSN:1436-2813

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Background and purpose: In recent years, new systemic therapies have been developed for hepatocellular carcinoma (HCC). The aim of this study was to evaluate the prognosis of patients with unresectable HCC treated with R0 hepatectomy after systemic therapy. Methods: Data from 27 patients who underwent hepatectomy for HCC after systemic therapy at six facilities were analyzed retrospectively. Cancer-specific survival (CSS) and recurrence-free survival (RFS) after hepatectomy were investigated using Kaplan–Meier curves. We examined the prognostic value of the oncological criteria of resectability for HCC reported by the Japanese Expert Consensus 2023. Results: R0 resection was performed in 24 of the 27 patients. Using the Response Evaluation Criteria in Solid Tumors, 0 patient had a complete response, 16 had a partial response, 6 had stable disease, and 2 had progressive disease. Median CSS was not evaluated, but the median RFS was 17.8 months. Patients with resectable and borderline resectable (BR) 1 cancers had a better prognosis than those with BR2 cancers. The group whose oncological criteria were improved by systemic therapy had a lower recurrence rate than the group whose oncological criteria were maintained, but no difference was observed in CSS. Conclusions: The findings of this study suggest that hepatectomy after systemic therapy may improve the prognosis of HCC patients.

    DOI: 10.1007/s00595-024-02930-x

    Web of Science

    Scopus

    PubMed

  • The Association of Transferrin Receptor with Prognosis and Biologic Role in Intrahepatic Cholangiocarcinoma Reviewed International journal

    Toshida, K; Itoh, S; Iseda, N; Izumi, T; Bekki, Y; Yoshiya, S; Toshima, T; Iwasaki, T; Oda, Y; Yoshizumi, T

    ANNALS OF SURGICAL ONCOLOGY   31 ( 13 )   8627 - 8637   2024.8   ISSN:1068-9265 eISSN:1534-4681

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Annals of Surgical Oncology  

    Background: Ferroptosis is a cell death caused by iron-dependent accumulation of lipid peroxidation. Transferrin receptor (TFR) is a ferroptosis-related protein responsible for iron transport. The detailed biologic role of TFR in intrahepatic cholangiocarcinoma (ICC) is not fully elucidated. Methods: The study enrolled 92 ICC patients who had undergone hepatic resection. Immunohistochemistry (IHC) assays were performed for TFR protein expression. The regulation of malignant activity and the effect on sensitivity to the ferroptosis-inducer artesunate by TFR were investigated in vitro. Results: Using IHC staining, 23 patients were categorized as TFR-positive. The TFR-positive group had a significantly larger tumor size and more microscopic vascular invasion. In the multivariate analysis, TFR positivity was an independent poor prognostic factor. In vitro TFR-knockdown (KD) significantly decreased the intracellular iron levels and the cell proliferation, migration, and invasion rates. Artesunate treatment significantly decreased cell viability, whereas cisplatin promoted ferroptosis. When iron transport into cells was inhibited by TFR-KD, ferroptosis was significantly suppressed. Expression of PD-L1 was induced by cisplatin, with a further increase observed when artesunate and cisplatin were used in combination. Conclusions: Transferrin receptor is a poor prognostic factor for ICC and contributes to sensitivity to ferroptosis.

    DOI: 10.1245/s10434-024-16065-3

    Web of Science

    Scopus

    PubMed

  • Proposal of "borderline resectable" colorectal liver metastases based on analysis of risk factors for early surgical failure Reviewed International journal

    Ninomiya, M; Itoh, S; Takeishi, K; Toshima, T; Yoshiya, S; Morita, K; Minagawa, R; Iguchi, T; Oki, E; Yoshizumi, T

    SURGERY TODAY   2024.8   ISSN:0941-1291 eISSN:1436-2813

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Purpose: We aimed to define borderline resectable colorectal liver metastases (CRLM) based on the analysis of risk factors for early surgical failure and investigate the efficacy of neoadjuvant chemotherapy in these patients. Methods: This was a retrospective analysis of a multi-institutional cohort of patients diagnosed with technically resectable CRLM. Early surgical failure within 6 months of liver surgery was defined as ESF6. We classified CRLM into three grades (A, B, and C) according to the definition of the Japanese Society for Cancer of the Colon and Rectum. Results: Among the 249 patients with technically resectable CRLM, 46 (18.5%) developed ESF6. The survival rate of these patients was significantly lower than that of the patients without ESF6. In the multivariate analysis of synchronous CRLM patients, no neoadjuvant chemotherapy, Grade B/C, and Charlson comorbidity index ≥ 3 were independent predictors of ESF6. Among patients with synchronous and Grade B/C CRLM, ESF6 rates, surgical failure-free survival, and overall survival in the neoadjuvant chemotherapy group were significantly better relative to the upfront surgery group. Conclusions: Patients with synchronous and Grade B/C CRLM are at a high risk of early surgical failure, have a poor long-term prognosis, and can be defined as borderline resectable and good candidates for neoadjuvant chemotherapy.

    DOI: 10.1007/s00595-024-02920-z

    Web of Science

    Scopus

    PubMed

  • The impact of perioperative synbiotics treatment in living-donor liver transplantation after induction of early enteral nutrition Reviewed International coauthorship International journal

    Yoshiya, S; Itoh, S; Toshima, T; Bekki, Y; Izumi, T; Iseda, N; Tsutsui, Y; Toshida, K; Nakayama, Y; Ishikawa, T; Yoshizumi, T

    SURGERY TODAY   2024.8   ISSN:0941-1291 eISSN:1436-2813

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Purpose: Infectious complications, particularly post-transplant sepsis, have a critical impact on postoperative outcomes. This study examined the effects of perioperative synbiotic treatment on postoperative outcomes in patients receiving early enteral nutrition. Methods: We reviewed 210 living-donor liver transplantation procedures and retrospectively analyzed the postoperative outcomes with and without perioperative synbiotic treatment (live lactic acid bacteria, bifidobacteria, and oligosaccharides) 5 days before and after living-donor liver transplantation. Results: The synbiotic group (n = 34) had significantly fewer male donors (38.2% vs. 61.9%, p = 0.011) and a higher proportion of ABO-incompatible grafts (52.9% vs. 25.6%, p = 0.021) than the non-synbiotic group (n = 176). The incidence of sepsis was significantly lower in the synbiotic group than in the non-synbiotic group (0% vs. 7.4%, p = 0.029), with a lower incidence rate of sepsis due to bacteremia with intestinal bacteria (0% vs. 4.6%, p = 0.089). There were no significant differences in the proportions of acute rejection, small-for-size graft syndrome, or postoperative liver function between the two groups. Furthermore, there was no significant difference in the graft survival rates after LDLT between two groups. (p = 0.24). Conclusion: Perioperative synbiotic treatment prevents post-transplant sepsis, even with early enteral nutrition.

    DOI: 10.1007/s00595-024-02918-7

    Web of Science

    Scopus

    PubMed

  • Value of gadoxetic acid-enhanced MR imaging for preoperative prediction of future liver regeneration after hemihepatectomy Reviewed International journal

    Fujita, N; Ushijima, Y; Itoyama, M; Okamoto, D; Ishimatsu, K; Tabata, K; Itoh, S; Ishigami, K

    JAPANESE JOURNAL OF RADIOLOGY   2024.8   ISSN:1867-1071 eISSN:1867-108X

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Journal of Radiology  

    Purpose: Liver resection is currently considered the most effective treatment for patients with liver cancer. To the best of our knowledge, no study has investigated the association between gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings and liver regeneration in patients who underwent hemihepatectomy. We aimed to clarify the relationship between the signal intensity (SI) of the liver parenchyma on gadoxetic acid-enhanced MRI and the degree of liver regeneration in patients who underwent hemihepatectomy. Materials and methods: Forty-one patients who underwent gadoxetic acid-enhanced MRI before hemihepatectomy were enrolled. We calculated the liver-to-erector spinae muscle SI ratio (LMR) in the hepatobiliary phase and the precontrast images. ΔLMR was calculated using the following equation: ΔLMR = (LMR in the hepatobiliary phase−LMR in the precontrast image)/LMR in the precontrast image. The preoperative and postoperative remnant liver volumes (LVs) were calculated using CT volumetry. We calculated the resection rate (RR) and liver regeneration index (LRI) using the following formulas: RR = Resected LV/Total LV × 100 and LRI = (postoperative remnant LV−preoperative remnant LV)/preoperative remnant LV × 100. The relationships among LRI, imaging, and clinicopathological factors were analyzed. Results: Univariate analysis showed RR and ΔLMR showed a positive correlation with LRI (ρ = 0.4133, p = 0.0072 and ρ = 0.7773, p < 0.001, respectively). Spleen volume showed a negative correlation with LRI (ρ = −0.3138, p = 0.0486). Stepwise multiple regression analysis showed ΔLMR and RR were independently correlated with LRI (β coefficient = 44.8771, p = 0.0198 and β coefficient = 1.9653, p < 0.001, respectively). Conclusion: ΔLMR may serve as a preoperative predictor of liver regeneration in patients undergoing hemihepatectomy.

    DOI: 10.1007/s11604-024-01629-w

    Web of Science

    Scopus

    PubMed

  • Association of serum lactate dehydrogenase with prognosis and tumor metabolism in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy Reviewed International journal

    Toshida, K; Itoh, S; Toshima, T; Yoshiya, S; Bekki, Y; Izumi, T; Iseda, N; Nakayama, Y; Ishikawa, T; Yoshizumi, T

    SURGERY TODAY   2024.8   ISSN:0941-1291 eISSN:1436-2813

     More details

    Authorship:Corresponding author   Language:English   Publisher:Surgery Today  

    Purpose: Treatment outcomes are predicted by analyzing peripheral blood markers such as serum lactate dehydrogenase (LDH). We conducted this study to investigate whether serum LDH levels can predict the prognosis of patients treated with atezolizumab plus bevacizumab (ATZ/BEV) therapy for hepatocellular carcinoma (HCC) and whether LDH levels correlate with metabolic changes. Methods: We enrolled 66 HCC patients treated with ATZ/BEV. Based on the change in serum LDH levels before and after treatment, the patients were divided into two groups, and the prognosis of each group was examined. Moreover, the association of LDH levels with tumor metabolism was analyzed by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). Results: There were 32 patients categorized as the LDH-decrease group. Kaplan–Meier survival analysis indicated worse progression-free survival (PFS) in the LDH-increase group than in the LDH-decrease group (p = 0.0029). Multivariate analysis showed that an increase in the LDH level was an independent risk factor for worse PFS (p = 0.0045). The baseline LDH level correlated significantly with a high maximum standardized uptake value of 18F-FDG, according to the PET/CT findings. Transcriptomic analyses of specimens resected after ATZ/BEV therapy showed downregulated mitochondria-related pathways. Conclusion: Serum LDH levels are a potential prognostic marker and an indicator of tumor metabolism.

    DOI: 10.1007/s00595-024-02914-x

    Web of Science

    Scopus

    PubMed

  • Prediction of portal venous pressure in living donor liver transplantation: A retrospective study Invited Reviewed International journal

    Kurihara, T; Itoh, S; Toshima, T; Toshida, K; Tomiyama, T; Kosai, Y; Tomino, T; Yoshiya, S; Nagao, Y; Morita, K; Ninomiya, M; Harada, N; Yoshizumi, T

    LIVER TRANSPLANTATION   2024.7   ISSN:1527-6465 eISSN:1527-6473

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Liver Transplantation  

    Liver transplantation is the definitive treatment for advanced liver cirrhosis with portal hypertension. In Japan, the scarcity of deceased donors leads to reliance on living donors, often resulting in smaller grafts. Managing portal venous pressure (PVP) is critical to prevent fatal posttransplant complications. This study explored the possibility of predicting intraoperative PVP. We analyzed 475 living donor liver transplant cases from 2006 to 2023, excluding those with acute liver failure or prior splenectomy or splenic artery embolization. Patients were divided into a training group (n=425) and a test group (n=50). We evaluated the correlation between preoperative factors and PVP at laparotomy, to predict PVP at laparotomy and closure. The predictive model was validated with the test group data. PVP at laparotomy could be predicted using correlated preoperative factors: prothrombin time (p<0.001), predicted splenic volume (p<0.001), and presence of a portosystemic shunt (p=0.002), as follows: Predicted PVP at laparotomy (mmHg)=25.818 - 0.077×[prothrombin time (%)]+0.004×[predicted splenic volume (ml)] - 2.067×[1: with a portosystemic shunt] (p<0.001; R=0.346). Additionally, PVP at closure could be predicted using correlated operative factors, including measured PVP at laparotomy, as follows: predicted PVP at closure (mmHg)=14.268+0.149×[measured PVP at laparotomy (mmHg)] - 0.040×[GV/SLV (%)] - 0.862×[1: splenectomy (if yes)] - 3.511×[1: splenic artery ligation without splenectomy (if yes)] (p<0.001; R=0.339).This study demonstrated the feasibility of predicting intraoperative PVP using preoperative factors in liver transplant patients with decompensated cirrhosis. This predictive approach could refine surgical planning, potentially improving patient outcomes.

    DOI: 10.1097/LVT.0000000000000433

    Web of Science

    Scopus

    PubMed

  • What Are Risk Factors for Graft Loss in Patients Who Underwent Simultaneous Splenectomy During Living-donor Liver Transplantation? Reviewed International journal

    Toshima, T; Harada, N; Itoh, S; Tomiyama, T; Toshida, K; Morita, K; Nagao, Y; Kurihara, T; Tomino, T; Kosai-Fujimoto, Y; Mimori, K; Yoshizumi, T

    TRANSPLANTATION   108 ( 7 )   1593 - 1604   2024.7   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Transplantation  

    Background. The consensus that portal venous pressure modulation, including splenectomy (Spx), prevents portal hypertension-related complications after living-donor liver transplantation (LDLT) has been established. However, little evidence about the risk factors for graft loss after simultaneous Spx during LDLT is available. This study aimed to identify the independent predictors of graft loss after simultaneous Spx during LDLT. Methods. Data of 655 recipients who underwent LDLT between 1997 and 2021 were collected and separated into the simultaneous Spx group (n=461) and no-Spx group (n=194). Results. The simultaneous Spx group had significantly lower serum total bilirubin levels, drained ascites volumes, and prothrombin time-international normalized ratios on postoperative day 14 than the no-Spx group (P<0.001 for each). Incidences of small-for-size graft syndrome (P<0.001), acute cellular rejection (P=0.002), and sepsis (P=0.007) were significantly lower in the Spx group. Graft survival of the Spx group was significantly better than that of the no-Spx group (P<0.001; hazard ratio [HR], 1.788; 95% confidence interval, 1.214-2.431). A multivariate analysis revealed that 3 variables, platelet count ≤4.0×104/mm3 (P=0.029; HR, 2.873), donor age ≥60 y old (P=0.013; HR, 6.693), and portal venous pressure at closure ≥20 mm Hg (P=0.010; HR, 3.891), were independent predictors of graft loss within 6 mo after simultaneous Spx during LDLT. Conclusions. Spx is a safe inflow modulation procedure with a positive impact on both postoperative complications and prognosis for most patients. However, patients with the 3 aforementioned independent factors could experience graft loss after LDLT.

    DOI: 10.1097/TP.0000000000004952

    Web of Science

    Scopus

    PubMed

  • Is preoperative weight reduction of living-donor liver transplant recipients and donors harmful to postoperative outcomes? Reviewed International journal

    Yoshiya, S; Itoh, S; Toshima, T; Izumi, T; Iseda, N; Tsutsui, Y; Toshida, K; Nakayama, Y; Ishikawa, T; Tanaka, Y; Ninomiya, M; Yoshizumi, T

    JOURNAL OF GASTROINTESTINAL SURGERY   28 ( 7 )   1033 - 1038   2024.7   ISSN:1091-255X eISSN:1873-4626

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Gastrointestinal Surgery  

    Purpose: Although the incidence of recipients and donors with overweight and obesity is increasing worldwide, few reports have focused on outcomes of preoperative weight reduction (WR) in living-donor liver transplantation (LDLT). Therefore, we examined the outcomes and the impact of WR on the postoperative course. Methods: We analyzed 217 consecutive LDLT procedures performed from 2017 to 2022. We divided the recipients and donors into a WR group and non-WR group. Results: Twenty-two recipients (10.1%) achieved WR (preoperative recipient WR [RWR] group), reducing their weight by 6.8% ± 6.0% within 2.2 ± 1.4 months with a significant decrease in body mass index (BMI) (P < .0001). The RWR group showed no significant differences in short-term postoperative outcomes (operative factors, postoperative liver function tests, amount of ascites, and morbidity) or in the graft survival rate as a long-term outcome (P = .24) compared with the non-RWR group. Forty-one donors (18.9%) achieved WR (preoperative donor WR [DWR] group), reducing their weight by 9.7% ± 6.3% within 3.2 ± 5.8 months with a significant decrease in BMI (P < .0001). Compared with the non-DWR group, the DWR group showed no significant differences in short-term postoperative outcomes between themselves and recipients or in the graft survival rate (P = .49). Furthermore, WR resulted in an increase to 32 donor-eligible and 6 recipient-eligible patients. Conclusion: WR in LDLT recipients and donors had no harmful effect on postoperative outcomes and should lead to increase recipients’ chance of undergoing LDLT and to expand the donor pool.

    DOI: 10.1016/j.gassur.2024.04.010

    Web of Science

    Scopus

    PubMed

  • Hand-assisted laparoscopic splenectomy and gastropancreatic fold division: a less-invasive simplified technique of Hassab's procedure for refractory esophagogastric varices Reviewed International journal

    Iwasaki, H; Ninomiya, M; Itoh, S; Takeishi, K; Higashi, H; Iseda, N; Izumi, T; Yoshiya, S; Toshima, T; Yoshizumi, T

    SURGERY TODAY   54 ( 7 )   807 - 811   2024.7   ISSN:0941-1291 eISSN:1436-2813

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Some patients with refractory esophagogastric varices require surgery, such as gastric devascularization and splenectomy (Hassab’s procedure). However, these patients are at risk of perioperative morbidities when undergoing devascularization to develop collateral vessels. We performed a more simplified procedure, splenectomy, and en bloc gastropancreatic fold division (GPFD) with hand-assisted laparoscopic surgery. Four patients with refractory esophagogastric varices and portal hypertension underwent splenectomy and GPFD. We reviewed patients’ perioperative laboratory and morphological data, operative variables, and postoperative outcomes. Esophagogastric varices improved in 3 (75%) of the 4 patients. In one patient, esophageal varices (F1RC0) were observed 3 years after surgery, but they required no treatment and only received follow-up. Treatment with splenectomy and GPFD is not only less invasive than Hassab’s procedure but also provides effective outcomes for refractory esophagogastric varices.

    DOI: 10.1007/s00595-023-02780-z

    Web of Science

    Scopus

    PubMed

  • Feasibility of venous cuff using an open round ligament or inferior mesenteric vein around the hepatic vein for a left lobe graft in living-donor liver transplantation Reviewed International journal

    Toshima, T; Itoh, S; Morita, K; Nagao, Y; Kurihara, T; Tomino, T; Kosai-Fujimoto, Y; Tomiyama, T; Toshida, K; Harada, N; Yoshizumi, T

    SURGERY TODAY   54 ( 7 )   812 - 816   2024.7   ISSN:0941-1291 eISSN:1436-2813

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Living-donor liver transplantation (LDLT) is an established treatment for patients with end-stage liver disease or acute liver failure, and outflow reconstruction is considered one of the most vital techniques in LDLT. To date, many strategies have been reported to prevent outflow obstruction, which can be refractory to liver dysfunction and can cause life-threatening graft loss or mortality. In addition, in this era of laparoscopic hepatectomy in donor surgery, especially LDLT using a left liver graft, it has been predicted that cutting the hepatic vein with automatic linear staplers will lead to more outflow-related problems than with conventional open hepatectomy because of the short neck of the anastomosis orifice. We herein review 10 cases of venoplasty performed with a novel venous cuff system using a donor’s round ligament around the hepatic vein in LDLT with a left lobe graft, which makes anastomosis of the hepatic vein sterically easy for postoperative venous patency.

    DOI: 10.1007/s00595-023-02791-w

    Web of Science

    Scopus

    PubMed

  • Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data Reviewed International journal

    Bekki, Y; Itoh, S; Toshima, T; Shimokawa, M; Yoshizumi, T

    HEPATOLOGY RESEARCH   54 ( 7 )   695 - 705   2024.7   ISSN:1386-6346 eISSN:1872-034X

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aim: The Japanese indication criteria for liver transplantation (LT) for hepatocellular carcinoma (HCC) have been updated based on living donor LT data to include either the Milan criteria (MC) or the 5-5-500 rule, which requires a nodule size of ≤5 cm, ≤5 nodules, and an alpha-fetoprotein (AFP) level ≤500 ng/mL. We aimed to validate the 5-5-500 rule and the MC for deceased donor LT (DDLT). Methods: Using national registry data from the United States from 2010 to 2014, we separated DDLT patients into four groups based on the MC and the 5-5-500 rule. The AFP values were stratified into categories: ≤100, 101–300, 301–500, and >500 ng/mL. Results: The 5-year survival rate was significantly lower for patients in the groups within MC/beyond 5-5-500 (56.3%) or beyond MC/5-5-500 (60.7%) than for patients in the groups within MC/5-5-500 (76.2%) and beyond MC/within 5-5-500 (72.3%) (p < 0.01). Hepatocellular carcinoma recurrence at 5 years was highest for the within MC/beyond 5-5-500 (25.4%) group, followed by the beyond MC/within 5-5-500 (13.1%), beyond MC/5-5-500 (9.6%), and within MC/5-5-500 (7.4%) groups. The stratified 5-year survival rates after DDLT were 76.5%, 72.4%, 58.4%, and 55.6% in the AFP ≤100, 101–300, 301–500, and >500 categories, respectively (p < 0.01). Conclusion: The 5-5-500 rule guides the appropriate selection of patients with HCC for DDLT. Patients with AFP levels from 300 to 500 ng/mL had inferior outcomes even when they met the 5-5-500 rule, so further investigation is needed to guide their treatment.

    DOI: 10.1111/hepr.14017

    Web of Science

    Scopus

    PubMed

  • What is the crux of successful living-donor liver transplantation for recipients aged 70 and beyond? Reviewed

    Toshima, T; Itoh, S; Nagao, Y; Yoshiya, S; Bekki, Y; Izumi, T; Iseda, N; Tsutsui, Y; Toshida, K; Yoshizumi, T

    ANNALS OF GASTROENTEROLOGICAL SURGERY   8 ( 4 )   668 - 680   2024.7   ISSN:2475-0328

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Annals of Gastroenterological Surgery  

    Aim: There is limited evidence regarding the feasibility of living-donor liver transplantation (LDLT) for patients aged over 70. The aims of this study were to assess postoperative outcomes in elderly recipients and to ascertain the potential feasibility and acceptability of LDLT. Methods: Data were collected from 762 recipients, including 26 in the elderly group (aged ≥70) and 736 in the younger group (aged <70), and reviewed even by propensity score matching (PSM). Results: No significant differences were observed in the frequency of postoperative complications between the two groups. Additionally, both groups exhibited a comparable 30-day mortality rate after LDLT (3.9% in both) and similar hospital stays (36 days vs. 40 days). The 1-, 3-, and 5-year graft survival rates in the elderly group were 92.0%, which was comparable to those in the younger group (p = 0.517), as confirmed by PSM. Notably, all donors for elderly patients were the children of the recipients, with an average age of 41.6 years, and grafts from donors aged ≥50 years were not utilized, signifying the use of high-quality grafts. Our inclusion criterion for elderly recipients was strictly defined as an ECOG-PS score of 0–2, which played a pivotal role in achieving favorable postoperative outcomes. Conclusion: LDLT can be performed safely for elderly patients aged 70 years or older, provided they have a preserved PS and receive high-quality grafts from younger donors, inevitably all children of elderly recipients. This approach yields acceptable long-term outcomes. Consequently, age alone should not serve as an absolute contraindication for LDLT.

    DOI: 10.1002/ags3.12769

    Web of Science

    Scopus

    PubMed

  • Venous reconstruction using a round ligament-covered prosthetic vascular graft in right-lobe living-donor liver transplantation: a technical report Reviewed International journal

    Tomino, T; Itoh, S; Toshima, T; Yoshiya, S; Nagao, Y; Harada, N; Yoshizumi, T

    SURGERY TODAY   54 ( 7 )   795 - 800   2024.7   ISSN:0941-1291 eISSN:1436-2813

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Purpose: To evaluate the short term-outcomes of venous reconstruction using a round ligament-covered prosthetic vascular graft and assess its effectiveness in the prevention of prosthetic vascular graft migration in right‑lobe living donor liver transplantation (LDLT). Methods and results: Thirty patients underwent reconstruction of the middle hepatic vein (MHV) tributaries during right lobe LDLT between January, 2021 and October, 2022. These patients were divided into the autologous vascular graft group (A group, n = 24) and the round ligament-covered prosthetic vascular graft group (RP group, n = 6). The computed tomography (CT) density ratio of the drainage area in the posterior segment of patent grafts was significantly higher in the RP group than in the A group (0.91 vs. 1.06, p = 0.0025). However, the patency rates of reconstructed MHV tributaries in the A and RP groups were 61% and 67%, respectively, with no significant difference between the groups (p = 0.72). Prosthetic vascular graft migration did not occur in the RP group. Conclusion: Venous reconstruction using round ligament-covered prosthetic vascular grafts is a feasible and simple method to prevent prosthetic vascular graft migration in right-lobe LDLT.

    DOI: 10.1007/s00595-024-02793-2

    Web of Science

    Scopus

    PubMed

  • Outcome of living donor liver transplantation for patients older than 70 years, with respect to preserved performance status and graft quality Reviewed International journal

    Toshima, T; Harada, N; Itoh, S; Nakayama, Y; Toshida, K; Tomiyama, T; Kosai-Fujimoto, Y; Tomino, T; Yoshiya, S; Nagao, Y; Kayashima, H; Yoshizumi, T

    LIVER TRANSPLANTATION   30 ( 5 )   559 - 562   2024.5   ISSN:1527-6465 eISSN:1527-6473

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Liver Transplantation  

    DOI: 10.1097/LVT.0000000000000308

    Web of Science

    Scopus

    PubMed

  • 特集 肝細胞癌の集学的治療 2.肝細胞癌治療の実際(6)肝移植

    吉住 朋晴, 戸島 剛男, 伊藤 心二

    臨床消化器内科   39 ( 5 )   581 - 588   2024.4   ISSN:0911601X eISSN:24332488

     More details

    Publisher:日本メディカルセンター  

    DOI: 10.19020/cg.0000003026

    CiNii Research

  • 特集 必携 消化器・一般外科医のための外科解剖アトラス Ⅱ 肝胆膵 3 左肝切除に必要な局所解剖

    戸島 剛男, 伊藤 心二, 吉住 朋晴

    手術   78 ( 4 )   475 - 485   2024.3   ISSN:00374423

     More details

    Publisher:金原出版  

    DOI: 10.18888/op.0000003803

    CiNii Research

  • Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma Reviewed International journal

    Toshida, K; Itoh, S; Yoshiya, S; Nagao, Y; Tomino, T; Izumi, T; Iseda, N; Toshima, T; Ninomiya, M; Yoshizumi, T

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   39 ( 3 )   576 - 586   2024.3   ISSN:0815-9319 eISSN:1440-1746

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Gastroenterology and Hepatology (Australia)  

    Aim: Pretreatment peripheral blood markers have value in predicting the treatment outcome of various cancers. In particular, the eosinophil count has recently gained attention. However, no study has reported the influence of the pretreatment eosinophil count on the outcomes of atezolizumab plus bevacizumab (ATZ/BEV), which is the recommended first-line systemic therapy for unresectable hepatocellular carcinoma (u-HCC). Methods: We enrolled 114 patients with u-HCC treated with ATZ/BEV (n = 48) or lenvatinib (n = 66). The patients receiving ATZ/BEV or lenvatinib were divided into two groups by calculating the cutoff value of the pretreatment eosinophil count. The groups were compared regarding the clinicopathological characteristics, outcomes, and incidence of adverse events (AEs). Results: Twenty-three of 48 patients (47.9%) who received ATZ/BEV therapy were categorized as the ATZ/BEV-eosinophil-high group, which had better responses than the ATZ/BEV-eosinophil-low group (P = 0.0090). Kaplan–Meier curves revealed a trend toward significantly better progression-free survival (PFS) in the ATZ/BEV-eosinophil-high group than the ATZ/BEV-eosinophil-low group (the median PFS: 4.7 months in the ATZ/BEV-eosinophil-low group vs 12.6 months in the ATZ/BEV-eosinophil-high group; P = 0.0064). Multivariate analysis showed that a low eosinophil count was an independent risk factor for worse PFS after ATZ/BEV therapy (P = 0.0424, hazard ratio: 2.24, 95% confidence interval: 1.02–4.89). AEs (≥ grade 3) were significantly more likely to occur in the ATZ/BEV-eosinophil-high group (P = 0.0285). The outcomes did not significantly differ between the LEN-eosinophil-high group and the LEN-eosinophil-low group. Conclusion: A high pretreatment eosinophil count predicted a better response to ATZ/BEV therapy for u-HCC and was associated with the incidence of AEs (≥ grade 3).

    DOI: 10.1111/jgh.16441

    Web of Science

    Scopus

    PubMed

  • 総特集 外科医の働き方改革を考える ◆テーマ2:働き方改革実現に向けた具体的な取り組み 1.チーム制─九州大学病院肝臓・脾臓・門脈・肝臓移植外科での取り組み

    吉屋 匠平, 伊藤 心二, 戸島 剛男, 吉住 朋晴

    手術   78 ( 1 )   27 - 31   2024.1   ISSN:00374423

     More details

    Publisher:金原出版  

    DOI: 10.18888/op.0000003667

    CiNii Research

  • A successful case of deceased-donor liver transplantation from a donor with Marfan syndrome: a case report Reviewed International journal

    Ishikawa, T; Itoh, S; Toshima, T; Nakayama, Y; Toshida, K; Tsutsui, Y; Iseda, N; Izumi, T; Yoshiya, S; Ninomiya, M; Yoshizumi, T

    SURGICAL CASE REPORTS   10 ( 1 )   14   2024.1   ISSN:2198-7793

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s40792-024-01807-y

    Web of Science

    PubMed

  • Treatment strategy for hepatocellular carcinoma recurrence in the transplant era: Focusing on the Japan criteria Reviewed International journal

    Yoshiya, S; Harada, N; Toshima, T; Toshida, K; Kosai, Y; Tomino, T; Nagao, Y; Kayashima, H; Itoh, S; Yoshizumi, T

    SURGERY TODAY   54 ( 1 )   64 - 72   2024.1   ISSN:0941-1291 eISSN:1436-2813

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Surgery Today  

    Purpose: To clarify the Japan criteria (JC), as proposed in 2019, in order to identify the most appropriate treatment methods for hepatocellular carcinoma (HCC) recurrence and assess the feasibility of pre-living donor liver transplantation (LDLT) downstaging within these criteria. Methods: The subjects of this study were 169 LDLT patients with HCC recurrence. We performed univariate and multivariate analyses of the factors contributing to HCC recurrence after LDLT and clarified the post-transplant outcomes of pre-LDLT downstaging. Results: Univariate and multivariate analysis identified beyond the JC (p = 0.0018) and a neutrophil-to-lymphocyte ratio > 2.01 (p = 0.029) as independent risk factors. Patients who met the JC had significantly higher recurrence-free and overall survival rates after LDLT (p < 0.0001) than those who did not (p = 0.0002). The post-transplant outcomes of patients within the JC after downstaging were significantly better than those of patients beyond the JC (p = 0.034) and equivalent to those within the JC without downstaging. Conclusion: Even for HCC recurrence, the JC could play an important role in deciding on the best treatment strategy, and downstaging within the JC had good post-transplant outcomes.

    DOI: 10.1007/s00595-023-02710-z

    Web of Science

    Scopus

    PubMed

  • Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma Reviewed International journal

    Toshida, K; Itoh, S; Iseda, N; Izumi, T; Yoshiya, S; Toshima, T; Ninomiya, M; Iwasaki, T; Oda, Y; Yoshizumi, T

    CANCER SCIENCE   115 ( 1 )   170 - 183   2024.1   ISSN:1347-9032 eISSN:1349-7006

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cancer Science  

    TP53-induced glycolysis and apoptosis regulator (TIGAR) is an important gene that encodes a regulatory enzyme of glycolysis and reactive oxygen species (ROS) detoxification and is associated with worse prognosis in various cancers. Ferroptosis is a recently identified type of programmed cell death that is triggered by iron-dependent lipid peroxidation. There are no reports on the prognostic impact of TIGAR on intrahepatic cholangiocarcinoma (ICC), and its role in ferroptosis is unclear. Ninety ICC patients who had undergone hepatic resection were enrolled. Immunohistochemical staining for TIGAR was performed. The regulation of malignant activity by TIGAR and the association between ferroptosis and TIGAR were investigated in vitro. Twenty-two (24.4%) patients were categorized into TIGAR-high and -low groups by immunohistochemical staining. There were no noticeable differences in background factors between the two groups, but TIGAR positivity was an independent prognostic factor in disease-free survival (hazard ratio [HR], 2.00; 95% confidence interval [CI], 1.04–3.85, p = 0.0378) and overall survival (HR, 2.10; 95% CI, 1.03–4.30, p = 0.00422) in a multivariate analysis. In vitro, TIGAR knockdown (KD) decreased cell motility (cell proliferation/migration/invasion/colony-forming capabilities) and elevated ROS and lipid peroxidation. This indicated that TIGAR KD induced ferroptosis. TIGAR KD-induced ferroptosis was suppressed using liproxstatin. TIGAR KD decreased the expression of glutathione peroxidase 4, known as factor-suppressing ferroptosis. The combination of TIGAR KD with cisplatin significantly induced more ferroptosis. In conclusion, TIGAR is associated with poor outcomes in ICC patients and resistance to ferroptosis.

    DOI: 10.1111/cas.15981

    Web of Science

    Scopus

    PubMed

  • Impact of albumin-lymphocyte-platelet-C-reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: Associated with nuclear factor erythroid 2-related factor 2 Reviewed International journal

    Iseda, N; Itoh, S; Toshida, K; Nakayama, Y; Ishikawa, T; Tsutsui, Y; Izumi, T; Bekki, Y; Yoshiya, S; Toshima, T; Yoshizumi, T

    HEPATOLOGY RESEARCH   54 ( 1 )   91 - 102   2024.1   ISSN:1386-6346 eISSN:1872-034X

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aim: To investigate the prognostic value of the preoperative albumin–lymphocyte–platelet–C-reactive protein (ALPC) index in patients with hepatocellular carcinoma (HCC) undergoing curative hepatectomy. We also evaluated the relationship between the ALPC index and the phosphorylated nuclear factor erythroid 2-related factor 2 (p-Nrf2) levels. Methods: Data were analyzed retrospectively from 256 patients who underwent resection for HCC. For cross-validation, patients were divided into the training and testing cohort. We assessed eight combinations of inflammatory markers for predictive value for recurrence. We examined the associations of the ALPC index with recurrence-free survival and overall survival in univariate and multivariate analyses (Cox proportional hazards model). Immunohistochemical staining of p-Nrf2 was performed on tumor samples of 317 patients who underwent hepatic resection for HCC. Results: A high preoperative ALPC index correlated with a high serum albumin concentration, small tumor size, low rate of poor differentiation, solitary tumor, early Barcelona Clinic Liver Cancer stage, and low rate of microscopic intrahepatic metastasis in the training dataset. A high preoperative ALPC index correlated with a high serum albumin concentration, high serum alpha-fetoprotein concentration, small tumor size, a low rate of poor differentiation and a low rate of microscopic intrahepatic metastasis in the testing dataset. A higher preoperative ALPC index was an independent predictor of longer recurrence-free survival and overall survival in the training and testing datasets. A high ALPC index was associated with negative p-Nrf2 expression in HCC tumor cells. Conclusions: We showed that a high ALPC index was an independent prognostic factor for patients with HCC undergoing curative hepatic resection.

    DOI: 10.1111/hepr.13958

    Web of Science

    Scopus

    PubMed

  • Clinical significance of mechanistic target of rapamycin expression in vessels that encapsulate tumor cluster-positive hepatocellular carcinoma patients who have undergone living donor liver transplantation Reviewed International journal

    Toshida, K; Itoh, S; Toshima, T; Yoshiya, S; Goto, R; Mita, A; Harada, N; Kohashi, K; Oda, Y; Yoshizumi, T

    ANNALS OF GASTROENTEROLOGICAL SURGERY   8 ( 1 )   163 - 171   2024.1   ISSN:2475-0328

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Annals of Gastroenterological Surgery  

    Background: There is limited published information regarding the expression of mechanistic target of rapamycin (mTOR) in vessels that encapsulate tumor cluster (VETC)-positive hepatocellular carcinoma (HCC). The mTOR inhibitor, everolimus, has been approved as an immunosuppressant for use in HCC patients after living donor liver transplantation (LDLT). Methods: Using a database of 214 patients who underwent LDLT for HCC, we examined the mTOR protein and angiopoietin-2 (Ang-2) in VETC-positive HCC by immunohistochemical staining. The presence of VETC and mTOR expression were evaluated in both primary and recurrent HCC lesions. Results: Forty-three of the 214 patients (20.1%) were VETC-positive, and 29 of these 43 patients (67.4%) expressed mTOR. Relative Ang-2 expression was significantly higher in the mTOR-positive than in the mTOR-negative group (p = 0.037). Thirty-four of the 214 patients experienced HCC recurrence after LDLT; 20 of these were operable. The primary lesions of six of these 20 patients were VETC-positive; five of these six patients also had VETC-positive recurrent lesions (p < 0.001). The expression of mTOR was significantly higher in the VETC-positive lesions (p = 0.0018). Conclusions: We showed that mTOR expression was higher in the VETC-positive primary and recurrent lesions than in the VETC-negative ones.

    DOI: 10.1002/ags3.12735

    Web of Science

    Scopus

    PubMed

  • 腫瘍クラスターを被包する血管(VETC)陽性の生体肝移植を受けた肝細胞患者におけるmTOR発現の臨床的意義(Clinical significance of mechanistic target of rapamycin expression in vessels that encapsulate tumor cluster-positive hepatocellular carcinoma patients who have undergone living donor liver transplantation)

    Toshida Katsuya, Itoh Shinji, Toshima Takeo, Yoshiya Shohei, Goto Ryoichi, Mita Atsuyoshi, Harada Noboru, Kohashi Kenichi, Oda Yoshinao, Yoshizumi Tomoharu

    Annals of Gastroenterological Surgery   8 ( 1 )   163 - 171   2024.1

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    腫瘍クラスターを被包する血管(VETC)陽性の肝細胞癌(HCC)におけるmTOR発現に関する報告は少ない。mTOR阻害物質であるエベロリムスが、生体肝移植(LDLT)後のHCC患者に対する免疫抑制剤として認可された。HCCに対してLDLTを施行した214例のデータを用いて、VETC陽性HCCにおけるmTOR蛋白質およびアンギオポエチン-2(Ang-2)の発現を免疫組織化学的染色により検討した。VETCおよびmTOR発現の有無を原発性および再発性HCC病変の両方で評価した。214例中43例(20.1%)はVETC陽性で、この43例中29例(67.4%)はmTORを発現していた。相対的Ang-2発現は、mTOR発現例でmTOR陰性例よりも有意に多かった(P=0.037)。214例中34例でLDLT後にHCCの再発が認められ、うち20例は手術適応であった。これら20例のうち6例の原発巣はVETC陽性で、この6例中5例は再発巣でもVETC陽性であった(P<0.001)。以上より、mTORの発現はVETC陽性病変で有意に多かった。VETC陽性の原発および再発病変において、VETC陰性病変と比較してmTOR発現高いことが示された。

  • Association of gut microbiota with portal vein pressure in patients with liver cirrhosis undergoing living donor liver transplantation Reviewed International journal

    Toshida K, Itoh S*, Kosai-Fujimoto Y, Ishikawa T, Nakayama Y, Tsutsui Y, Iseda N, Izumi T, Bekki Y, Yoshiya S, Toshima T, Nakamuta M, Yoshizumi T

    JGH Open   7 ( 12 )   982 - 989   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1002/jgh3.13018

  • Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial Reviewed International journal

    Kayashima H, Itoh S*, Shimokawa M, Hayashi H, Takamori H, Fukuzawa K, Ninomiya M, Araki K, Yamashita Y-i, Sugimachi K, Uchiyama H, Morine Y, Utsunomiya T, Uwagawa T, Maeda T, Baba H, Yoshizumi T

    Int J Clin Oncol.   28 ( 11 )   1520 - 1529   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1007/s10147-023-02399-7

  • Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer Reviewed International journal

    Iseda, N; Iguchi, T; Hirose, K; Itoh, S; Honboh, T; Sadanaga, N; Matsuura, H

    AMERICAN SURGEON   89 ( 11 )   4452 - 4458   2023.11   ISSN:0003-1348 eISSN:1555-9823

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:American Surgeon  

    Background: Increasing evidence indicates that increased systemic inflammation is correlated with poorer cancer-specific survival in various cancer types. This study aimed to evaluate the prognostic value of various combinations of inflammatory factors in patients who underwent surgical resection for pancreatic cancer (PC). Methods: We retrospectively analyzed 97 consecutive patients with PC who underwent pancreatectomy. We assessed the predictive impact for recurrence using a combination of 5 inflammatory markers and focused on the lymphocyte-C-reactive protein ratio (LCR) to elucidate its prognostic and predictive value for recurrence-free survival (RFS) and overall survival (OS) in univariate and multivariate analyses using the Cox proportional hazards model. Results: Low preoperative LCR was correlated with low serum hemoglobin, low serum albumin concentration, high frequency of microscopic vascular invasion, and high frequency of microscopic perineural invasion. The low LCR group had significantly worse RFS and OS. Lower preoperative LCR was an independent predictor of shorter RFS and OS in this cohort. Discussion: Preoperative LCR is a novel and convenient prognostic marker for patients with PC. Patients with low LCR may require more favorable intensive therapy.

    DOI: 10.1177/00031348221117034

    Web of Science

    Scopus

    PubMed

  • Caution to Poor Adherence With Immunosuppressant Medication That Causes Coma-Onset Autoimmune Encephalitis: A Case Report and Literature Review Reviewed International journal

    Toshida, K; Toshima, T; Itoh, S; Yoshiya, S; Mukaino, T; Fujii, T; Watanabe, M; Yamasaki, R; Isobe, N; Yoshizumi, T

    TRANSPLANTATION PROCEEDINGS   55 ( 8 )   1968 - 1971   2023.10   ISSN:0041-1345 eISSN:1873-2623

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Transplantation Proceedings  

    Autoimmune encephalitis after liver transplantation (LT) is a rare disorder. This is because patients are usually in an immunosuppressed state after LT. Here, we report a rare case of autoantibody-negative autoimmune-encephalitis-induced coma after living-donor (LD) LT. A 45-year-old woman who underwent LDLT for primary biliary cholangitis (PBC) was brought to our hospital with the chief complaint of cognitive deficiency and an episode of memory loss. Physical examination, laboratory tests, and cerebrospinal fluid analysis revealed no significant findings. However, diffusion-weighted magnetic resonance imaging showed hyperintensity in the bilateral hippocampus. No autoantibodies associated with autoimmune encephalitis were detected. The diagnosis of antibody-negative autoimmune encephalitis was made on the basis of low immunosuppressive drug levels in the blood (indicative of poor adherence) and the presence of PBC as the autoimmune disease. The patient regained consciousness after intravenous methylprednisolone pulse therapy and plasma exchange. This case highlights that when examining patients with impaired consciousness after LDLT, it is important to consider autoimmune encephalitis as a potential diagnosis.

    DOI: 10.1016/j.transproceed.2023.07.005

    Web of Science

    Scopus

    PubMed

  • 急性胆嚢炎に対する腹腔鏡下胆嚢摘出術のtextbook outcome(Textbook outcome in the laparoscopic cholecystectomy of acute cholecystitis) International journal

    Iseda Norifumi, Iguchi Tomohiro, Itoh Shinji, Sasaki Shun, Honboh Takuya, Yoshizumi Tomoharu, Sadanaga Noriaki, Matsuura Hiroshi

    Asian Journal of Endoscopic Surgery   16 ( 4 )   741 - 746   2023.10   ISSN:1758-5902

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:John Wiley & Sons Australia, Ltd  

    腹腔鏡下胆嚢摘出術が施行された急性胆嚢炎患者189例を対象に、臨床転帰を評価する新たな複合指標であるtextbook outcome(TO)を検討した。TOは、開腹手術への移行、術中合併症、Clavien-Dindo分類でGrade II以上の術後合併症、10日以上の在院期間の延長、術後30日以内の再入院がない腹腔鏡下胆嚢摘出術と定義した。TOは154例で達成した。開腹手術への移行は10例、術中合併症は1例、術後合併症は5例で発生し、29例で在院期間が10日以上であった。患者をTO達成群154例(男性107例、女性47例、年齢中央値63歳)と非達成群35例(男性23例、女性12例、年齢中央値74歳)に分類した。医療費はTO達成群が有意に低かった。多変量解析の結果、70歳以上、ヘモグロビン濃度11.9g/dL未満、白血球数18000/μL以上がTOの非達成を予測する独立因子であった。

  • Effect of Early Enteral Nutrition on Graft Loss After Living Donor Liver Transplantation: A Propensity Score Matching Analysis Reviewed International journal

    Tomino T, Harada N, Toshida K, Tomiyama T, Kosai Y, Kurihara T, Yoshiya S, Takeishi K, Toshima T, Nagao Y, Morita K, Iguchi T, Itoh S, Yoshizumi T

    Transplant Proc.   55 ( 9 )   2164 - 2170   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi:10.1016/j.transproceed.2023.07.029

  • Transferrin Receptor is Associated with Sensitivity to Ferroptosis Inducers in Hepatocellular Carcinoma Reviewed International journal

    Hiromatsu M, Toshida K, Itoh S*, Harada N, Kohashi K, Oda Y, Yoshizumi T

    Ann Surg Oncol.   30 ( 13 )   8675 - 8689   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1245/s10434-023-14053-7

  • Curative surgery for multiple hepatocellular carcinomas after lenvatinib plus transarterial chemoembolization: a case report Reviewed International journal

    Shiraishi, J; Itoh, S; Tomino, T; Yoshiya, S; Nagao, Y; Morita, K; Kayashima, H; Harada, N; Ichiki, Y; Yoshizumi, T

    JOURNAL OF SURGICAL CASE REPORTS   2023 ( 8 )   rjad485   2023.8   ISSN:2042-8812

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Surgical Case Reports  

    Surgical therapy following lenvatinib (LEN) plus transarterial chemoembolization (TACE) is a useful therapeutic option for intermediate-stage hepatocellular carcinoma (HCC). A 66-year-old man with a history of hepatitis C was detected four masses in the caudate lobe and segment 6/7 of the liver, with a maximum lesion diameter of 14 cm by computed tomography. The patient was diagnosed with intermediate-stage HCC and received LEN plus TACE. After resuming LEN for 8 weeks, computed tomography showed weakened stained areas of the tumors, and no new lesions. Thus, the patient was evaluated as having a partial response in the modified Response Evaluation Criteria in Solid Tumors. The patient underwent hepatic caudate lobectomy, partial hepatectomy of S6/7, and S6 microwave coagulation therapy for radical resection. The patient is currently alive and recurrence-free at 12 months postoperatively. In patients with multiple HCC lesions, hepatic resection combined with local therapy might be an effective treatment option.

    DOI: 10.1093/jscr/rjad485

    Web of Science

    Scopus

    PubMed

  • Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment Reviewed International journal

    Toshida K, Itoh S*, Nakayama Y, Tsutsui Y, Kosai-Fujimoto Y, Tomino T, Yoshiya S, Nagao Y, Harada N, Kohashi K, Oda Y, Yoshizumi T

    Int J Clin Oncol.   28 ( 8 )   1082 - 1091   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1007/s10147-023-02358-2

  • Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer Reviewed International journal

    Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C

    Br J Cancer   128 ( 8 )   1603 - 1608   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1038/s41416-023-02189-y.

  • Clinical association between intraoperative ICG fluorescence imaging pattern, preoperative Gd-EOB-DTPA-enhanced MRI findings and histological differentiation in hepatocellular carcinoma Reviewed International journal

    TominoT, Itoh S*, Fujita N, Okamoto D, Nakayama Y, Toshida K, Tomiyama T, Tsutsui Y, Kosai Y, Kuri

    Hepatol Res.   53 ( 8 )   723 - 736   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1111/hepr.13902

  • Surgical treatment of hepatocellular carcinoma after Fontan operation: three case reports and review of the literature Reviewed International journal

    Shiraishi, J; Itoh, S; Tomino, T; Yoshiya, S; Nagao, Y; Kayashima, H; Harada, N; Sakamoto, I; Tsutsui, H; Yoshizumi, T

    CLINICAL JOURNAL OF GASTROENTEROLOGY   16 ( 4 )   559 - 566   2023.8   ISSN:1865-7257 eISSN:1865-7265

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Clinical Journal of Gastroenterology  

    We herein describe three patients with Fontan-associated liver disease who developed hepatocellular carcinoma (HCC). The first patient was a 28-year-old woman who had undergone the Fontan operation (FO) at the age of 4 years. She was diagnosed with HCC (cT4aN0M0, Stage IVA, UICC 8th edition), for which she underwent extended posterior right sectionectomy and partial hepatectomy of S2. She developed recurrence of peritoneal dissemination after 12 months, and she was alive 18 months after surgery. The second patient was a 43-year-old man who had undergone the FO at the age of 3 years. He was diagnosed with HCC (cT2N0M0, Stage II), for which he underwent laparoscopic-assisted partial hepatectomy of S3. He remained free from recurrent HCC for 17 months. The third patient was a 21-year-old woman who had undergone the FO at the age of 3 years. She was diagnosed with HCC (cT3N0M0, Stage III), for which she underwent laparoscopic-assisted partial hepatectomy of S2 and S4. She remained free from recurrent HCC for 30 months. We reviewed 18 surgical cases of HCC arising from Fontan-associated liver disease, including our 3 cases, and found that a high preoperative alpha-fetoprotein concentration might be a predictor of HCC recurrence.

    DOI: 10.1007/s12328-023-01795-w

    Web of Science

    Scopus

    PubMed

  • Clinical association between intraoperative indocyanine green fluorescence imaging pattern, preoperative Gd-EOB-DTPA-enhanced magnetic resonance imaging findings, and histological differentiation in hepatocellular carcinoma Reviewed International journal

    Tomino, T; Itoh, S; Fujita, N; Okamoto, D; Nakayama, Y; Toshida, K; Tomiyama, T; Tsutsui, Y; Kosai, Y; Kurihara, T; Nagao, Y; Morita, K; Harada, N; Ushijima, Y; Kohashi, K; Ishigami, K; Oda, Y; Yoshizumi, T

    HEPATOLOGY RESEARCH   53 ( 8 )   723 - 736   2023.8   ISSN:1386-6346 eISSN:1872-034X

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aim: We aimed to evaluate the association between the intraoperative indocyanine green (ICG) fluorescence imaging (FI) pattern, preoperative magnetic resonance imaging (MRI) findings using gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA), preoperative diffusion-weighted imaging (DWI) of MRI, and histological differentiation of hepatocellular carcinoma (HCC). Methods: We retrospectively reviewed the data for 80 tumors of 64 patients. Intraoperative ICG FI patterns were classified into cancerous or rim-positive type. We evaluated the signal intensity ratio of the tumor and the surrounding liver tissue in the portal phase (SIRPP) and intensity in the hepatobiliary phase (HBP) of Gd-EOB-DTPA-enhanced MRI, the apparent diffusion coefficient (ADC) in the DWI of MRI, and clinicopathologic factors. Results: In the rim-positive group, the rate of poorly differentiated HCC and hypointensity type in HBP were significantly higher, and SIRPP and ADC were significantly lower than the rim-negative group. In the cancerous group, the rate of well or moderately differentiated HCC and hyperintensity type in HBP, SIRPP, and ADC were significantly higher than the noncancerous group. Multivariate analysis identified low SIRPP, low ADC, and hypointensity type in HBP as the significant predictive factors for rim-positive HCC and high SIRPP, high ADC, and hyperintensity type in HBP as the significant predictive factors for cancerous HCC. The positive rate of programmed cell death 1-ligand 1 and vessels that encapsulate tumor clusters status of the rim-positive HCC and HCC with low SIRPP were significantly higher than the control group. Conclusions: The intraoperative ICG FI pattern of HCC closely correlated with histological differentiation, preoperative SIRPP and intensity type in the Gd-EOB-DTPA MRI, and preoperative ADC in the DWI of MRI.

    DOI: 10.1111/hepr.13902

    Web of Science

    Scopus

    PubMed

  • 特集 肝胆膵外科手術における術中トラブルシューティング I. 肝臓 1.開腹肝切除術における肝静脈・下大静脈出血への対処法

    吉屋 匠平, 原田 昇, 伊藤 心二, 戸島 剛男, 吉住 朋晴

    外科   85 ( 8 )   863 - 867   2023.7   ISSN:0016593X eISSN:24329428

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka85_863

    CiNii Research

  • The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child-Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma Reviewed International journal

    Toshida K, Itoh S*, Kayashima H, Nagao Y, Yoshiya S, Tomino T, Fujimoto YK, Tsutsui Y, Nakayama Y, Harada N, Yoshizumi T

    Hepatol Res.   53 ( 6 )   522 - 530   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1111/hepr.13885

  • Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Hepatocellular Carcinoma Reviewed International journal

    30 ( 6 )   3378 - 3389   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1245/s10434-022-13058-y

  • Prognostic Impact of the Preoperative Systemic Inflammation Score in Patients With Pancreatic Ductal Adenocarcinoma Reviewed International journal

    Iguchi, T; Iseda, N; Hirose, K; Itoh, S; Harada, N; Ninomiya, M; Sugimachi, K; Honboh, T; Maeda, T; Sadanaga, N; Matsuura, H

    AMERICAN SURGEON   89 ( 6 )   2213 - 2219   2023.6   ISSN:0003-1348 eISSN:1555-9823

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:American Surgeon  

    Backgroud: The systemic inflammation score (SIS), which is based on the preoperative lymphocyte-to-monocyte ratio (LMR) and serum albumin (Alb) level, is a prognostic indicator for several cancer types. However, the prognostic significance of the SIS in pancreatic ductal adenocarcinoma (PDAC) remains unknown. Methods: Seventy-eight patients who underwent radical surgery for PDAC were categorized as follows: SIS 0 (LMR ≥3.51 and Alb ≥4.0 g/dl), n = 26; SIS 1 (LMR <3.51 or Alb <4.0 g/dl), n = 29 and SIS 2 (LMR <3.51 and Alb <4.0 g/dl), n=23. Results: The tumour size sequentially increased in SIS 0, 1 and 2 groups. A higher SIS was associated with increased vascular invasion, perineural invasion and surgical margin positivity rate. Recurrence-free survival (RFS) rates between the SIS 1 and 2 groups showed no significant difference However, patients of the SIS 1 and 2 groups had poorer outcomes than those of the SIS 0 group for RFS. Overall survival (OS) rates between the SIS 1 and 2 groups also showed no significant difference. However, patients of the SIS 1 and 2 groups had poorer outcomes than those of the SIS 0 group for OS. The SIS was an independent prognostic factor for RFS and OS. Discussion: The SIS is a simplified prognostic factor for patients with PDAC.

    DOI: 10.1177/00031348221086782

    Web of Science

    Scopus

    PubMed

  • Prognostic significance for recurrence of FGFR2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection Reviewed International journal

    Toshida K, Itoh S*, Yugawa K, Kosai Y, Tomino T, Yoshiya S, Nagao Y, Kayashima H, Harada N, Kohashi K, Oda Y, Yoshizumi T

    Hepatol Res.   53 ( 5 )   432 - 439   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1111/hepr.13875.

  • A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients Reviewed International journal

    Tomiyama T, Suzuki R, Harada N, Tamura T, Toshida K, Kosai-Fujimoto Y, Tomino T, Yoshiya S, Nagao Y, Takeishi K, Itoh S, Kobayashi N, Ito H, Yoshio S, Kanto T, Yoshizumi T, Fukuhara T

    Front Cell Infect Microbiol.   13   1197349   2023.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.3389/fcimb.2023.1197349

  • Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection Reviewed International journal

    Toshida, K; Itoh, S; Yugawa, K; Kosai, Y; Tomino, T; Yoshiya, S; Nagao, Y; Kayashima, H; Harada, N; Kohashi, K; Oda, Y; Yoshizumi, T

    HEPATOLOGY RESEARCH   53 ( 5 )   432 - 439   2023.5   ISSN:1386-6346 eISSN:1872-034X

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Hepatology Research  

    Aims: The fibroblast growth factor receptor 2 (FGFR2) fusion gene is frequently found as a genetic abnormality in the FGFR pathway in patients with intrahepatic cholangiocarcinoma (ICC). The FGFR fusion protein, produced from the FGFR fusion gene, is thought to cause tumor cell growth. To date, there have been few reports on the relationship between pathologic FGFR2 expression and prognosis in patients who have undergone hepatectomy for ICC, and on the relationship between FGFR2 and tumor-infiltrating lymphocytes (TILs). Methods and Results: We enrolled 92 patients who underwent hepatectomy for ICC and performed immunohistochemical staining for FGFR2 and cluster of differentiation 8, and hematoxylin and eosin staining for evaluating TILSs. The relationships between the FGFR2 and clinicopathological characteristics and outcomes were analyzed, and patients were classified into positive (n = 18) and negative (n = 74) FGFR2 groups. The FGFR2-positive group contained more men (p < 0.0001) and had lower serum albumin (p = 0.0355) and higher carcinoembryonic antigen (p = 0.0099). Furthermore, multivariable analyses revealed that the FGFR2-positive group had worse disease-free survival (DFS) (p = 0.0002). Multivariate analysis showed that the independent prognostic factors for DFS were maximum tumor size (≥5 cm) (p = 0.0011), tumor localization (perihilar type) (p = 0.0180), and FGFR2 positivity (p = 0.0029). There was no significant difference in TILs count between the two groups. Conclusion: We showed that FGFR2 high expression was an independent prognostic factor for recurrence of resected ICC.

    DOI: 10.1111/hepr.13875

    Web of Science

    Scopus

    PubMed

  • 特集 外科手術と感染症 I. 総論 14. 肝移植後の免疫抑制下における感染症対策

    吉屋 匠平, 原田 昇, 戸島 剛男, 伊藤 心二, 吉住 朋晴

    外科   85 ( 5 )   489 - 494   2023.4   ISSN:0016593X eISSN:24329428

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka85_489

    CiNii Research

  • Textbook outcome in the laparoscopic cholecystectomy of acute cholecystitis Reviewed International journal

    Iseda N, Iguchi T, Itoh S*, Sasaki S, Honboh T, Yoshizumi T, Sadanaga N, Matsuura H

    Asian J Endosc Surg.   16 ( 4 )   741 - 746   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1111/ases.13238

  • Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis Reviewed International journal

    Fukunaga, A; Takata, K; Itoh, S; Yamauchi, R; Tanaka, T; Yokoyama, K; Shakado, S; Kohashi, K; Yoshizumi, T; Hirai, F

    CLINICAL JOURNAL OF GASTROENTEROLOGY   16 ( 2 )   224 - 228   2023.4   ISSN:1865-7257 eISSN:1865-7265

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Clinical Journal of Gastroenterology  

    A combined therapy of atezolizumab and bevacizumab (atezo/bev) is used as the first-line treatment for unresectable hepatocellular carcinoma (HCC). In this study, we report the case of curative hepatic resection in a 77-year-old man who initially had unresectable advanced-stage HCC with lung metastases. This rare hepatectomy conversion was owing to the administration of atezo/bev. Notwithstanding the side effects of immune-related adverse event hepatitis and intratumoral hemorrhage developed during atezo/bev treatment; after seven treatment cycles, the patient’s tumor markers normalized, the tumor shrank markedly, and the metastasis disappeared. Subsequently, conversion therapy with hepatic resection was performed, and pathology confirmed complete tumor necrosis. No cancer recurrence was observed at the 8-month postoperative follow-up, and the patient remained drug free.

    DOI: 10.1007/s12328-022-01744-z

    Web of Science

    Scopus

    PubMed

  • Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma Invited Reviewed International journal

    Toshida K, Itoh S*, Harada N, Morinaga A, Yugawa K, Tomiyama T, Kosai-Fujimoto Y, Tomino T, Kurihara T, Nagao Y, Morita K, Oda Y, Yoshizumi T

    Cancer Sci.   114 ( 3 )   937 - 947   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1111/cas.15644

  • 食道癌手術症例における入院前周術期支援の意義

    原武 直紀, 清松 丈浩, 淀川 千穂, 須古井 和美, 伊藤 心二, 和田 尚久, 水元 一博, 中川 尚志

    臨牀と研究   100 ( 3 )   368 - 372   2023.3   ISSN:0021-4965

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:大道学館出版部  

    食道癌手術症例における入院前周術期支援の介入の有無と術後合併症との関連について検討し、入院前周術期支援の有用性について検証した。2018年4月~2020年9月にかけて、食道癌手術症例120例を、入院前周術期支援を開始した2019年10月前後で入院時支援介入なし群75例と介入あり群45例に分類した。術後合併症は全体で51例(43%)に認められ、内容としては最多が肺炎で16例(13.9%)、嚥下障害・反回神経麻痺が14例(12.2%)、不整脈8例(7.0%)であった。介入なし群での合併症頻度は75例中37例(49%)であったのに対して、介入あり群で45例中14例(31%)と介入あり群の方が合併症の発生頻度が低かった。周術期支援による術後合併症の減少が示唆される結果が得られ、他癌腫への応用も視野に、周術期支援の充実を図ることが重要と考えられた。

  • 特集 肝移植手術を再考する レシピエント手術における血行再建

    原田 昇, 戸島 剛男, 伊藤 心二, 松浦 俊治, 吉住 朋晴

    手術   77 ( 1 )   67 - 76   2023.1   ISSN:00374423

     More details

    Publisher:金原出版  

    DOI: 10.18888/op.0000003119

    CiNii Research

  • Current understanding of liver resection in the treatment of hepatocellular carcinoma

    Kurihara Takeshi, Itoh Shinji, Hidaka Masaaki, Eguchi Susumu, Yoshizumi Tomoharu

    Kanzo   64 ( 1 )   1 - 11   2023.1   ISSN:04514203 eISSN:18813593

     More details

    Authorship:Corresponding author   Language:Japanese   Publisher:The Japan Society of Hepatology  

    <p>To organize the current status and understanding of liver resection in the treatment of hepatocellular carcinoma, a questionnaire survey was conducted. The Kyushu Liver Surgery Study Group was sponsoring 15 institutions including hepatologists and liver surgeons. Regarding the excision borderline, hepatologists felt limited by numbers and Vps, while surgeons felt limited by Vvs. In the case of BCLC-B, hepatologists had few choices for resection even if the treatment succeeded. Surgeons chose treatment for the conversion surgery attempt in the case of portal vein proximity, but hepatologists chose resection as a result after successful treatment. For the conversion attempt, most hepatologists hoped to use drug therapy or local treatment. It has become clear that hepatologists and surgeons must further change their mindset to perform hepatic resection and local or systemic therapy in the treatment of hepatocellular cancer.</p>

    DOI: 10.2957/kanzo.64.1

    Scopus

    CiNii Research

  • Predictive Factors for the Resectable Type of Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplant Reviewed International journal

    Kurihara T, Harada N, Morinaga A, Tomiyama T, Toshida K, Kosai Y, Tomino T, Toshima T, Nagao Y, Morita K, Itoh S, Yoshizumi T

    Transplant Proc.   55 ( 1 )   191 - 196   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1016/j.transproceed.2022.09.031

  • Preoperative serum brain-derived neurotrophic factor as a predictive biomarker for sepsis after living-donor liver transplantation Reviewed International journal

    Tsutsui Y, Yoshio S, Tomiyama T, Shimagaki T, Itoh S, Harada N, Yoshida Y, Yoshikawa S, Kakazu E, Kanto T, Yoshizumi T.

    Hepatol Res.   53 ( 1 )   72 - 83   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1111/hepr.13834

  • A rare case of unresectable, microsatellite instability-high hepatocellular carcinoma and an examination of the tumor microenvironment Reviewed International journal

    Tomiyama, T; Itoh, S; Toshida, K; Morinaga, A; Fujimoto-Kosai, Y; Tomino, T; Kurihara, T; Nagao, Y; Morita, K; Harada, N; Kohashi, K; Eguchi, Y; Oda, Y; Mori, M; Yoshizumi, T

    INTERNATIONAL CANCER CONFERENCE JOURNAL   12 ( 1 )   81 - 86   2023.1   ISSN:2192-3183

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s13691-022-00585-4

    Web of Science

    PubMed

  • Donor Skeletal Muscle Quality Affects Graft Mortality After Living Donor Liver Transplantation- A Single Center, Retrospective Study Reviewed International journal

    Tomiyama, T; Harada, N; Toshima, T; Nakayama, Y; Toshida, K; Morinaga, A; Kosai-Fujimoto, Y; Tomino, T; Kurihara, T; Takeishi, K; Nagao, Y; Morita, K; Itoh, S; Yoshizumi, T

    TRANSPLANT INTERNATIONAL   35   10723   2022.12   ISSN:0934-0874 eISSN:1432-2277

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Transplant International  

    The recipient muscle status is closely associated with postoperative poor survival in recipients of living donor liver transplantation (LDLT). However, it is uncertain whether LDLT donor muscle quality and quantity affect graft quality. Hence, we analyzed the correlation between donor muscle status and graft function. We measured the skeletal muscle mass index (SMI) and intramuscular adipose tissue content (IMAC) of 380 LDLT donors. We examined the correlation between donor SMI or IMAC and graft mortality, the occurrence rates of small-for-size graft (SFSG) syndrome, and 6-month graft survival rates. The donor SMI had no effect on the occurrence of SFSG syndrome and graft survival, while a high IMAC in both male and female donors was significantly correlated with the rate of SFSG syndrome [high vs low: (male donors) 15.8% vs. 2.5%, p = 0.0003; (female donors) 12.8% vs. 3.1%, p = 0.0234] and 6-month graft survival rates [(male donors) 87.7% vs 95.9%, p = 0.02; (female donors) 83.0% vs. 99.0%, p < 0.0001]. Multivariate analysis revealed that a high donor IMAC (HR; 5.42, CI; 2.13–13.8, p = 0.0004) was an independent risk factor for 6-month graft survival, and the donor IMAC is useful for donor selection for high-risk recipients.

    DOI: 10.3389/ti.2022.10723

    Web of Science

    Scopus

    PubMed

  • 特集 病態に応じた栄養療法の重要性 II. 各論 7.肝硬変を伴う肝癌患者の術前栄養状態の評価と栄養療法の実際

    冨野 高広, 伊藤 心二, 原田 昇, 吉住 朋晴

    外科   84 ( 13 )   1362 - 1367   2022.12   ISSN:0016593X eISSN:24329428

     More details

    Publisher:南江堂  

    DOI: 10.15106/j_geka84_1362

    CiNii Research

  • Autoimmune Hepatitis in an Immunosuppression-Free Patient Who Underwent Living Donor Liver Transplantation From an Identical Twin: A Case Report Reviewed International journal

    Toshida, K; Toshima, T; Harada, N; Nakayama, Y; Tomiyama, T; Morinaga, A; Kosai-Fujimoto, Y; Tomino, T; Kurihara, T; Nagao, Y; Morita, K; Itoh, S; Yoshizumi, T

    TRANSPLANTATION PROCEEDINGS   54 ( 10 )   2791 - 2793   2022.12   ISSN:0041-1345 eISSN:1873-2623

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Transplantation Proceedings  

    Although there have been a few liver transplantations (LTs) between identical twins, to our knowledge hepatic damage after LT in an immunosuppressant-free patient has not been reported. Autoimmune liver disease recurrence after LT is also a postoperative problem. In this follow-up to our previous report, we present the case of a 57-year-old man with acute liver failure who underwent living donor liver transplantation (LDLT) from an identical twin. Six months after LDLT, the patient was free from immunosuppressive medication and showed good liver function. However, 1 year after LDLT, he developed liver damage and was diagnosed with autoimmune hepatitis by liver biopsy. His liver function was improved with steroid pulse therapy and the resumption of immunosuppressive medications. Even after LDLT from an identical twin, careful management is required for patients to remain free of immunosuppressive medications, considering the background liver disease.

    DOI: 10.1016/j.transproceed.2022.09.022

    Web of Science

    Scopus

    PubMed

  • Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Reviewed International journal

    Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, Sugimoto R, Senju T, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y.

    Target Oncol.   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Caution for living donor liver transplantation with congenital portosystemic shunt: a case report Reviewed International journal

    Nagao, Y; Toshida, K; Morinaga, A; Tomiyama, T; Kosai, Y; Shimagaki, T; Tomino, T; Wang, HL; Kurihara, T; Toshima, T; Morita, K; Itoh, S; Harada, N; Yoshizumi, T

    SURGICAL CASE REPORTS   8 ( 1 )   190   2022.10   ISSN:2198-7793

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s40792-022-01533-3

    Web of Science

    PubMed

  • Prevention of bile duct injury using indocyanine green fluorescence in laparoscopic liver cyst fenestration for giant liver cyst: a case report Reviewed International journal

    Shimagaki, T; Itoh, S; Toshida, K; Tomiyama, T; Morinaga, A; Kosai, Y; Tomino, T; Kurihara, T; Nagao, Y; Morita, K; Harada, N; Yoshizumi, T

    JOURNAL OF SURGICAL CASE REPORTS   2022 ( 10 )   rjac479   2022.10   ISSN:2042-8812

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Surgical Case Reports  

    The case is a 78-year-old female. A giant liver cyst was pointed out by abdominal echo from 7 years ago, but because the size of the cyst tended to increase, it was decided to operate taking into account the risk of the cyst rupturing. Laparoscopic surgery was started, and the cyst contents did not fluorescent when observed by the indocyanine green (ICG) fluorescence method. Laparoscopic liver cyst fenestration was performed using the ICG fluorescence method, paying attention to the damage to the bile duct excluded by the cyst. The opened cyst was filled with the greater omentum. In this report, we describe that the ICG fluorescence method can evaluate the presence or absence of bile leakage from the hepatic dissection and the running of the bile duct on the inner wall of the cyst, and is considered to contribute to safer laparoscopic liver cyst fenestration.

    DOI: 10.1093/jscr/rjac479

    Web of Science

    Scopus

    PubMed

  • Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation. Reviewed International journal

    Tomiyama T, Shimokawa M, Harada N, Toshida K, Morinaga A, Kosai-Fujimoto Y, Tomino T, Kurihara T, Nagao Y, Toshima T, Morita K, Itoh S, Yoshizumi T.

    Hepatol Res   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 先天性門脈体循環シャントがみられる生体肝移植の留意点 1症例報告(Caution for living donor liver transplantation with congenital portosystemic shunt: a case report) Reviewed

    Nagao Yoshihiro, Toshida Katsuya, Morinaga Akinari, Tomiyama Takahiro, Kosai Yukiko, Shimagaki Tomonari, Tomino Takahiro, Wang Huanlin, Kurihara Takeshi, Toshima Takeo, Morita Kazutoyo, Itoh Shinji, Harada Noboru, Yoshizumi Tomoharu

    Surgical Case Reports   8   1 of 5 - 5 of 5   2022.10

     More details

    Language:English   Publisher:Springer Berlin Heidelberg  

    症例は39歳女性で、生体移植のためにドナー肝切除を施行された。合併症はなく、術前MD-CTでは残肝容積は429mL(40.5%)を示し、先天性門脈体循環シャントの拡張が認められた。シャント径は9cmに及び、左胃静脈(LGV)から左腎静脈(LRV)への流入を認めたが、臨床検査所見に異常はなかった。術中所見では肝臓の外観は正常であり、手術時間は320分、推定出血量は245mLで術後経過は良好であった。しかし、術後9日目、活動量低下と記憶障害をきたし、軽度脳症と全身性血中アンモニア高値が検出された。MD-CTでは明らかな門脈血栓はみられなかったが、門脈幹の狭小化と門脈血流の低下を認め、先天性門脈体循環シャントへの盗血が疑われた。さらに、プロトロンビン時間-国際標準化比(PT-INR)とD-ダイマーの上昇が確認されたことから、門脈血流不良による門脈微小血栓の存在が示唆された。このため、右大腿静脈アプローチによるバルーン閉塞下逆行性経静脈的塞栓術(B-RTO)を行うこととし、門脈圧を13mmHgに設定してLGV-LRVシャントを閉塞した。術後、肝性脳症と高アンモニア血症の改善が得られ、PT-INRも正常化しB-RTO施行後9日目に退院となった。6ヵ月後のMD-CTでは門脈幹の拡大と残肝の再生促進が得られていた。

  • Prognostic Impact of Lymphocyte-to-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Pancreatic Cancer. Iseda N, Iguchi T, Hirose K, Itoh S, Honboh T, Sadanaga N, Matsuura H. Reviewed International journal

    Iseda N, Iguchi T, Hirose K, Itoh S, Honboh T, Sadanaga N, Matsuura H.

    Am Surg.   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Outcomes of living-donor liver transplantation for acute-on-chronic liver failure based on newly proposed criteria in Japan Reviewed International journal

    Toshima T, Harada N, Itoh S, Morita K, Nagao Y, Kurihara T, Tomino T, Kosai-Fujimoto Y, Morinaga A, Tomiyama T, Yoshizumi T.

    Clin Transplant.   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Impact of JMJD6 on intrahepatic cholangiocarcinoma Reviewed International journal

    Kosai-Fujimoto, Y; Itoh, S; Yugawa, K; Fukuhara, T; Okuzaki, D; Toshima, T; Harada, N; Oda, Y; Yoshizumi, T; Mori, M

    MOLECULAR AND CLINICAL ONCOLOGY   17 ( 2 )   131   2022.8   ISSN:2049-9450 eISSN:2049-9469

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Molecular and Clinical Oncology  

    The association of Jumonji domain-containing 6 (JMJD6) with the prognosis of various types of cancer has been demonstrated, except in intrahepatic cholangiocarci-noma (ICC). The present study aimed to clarify the impact of JMJD6 on ICC. The liver specimens of 51 patients who underwent surgery for ICC were analyzed for JMJD6 expression using immunohistochemistry staining. The relationship between clinicopathological factors and JMJD6 expression was investigated. The cellular activity was also evaluated in JMJD6 knocked down cells with Transwell migration assay and viability assay. In the immunohistochemistry staining of clinical samples, high expression of JMJD6 was seen in 32 of 51 samples. High expression was also associated with improved overall survival (OS) and recurrence-free survival (RFS) (P=0.0033 and 0.048, respectively). Further analyses revealed that higher JMJD6 expression was one of the improved independent prognostic factors of OS and RFS. Expression of JMJD6 was knocked down in commercial culture cell lines of ICC, and RNA and protein were extracted to analyze the downstream gene expression using RNA-sequencing and western blotting. JMJD6 knockdown was associated with higher programmed death-ligand 1 (PD-L1) expression in RNA-sequencing and western blotting. In addition, PD-L1 expression was higher in JMJD6 low expression clinical samples when measured using immunohistochemistry staining. In conclusion, high expression of JMJD6 was an independent favorable prognostic factor of ICC. JMJD6 may influence the prognosis of ICC through the regulation of PD-L1 expression.

    DOI: 10.3892/mco.2022.2564

    Web of Science

    Scopus

    PubMed

  • Impact of JMJD6 on intrahepatic cholangiocarcinoma. Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M. Reviewed International journal

    Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M.

    Mol Clin Oncol.   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. Reviewed International journal

    Toshida K, Itoh S, Tomiyama T, Morinaga A, Kosai Y, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Yoshizumi T.

    JGH Open   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Up-regulated LRRN2 expression as a marker for graft quality in living donor liver transplantation. Invited Reviewed International journal

    Tomiyama T, Yamamoto T, Takahama S, Toshima T, Itoh S, Harada N, Shimokawa M, Okuzaki D, Mori M, Yoshizumi T.

    Hepatol Commun.   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma Reviewed International journal

    Iseda N, Itoh S, Toshida K, Tomiyama T, Morinaga A, Shimokawa M, Shimagaki T, Wang H, Kurihara T, Toshima T, Nagao Y, Harada N, Yoshizumi T, Mori M.

    Cancer Sci.   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Liver transplantation for hepatocellular carcinoma in the present era

    YOSHIZUMI Tomoharu, HARADA Noboru, ITOH Shinji

    Nippon Shokakibyo Gakkai Zasshi   119 ( 5 )   432 - 437   2022.5   ISSN:04466586 eISSN:13497693

     More details

    Language:Japanese   Publisher:The Japanese Society of Gastroenterology  

    DOI: 10.11405/nisshoshi.119.432

    Scopus

    PubMed

    CiNii Research

  • Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma Reviewed International journal

    Tomiyama T, Itoh S, Iseda N, Toshida K, Morinaga A, Yugawa K, Fujimoto YK, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Kohashi K, Oda Y, Mori M, Yoshizumi T.

    Oncol Lett.   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Association between Sarcopenia and Omega-3 Polyunsaturated Fatty Acid in Patients with Hepatocellular Carcinoma Reviewed International journal

    Itoh S, Nagao Y, Morita K, Kurihara T, Tomino T, Kosai-Fujimoto Y, Harada N, Fujita N, Ushijima Y, Mori M, Yoshizumi T.

    JMA J   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status Reviewed International journal

    Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Yugawa K, Shimokawa M, Shimagaki T, Wang H, Kurihara T, Kitamura Y, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M.

    Hepatol Commun.   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • The ratio of serum des-gamma-carboxy prothrombin to tumor volume as a new biomarker for early recurrence of resected hepatocellular carcinoma Reviewed International journal

    Shimagaki T, Yoshizumi T, Itoh S, Iseda N, Tomiyama T, Morinaga A, Wang H, Kurihara T, Nagao Y, Toshima T, Harada N, Kinjo N, Maeda T, Mori M.

    Hepatol Res.   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Prognostic Impact of the Preoperative Systemic Inflammation Score in Patients With Pancreatic Ductal Adenocarcinoma Reviewed International journal

    Iguchi T, Iseda N, Hirose K, Itoh S, Harada N, Ninomiya M, Sugimachi K, Honboh T, Maeda T, Sadanaga N, Matsuura H.

    Am Surg   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Clinical effects of the use of the indocyanine green fluorescence imaging technique in laparoscopic partial liver resection. Reviewed International journal

    Itoh S, Tomiyama T, Morinaga A, Kurihara T, Nagao Y, Toshima T, Morita K, Harada N, Mori M, Yoshizumi T.

    Ann Gastroenterol Surg.   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Gastric Tube-Preserving Pancreaticoduodenectomy Using Intraoperative Blood Perfusion Imaging After Esophagectomy Reviewed International journal

    Watanabe, K; Harada, N; Shimagaki, T; Wang, HL; Kurihara, T; Nagao, Y; Toshima, T; Itoh, S; Yoshizumi, T; Mori, M

    PANCREAS   51 ( 2 )   E21 - E22   2022.2   ISSN:0885-3177 eISSN:1536-4828

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Pancreas  

    DOI: 10.1097/MPA.0000000000001976

    Web of Science

    Scopus

    PubMed

  • Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019 Reviewed International journal

    Nakano, M; Yatsuhashi, H; Bekki, S; Takami, Y; Tanaka, Y; Yoshimaru, Y; Honda, K; Komorizono, Y; Harada, M; Shibata, M; Sakisaka, S; Shakado, S; Nagata, K; Yoshizumi, T; Itoh, S; Sohda, T; Oeda, S; Nakao, K; Sasaki, R; Yamashita, T; Ido, A; Mawatari, S; Nakamuta, M; Aratake, Y; Matsumoto, S; Maeshiro, T; Goto, T; Torimura, T

    SCIENTIFIC REPORTS   12 ( 1 )   1517   2022.1   ISSN:2045-2322

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Scientific Reports  

    We examined the epidemiological trends, including the distribution of sex, age, and disease etiology, in HCC incident cases, over 24 years. Data of 20,547 HCC patients (1996–2019) were analyzed in this prospective study. We divided the study period into four 6-yearly quarters. HCC etiology was categorized as hepatitis B virus (HBV) infection, HBV + hepatitis C virus (HCV) infection, HCV infection, and both negative (non-BC). The incident cases of HCC per quarter of the study period were 4311 (21.0%), 5505 (26.8%), 5776 (28.1%), and 4955 (24.1%), sequentially. Overall, 14,020 (68.2%) patients were male. The number of HCC cases in patients < 60 years, 60–69 years, 70–79 years, and ≥ 80 years were 3711 (18.1%), 6652 (32.4%), 7448 (36.2%), and 2736 (13.3%), respectively. The average age of newly-diagnosed patients increased in each quarter. HCC was associated with HBV, HBV + HCV, and HCV infections and non-BC in 2997 (14.6%), 187 (0.9%), and 12,019 (58.5%), and 5344 (26.0%) cases, respectively. The number of HCV-associated cases decreased in each quarter, while that of non-BC-associated cases increased. HCC incident cases tend to increase in the elderly and in non-BC patients; in contrast, HCC incident cases due to HCV tend to decrease.

    DOI: 10.1038/s41598-022-05444-z

    Web of Science

    Scopus

    PubMed

  • Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response Invited Reviewed International journal

    Harimoto N, Itoh S, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M, Watanabe A, Araki K, Yoshizumi T, Shirabe K.

    Anticancer Res.   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019 Reviewed International journal

    Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T.

    Sci Rep.   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. Invited Reviewed International journal

    Shinji Itoh, Eiji Tsujita, Kengo Fukuzawa, Keishi Sugimachi, Tomohiri Iguchi, Mizuki Ninomiya, Takashi Maeda, Kiyashi Kajiyama, Eisuke Adachi, Hideaki Uchiyama, Tohru Utsunomiya, Yasuharu Ikeda, Soichirou Maekawa, Takeo Toshima, Noboru Harada, Tomoharu Yoshizumi, Masaki Mori

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.pan.2021.08.003

  • Retrospective evaluation of the effect of Ninjin'yoeito in hepatocellular carcinoma patients treated with lenvatinib. Invited Reviewed International journal

    Katsuya Toshida, Shinji Itoh, Tomoharu Yoshizumi, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Takeo Toshima, Yoshihiro Nagao, Noboru Harada, Kojiro Hata, Yoko Makihara, Hiroyuki Watanabe, Masaki Mori

    Surgery today   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00595-021-02358-7

  • Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. Invited Reviewed International journal

    Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Takeo Toshima, Yoshihiro Nagao, Noboru Harada, Yoshinao Oda, Masaki Mori

    International journal of clinical oncology   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-021-01985-x

  • Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma. Invited Reviewed International journal

    Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Norifumi Iseda, Akinari Morinaga, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Akihiro Nishie, Kousei Ishigami, Masaki Mori

    JGH open : an open access journal of gastroenterology and hepatology   5 ( 7 )   785 - 792   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/jgh3.12588

  • Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma. Invited Reviewed International journal

    Kyohei Yugawa, Shinji Itoh, Tomoharu Yoshizumi, Akinari Morinaga, Norifumi Iseda, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Yoshinao Oda, Masaki Mori

    International journal of clinical oncology   2021.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-021-01962-4

  • Impact of Capicua on Pancreatic Cancer Progression Reviewed International journal

    Yoshiya, Shohei; Itoh, Shinji; Yoshizumi, Tomoharu; Yugawa, Kyohei; Kurihara, Takeshi; Toshima, Takeo; Harada, Noboru; Hashisako, Mikiko; Yonemasu, Hirotoshi; Fukuzawa, Kengo; Oda, Yoshinao; Mori, Masaki

    ANNALS OF SURGICAL ONCOLOGY   28 ( 6 )   3198 - 3207   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-020-09339-z

  • Identification of SLC38A7 as a Prognostic Marker and Potential Therapeutic Target of Lung Squamous Cell Carcinoma. Invited Reviewed International journal

    Naoki Haratake, Qingjiang Hu, Tatsuro Okamoto, Tomoko Jogo, Gouji Toyokawa, Fumihiko Kinoshita, Tomoyoshi Takenaka, Tetsuzo Tagawa, Norifumi Iseda, Shinji Itoh, Yuichi Yamada, Yoshinao Oda, Mototsugu Shimokawa, Chie Kikutake, Mikita Suyama, Motoko Unoki, Hiroyuki Sasaki, Masaki Mori

    Annals of Surgery   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/SLA.0000000000005001

  • The Significant Prognostic Factors in Prolonged Intensive/High Care Unit Stay After Living Donor Liver Transplantation. Invited Reviewed International journal

    Shohei Yoshiya, Noboru Harada, Takahiro Tomiyama, Kazuki Takeishi, Takeo Toshima, Tomohiro Iguchi, Shinji Itoh, Mizuki Ninomiya, Tomoharu Yoshizumi, Masaki Mori

    Transplantation proceedings   53 ( 5 )   1630 - 1638   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transproceed.2021.02.020

  • Prognostic Impact of Vessels that Encapsulate Tumor Cluster (VETC) in Patients who Underwent Liver Transplantation for Hepatocellular Carcinoma. Invited Reviewed International journal

    Junji Kawasaki, Takeo Toshima, Tomoharu Yoshizumi, Shinji Itoh, Yohei Mano, Huanlin Wang, Norifumi Iseda, Noboru Harada, Yoshinao Oda, Masaki Mori

    Annals of surgical oncology   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-021-10209-5

  • Feasibility of hepatic resection for liver metastasis of head-and-neck carcinoma or esophageal carcinoma: a multi-center experience. Invited Reviewed International journal

    Takeshi Kurihara, Shinji Itoh, Yasue Kimura, Eiji Oki, Tomoharu Yoshizumi, Mioko Matuo, Ryuji Yasumatsu, Keishi Sugimachi, Masaru Morita, Tetsuya Kusumoto, Kengo Fukuzawa, Naoya Yoshida, Hideo Baba, Masaki Mori

    Surgery today   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00595-021-02305-6

  • Prognostic significance of systemic inflammation score in patients who undergo hepatic resection for hepatocellular carcinoma Reviewed International journal

    Inokuchi, Shoichi; Itoh, Shinji; Yoshizumi, Tomoharu; Morinaga, Akinari; Toshima, Takeo; Takeishi, Kazuki; Nagao, Yoshihiro; Harada, Noboru; Ikegami, Toru; Shimokawa, Mototsugu; Mori, Masaki

    LANGENBECKS ARCHIVES OF SURGERY   406 ( 3 )   773 - 779   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00423-021-02103-1

  • Which is better to use "body weight" or "standard liver weight", for predicting small-for-size graft syndrome after living donor liver transplantation? Invited Reviewed International journal

    Takeo Toshima, Tomoharu Yoshizumi, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshihiro Nagao, Shinji Itoh, Noboru Harada, Masaki Mori

    Annals of gastroenterological surgery   5 ( 3 )   363 - 372   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ags3.12412

  • Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. Invited Reviewed International journal

    Sachiyo Yoshio, Tomonari Shimagaki, Ryuki Hashida, Takumi Kawaguchi, Yuriko Tsutsui, Yuzuru Sakamoto, Yuichi Yoshida, Hironari Kawai, Shiori Yoshikawa, Taiji Yamazoe, Taizo Mori, Yosuke Osawa, Shinji Itoh, Moto Fukai, Tomoharu Yoshizumi, Akinobu Taketomi, Masaki Mori, Tatsuya Kanto

    Hepatology research : the official journal of the Japan Society of Hepatology   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.13667

  • A no-ligation technique to prevent intraoperative hepatic artery dissection in living-donor liver transplantation Invited Reviewed International journal

    Itoh, Shinji; Yoshizumi, Tomoharu; Harada, Noboru; Toshima, Takeo; Nagao, Yoshihiro; Kurihara, Takeshi; Wang, Huanlin; Shimagaki, Tomonari; Ikegami, Toru; Mori, Masaki

    SURGERY TODAY   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00595-021-02276-8

  • ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma Reviewed International journal

    Iseda, Norifumi; Itoh, Shinji; Yoshizumi, Tomoharu; Yugawa, Kyohei; Morinaga, Akinari; Tomiyama, Takahiro; Toshima, Takeo; Kohashi, Kenichi; Oda, Yoshinao; Mori, Masaki

    HEPATOLOGY COMMUNICATIONS   5 ( 4 )   675 - 688   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep4.1659

  • Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes Reviewed International journal

    Yugawa, Kyohei; Itoh, Shinji; Yoshizumi, Tomoharu; Iseda, Norifumi; Tomiyama, Takahiro; Toshima, Takeo; Harada, Noboru; Kohashi, Kenichi; Oda, Yoshinao; Mori, Masaki

    MODERN PATHOLOGY   34 ( 4 )   798 - 807   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41379-020-00702-9

  • Suppression of optineurin impairs the progression of hepatocellular carcinoma through regulating mitophagy Reviewed International journal

    Inokuchi, Shoichi; Yoshizumi, Tomoharu; Toshima, Takeo; Itoh, Shinji; Yugawa, Kyohei; Harada, Noboru; Mori, Hiroyuki; Fukuhara, Takasuke; Matsuura, Yoshiharu; Mori, Masaki

    CANCER MEDICINE   10 ( 5 )   1501 - 1514   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cam4.3519

  • Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status Reviewed International journal

    Yugawa, Kyohei; Itoh, Shinji; Iseda, Norifumi; Kurihara, Takeshi; Kitamura, Yoshiyuki; Toshima, Takeo; Harada, Noboru; Kohashi, Kenichi; Baba, Shingo; Ishigami, Kousei; Oda, Yoshinao; Yoshizumi, Tomoharu; Mori, Masaki

    SCIENTIFIC REPORTS   11 ( 1 )   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-021-85186-6

  • CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma Reviewed International journal

    Yugawa, Kyohei; Itoh, Shinji; Yoshizumi, Tomoharu; Iseda, Norifumi; Tomiyama, Takahiro; Morinaga, Akinari; Toshima, Takeo; Harada, Noboru; Kohashi, Kenichi; Oda, Yoshinao; Mori, Masaki

    HEPATOLOGY COMMUNICATIONS   5 ( 2 )   334 - 348   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/hep4.1643

  • Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p Reviewed International journal

    Yugawa, Kyohei; Yoshizumi, Tomoharu; Mano, Yohei; Itoh, Shinji; Harada, Noboru; Ikegami, Toru; Kohashi, Kenichi; Oda, Yoshinao; Mori, Masaki

    EJSO   47 ( 2 )   384 - 393   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ejso.2020.08.002

  • Simultaneous splenectomy improves outcomes after adult living donor liver transplantation Reviewed International journal

    Yoshizumi, Tomoharu; Itoh, Shinji; Shimokawa, Mototsugu; Inokuchi, Shoichi; Harada, Noboru; Takeishi, Kazuki; Mano, Yohei; Yoshiya, Shohei; Kurihara, Takeshi; Nagao, Yoshihiro; Ikegami, Toru; Soejima, Yuji; Mori, Masaki

    JOURNAL OF HEPATOLOGY   74 ( 2 )   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jhep.2020.08.017

  • Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma Invited Reviewed International journal

    Suzuki, Hideo; Kohjima, Motoyuki; Tanaka, Masatake; Goya, Takeshi; Itoh, Shinji; Yoshizumi, Tomoharu; Mori, Masaki; Tsuda, Mariko; Takahashi, Motoi; Kurokawa, Miho; Imoto, Koji; Tashiro, Shigeki; Kuwano, Akifumi; Kato, Masaki; Okada, Seiji; Nakamuta, Makoto; Ogawa, Yoshihiro

    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   2021   2021.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1155/2021/8813410

  • Immune microenvironment in primary and metastatic liver cancers Invited Reviewed International journal

    Itoh, Shinji; Yugawa, Kyohei; Yoshizumi, Tomoharu; Oda, Yoshinao; Mori, Masaki

    HEPATOLOGY RESEARCH   51 ( 1 )   3 - 4   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.13607

  • Which is better to use "body weight" or "standard liver weight", for predicting small-for-size graft syndrome after living donor liver transplantation? Reviewed International journal

    Toshima, Takeo; Yoshizumi, Tomoharu; Shimagaki, Tomonari; Wang, Huanlin; Kurihara, Takeshi; Nagao, Yoshihiro; Itoh, Shinji; Harada, Noboru; Mori, Masaki

    ANNALS OF GASTROENTEROLOGICAL SURGERY   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ags3.12412

  • Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Reviewed International journal

    Kojiro Hata, Kimitaka Suetsugu, Nobuaki Egashira, Yoko Makihara, Shinji Itoh, Tomoharu Yoshizumi, Masatake Tanaka, Motoyuki Kohjima, Hiroyuki Watanabe, Satohiro Masuda, Ichiro Ieiri

    Cancer chemotherapy and pharmacology   86 ( 6 )   803 - 813   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00280-020-04178-x

  • Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma Reviewed International journal

    Inokuchi, Shoichi; Itoh, Shinji; Yoshizumi, Tomoharu; Yugawa, Kyohei; Yoshiya, Shohei; Toshima, Takeo; Takeishi, Kazuki; Iguchi, Tomohiro; Sanefuji, Kensaku; Harada, Noboru; Sugimachi, Keishi; Ikegami, Toru; Kohashi, Kenichi; Taguchi, Kenichi; Yonemasu, Hirotoshi; Fukuzawa, Kengo; Oda, Yoshinao; Mori, Masaki

    PANCREATOLOGY   20 ( 6 )   1175 - 1182   2020.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.pan.2020.07.011

  • Use of Mycophenolate Mofetil Suspension as Part of Induction Therapy After Living-Donor Liver Transplant Reviewed International journal

    Harada, Noboru; Yoshizumi, Tomoharu; Yoshiya, Shohei; Takeishi, Kazuki; Toshima, Takeo; Itoh, Shinji; Ikegami, Toru; Fukuda, Mio; Masuda, Satohiro; Mori, Masaki

    EXPERIMENTAL AND CLINICAL TRANSPLANTATION   18 ( 4 )   485 - 490   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.6002/ect.2020.0041

  • Association of inflammatory biomarkers with long-term outcomes after curative surgery for mass-forming intrahepatic cholangiocarcinoma Reviewed

    Masafumi Ohira, Tomoharu Yoshizumi, Kyohei Yugawa, Yukiko Kosai-Fujimoto, Shoichi Inokuchi, Takashi Motomura, Yohei Mano, Takeo Toshima, Shinji Itoh, Noboru Harada, Toru Ikegami, Yuji Soejima, Akinobu Taketomi, Masaki Mori

    Surgery today   50 ( 4 )   379 - 388   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00595-019-01905-7

  • Is sarcopenic obesity superior to sarcopenia as a predicting indicator in patients with hepatocellular carcinoma following hepatic resection? Reviewed International journal

    Itoh, Shinji; Yoshizumi, Tomoharu; Mori, Masaki

    HEPATOBILIARY SURGERY AND NUTRITION   9 ( 2 )   202 - 204   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21037/hbsn.2019.09.14

  • Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation Reviewed

    Takeo Toshima, Tomoharu Yoshizumi, Shoichi Inokuchi, Yukiko Kosai-Fujimoto, Takeshi Kurihara, Shohei Yoshiya, Yohei Mano, Kazuki Takeishi, Shinji Itoh, Noboru Harada, Toru Ikegami, Yuji Soejima, Mototsugu Shimokawa, Yoshihiko Maehara, Masaki Mori

    HPB   22 ( 4 )   511 - 520   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.hpb.2019.08.008

  • Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma Reviewed

    Masahiro Shimokawa, Tomoharu Yoshizumi, Shinji Itoh, Norifumi Iseda, Kazuhito Sakata, Kyohei Yugawa, Takeo Toshima, Noboru Harada, Toru Ikegami, Masaki Mori

    Cancer Science   111 ( 4 )   1228 - 1240   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.14320

  • Living-Donor Liver Transplantation for Patients With Extrahepatic Malignancy A Series of 14 Patients in a Single Institution Reviewed

    Yukiko Kosai-Fujimoto, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Norifumi Iseda, Shoichi Inokuchi, Kyohei Yugawa, Shohei Yoshiya, Takeo Toshima, Kazuki Takeishi, Shinji Itoh, Noboru Harada, Toru Ikegami, Masaki Mori

    Transplantation Proceedings   52 ( 3 )   889 - 893   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transproceed.2019.12.041

  • Prognostic impact of 8-hydroxy-deoxyguanosine and its repair enzyme 8-hydroxy-deoxyguanosine DNA glycosylase in hepatocellular carcinoma Reviewed

    Kyohei Yugawa, Shinji Itoh, Tomoharu Yoshizumi, Shohei Yoshiya, Kazuki Takeishi, Takeo Toshima, Noboru Harada, Toru Ikegami, Kenichi Kohashi, Yoshinao Oda, Masaki Mori

    Pathology International   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/pin.12952

  • Prognostic Impact of Osteopenia in Patients Who Underwent Living Donor Liver Transplantation for Hepatocellular Carcinoma Reviewed

    Takeo Toshima, Tomoharu Yoshizumi, Yukiko Kosai-Fujimoto, Shoichi Inokuchi, Shohei Yoshiya, Kazuki Takeishi, Shinji Itoh, Noboru Harada, Toru Ikegami, Yuji Soejima, Masaki Mori

    World journal of surgery   44 ( 1 )   258 - 267   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00268-019-05206-5

  • Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria Reviewed

    Yusuke Yonemura, Tomoharu Yoshizumi, Shoichi Inokuchi, Yukiko Kosai-Fujimoto, Noboru Harada, Shinji Itoh, Takeo Toshima, Kazuki Takeishi, Shohei Yoshiya, Masaki Mori

    Annals of Gastroenterological Surgery   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ags3.12335

  • Impact of middle hepatic artery reconstruction after living donor liver transplantation using the left lobe Reviewed

    Noboru Harada, Tomoharu Yoshizumi, Hideaki Uchiyama, Toru Ikegami, Shinji Itoh, Kazuki Takeishi, Takeo Toshima, Yoshihiro Nagao, Shohei Yoshiya, Masaki Mori

    Clinical Transplantation   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ctr.13850

  • Surgical Indications for Hepatocellular Carcinoma with Non-hypervascular Hypointense Nodules Detected by Gd-EOB-DTPA-Enhanced MRI Reviewed

    Kazuki Takeishi, Tomoharu Yoshizumi, Shinji Itoh, Kyohei Yugawa, Shohei Yoshiya, Takeo Toshima, Noboru Harada, Toru Ikegami, Akihiro Nishie, Masaki Mori

    Annals of Surgical Oncology   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-020-08419-4

  • Prognostic nutritional index is superior as a predictor of prognosis among various inflammation-based prognostic scores in patients with hepatocellular carcinoma after curative resection Reviewed

    Daisuke Imai, Takashi Maeda, Mototsugu Shimokawa, Huanlin Wang, Shohei Yoshiya, Kazuki Takeishi, Shinji Itoh, Noboru Harada, Toru Ikegami, Tomoharu Yoshizumi, Masaki Mori

    Hepatology Research   50 ( 1 )   101 - 109   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.13431

  • Extensive Thrombectomy as a Legitimate Strategy in Living Donor Liver Transplantation With Advanced Portal Vein Thrombosis Reviewed

    Toru Ikegami, Tomoharu Yoshizumi, Yuriko Tsutsui, Noboru Harada, Shinji Itoh, Shohei Yoshiya, Daisuke Imai, Hideaki Uchiyama, Masaki Mori

    Liver Transplantation   25 ( 12 )   1768 - 1777   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.25623

  • The evolution of surgical treatment for gastrointestinal cancers Reviewed

    Yoshihiko Maehara, Yuji Soejima, Tomoharu Yoshizumi, Naoyuki Kawahara, Eiji Oki, Hiroshi Saeki, Tomohiko Akahoshi, Toru Ikegami, Yo ichi Yamashita, Tadashi Furuyama, Keishi Sugimachi, Noboru Harada, Tetsuzo Tagawa, Norifumi Harimoto, Shinji Itoh, Hideto Sonoda, Koji Ando, Yuichiro Nakashima, Yoshihiro Nagao, Nami Yamashita, Yuta Kasagi, Takafumi Yukaya, Takeshi Kurihara, Ryosuke Tsutsumi, Shinkichi Takamori, Shun Sasaki, Tetsuo Ikeda, Yoshikazu Yonemitsu, Takasuke Fukuhara, Hiroyuki Kitao, Makoto Iimori, Yuki Kataoka, Takeshi Wakasa, Masami Suzuki, Koji Teraishi, Yasuto Yoshida, Masaki Mori

    International Journal of Clinical Oncology   24 ( 11 )   1333 - 1349   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-019-01499-7

  • Elevation of Mac-2 binding protein glycosylation isomer after hepatectomy is associated with post-hepatectomy liver failure, total Pringle time, and renal dysfunction Reviewed

    Daisuke Imai, Takashi Maeda, Huanlin Wang, Kensaku Sanefuji, Hiroto Kayashima, Shohei Yoshiya, Kazuki Takeishi, Shinji Itoh, Noboru Harada, Toru Ikegami, Tomoharu Yoshizumi, Masaki Mori

    Annals of Gastroenterological Surgery   3 ( 5 )   515 - 522   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ags3.12271

  • IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer Reviewed

    240   115 - 123   2019.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Tumor immune reactions not only provide host defense but also accelerate tumor immune escape and phenotype switching. Here, we examined the association of programmed cell death ligand 1 (PD-L1) expression with epithelial-mesenchymal transition (EMT)–associated markers in pancreatic ductal adenocarcinoma (PDA) within the context of the tumor microenvironment. Materials and methods: PDA samples from 36 patients were analyzed for PD-L1, vimentin, E-cadherin, and Snail expressions and for PDA cell and immune cell infiltration. PD-L1 expression and EMT in PDA cell lines under conditions of altering interferon gamma (IFN-γ) signals were also assessed. Results: Immunohistochemistry revealed a significant correlation between vimentin and PD-L1 expression, whereas double staining showed them to be simultaneously expressed by PDA cells. Positive vimentin expression was associated with the infiltration of a lower number of CD8 + T cells and a higher number of FoxP3 + cells and poor patient prognosis (P = 0.03). PDA tumor cells promoted PD-L1 expression and EMT under the presence of IFN-γ which was inhibited by the signal transducer and activator of transcription (STAT)1 small interfering RNA. Conclusions: Strong correlations were observed between PD-L1 expression, EMT, and the immunosuppressive tumor microenvironment. Targeting STAT1 combined with PD-1/PD-L1 immunotherapy may improve outcomes for patients with PDA.

    DOI: 10.1016/j.jss.2019.02.038

  • The role of DNA repair glycosylase OGG1 in intrahepatic cholangiocarcinoma Reviewed

    Kazuhito Sakata, Tomoharu Yoshizumi, Takuma Izumi, Masahiro Shimokawa, Shinji Itoh, Toru Ikegami, Noboru Harada, Takeo Toshima, Yohei Mano, Masaki Mori

    Anticancer research   39 ( 6 )   3241 - 3248   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.13465

  • Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer Reviewed

    Shohei Yoshiya, Kengo Fukuzawa, Shoichi Inokuchi, Yukiko Kosai-Fujimoto, Kensaku Sanefuji, Kentaro Iwaki, Akira Motohiro, Shinji Itoh, Noboru Harada, Toru Ikegami, Tomoharu Yoshizumi, Masaki Mori

    Journal of Gastrointestinal Surgery   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11605-019-04324-8

  • Ectopic localization of autophagosome in fatty liver is a key factor for liver regeneration Reviewed

    Yoshihiro Matsumoto, Tomoharu Yoshizumi, Takeo Toshima, Kazuki Takeishi, Takasuke Fukuhara, Shinji Itoh, Toru Ikegami, Yuji Soejima, Masaki Mori

    Organogenesis   15 ( 1 )   24 - 34   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/15476278.2019.1633872

  • Skeletal muscle mass predicts the prognosis of patients with intrahepatic cholangiocarcinoma Reviewed

    Kyohei Yugawa, shinji itoh, Takeshi Kurihara, Shohei Yoshiya, Yohei Mano, kazuki takeishi, Noboru Harada, Toru Ikegami, Yuji Soejima, Masaki Mori, Tomoharu Yoshizumi

    American Journal of Surgery   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.amjsurg.2019.03.010

  • Impact of hepatic artery size mismatch between donor and recipient on outcomes after living-donor liver transplantation using the right lobe Reviewed

    Noboru Harada, Tomoharu Yoshizumi, Hideaki Uchiyama, Yuji Soejima, Toru Ikegami, shinji itoh

    Clinical Transplantation   33 ( 1 )   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ctr.13444

  • Feasibility of All-in-One Venoplasty With a Venous Cuff Using an Opened Round Ligament for the Right Lobe Graft in Living Donor Liver Transplantation Reviewed

    Takeo Toshima, Tomoharu Yoshizumi, Masahiro Shimokawa, Toru Ikegami, Noboru Harada, shinji itoh, Yohei Mano, Takashi Motomura, Yuji Soejima, Yoshihiko Maehara

    Liver Transplantation   25 ( 1 )   171 - 175   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.25339

  • Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver Reviewed

    N. Harimoto, H. Nakagawara, K. Shirabe, Tomoharu Yoshizumi, shinji itoh, Toru Ikegami, Yuji Soejima, Y. Maehara, Y. Ishida, C. Tateno, Y. Tanaka

    Transplantation Proceedings   50 ( 10 )   3858 - 3862   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transproceed.2018.06.035

  • Impact of osteopenia in liver cirrhosis Special reference to standard bone mineral density with age Reviewed

    Takeo Toshima, Tomoharu Yoshizumi, Toru Ikegami, Noboru Harada, shinji itoh, Yohei Mano, Takashi Motomura, Yuji Soejima, Yoshihiko Maehara

    Anticancer research   38 ( 11 )   6465 - 6471   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.13009

  • Lymphocyte-to-Monocyte Ratio Is a Predictor of Survival After Liver Transplantation for Hepatocellular Carcinoma Reviewed

    Yohei Mano, Tomoharu Yoshizumi, Kyohei Yugawa, Masafumi Ohira, Takashi Motomura, Takeo Toshima, shinji itoh, Noboru Harada, Toru Ikegami, Yuji Soejima, Yoshihiko Maehara

    Liver Transplantation   24 ( 11 )   1603 - 1611   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.25204

  • Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma A Multi-institutional Study Reviewed

    Norifumi Harimoto, Tomoharu Yoshizumi, Shoichi Inokuchi, shinji itoh, Eisuke Adachi, Yasuharu Ikeda, Hideaki Uchiyama, Tohru Utsunomiya, Kiyoshi Kajiyama, Koichi Kimura, Fumiaki Kishihara, Keishi Sugimachi, Eiji Tsujita, Mizuki Ninomiya, Kengo Fukuzawa, Takashi Maeda, Ken Shirabe, Yoshihiko Maehara

    Annals of Surgical Oncology   25 ( 11 )   3316 - 3323   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-018-6672-6

  • Serum asunaprevir and daclatasvir concentrations and outcomes in patients with recurrent hepatitis C who have undergone living donor liver transplantation Reviewed

    Noboru Harada, Tomoharu Yoshizumi, Toru Ikegami, shinji itoh, Norihiro Furusho, Masaki Kato, Shinji Shimoda, Takasuke Fukuhara, Yuji Soejima, Yoshihiko Maehara

    Anticancer research   38 ( 9 )   5513 - 5520   2018.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.12885

  • Long-term Outcomes and Risk Factors after Adult Living Donor Liver Transplantation Reviewed

    Daisuke Imai, Tomoharu Yoshizumi, Kazuhito Sakata, Toru Ikegami, shinji itoh, Noboru Harada, Takashi Motomura, Takeo Toshima, Yohei Mano, Yuji Soejima, Yoshihiko Maehara

    Transplantation   102 ( 9 )   e382 - e391   2018.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/TP.0000000000002324

  • Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma Reviewed

    Hirohisa Okabe, Tomoharu Yoshizumi, Yo Ichi Yamashita, Katsunori Imai, Hiromitsu Hayashi, Shigeki Nakagawa, shinji itoh, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Toru Beppu, Shinichi Aishima, Ken Shirabe, Hideo Baba, Yoshihiko Maehara

    PloS one   13 ( 9 )   2018.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0203856

  • Impact of Splenic Volume and Splenectomy on Prognosis of Hepatocellular Carcinoma Within Milan Criteria After Curative Hepatectomy Reviewed

    Kazuki Takeishi, Hirofumi Kawanaka, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Ken Shirabe, Yoshihiko Maehara

    World Journal of Surgery   42 ( 4 )   1120 - 1128   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00268-017-4232-z

  • Potential effect of recombinant thrombomodulin on ischemia–reperfusion liver injury in rats Reviewed

    48 ( 5 )   391 - 396   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aim: Liver ischemia–reperfusion (I/R) injury is a severe complication of liver surgery. However, the responsible molecular mechanism remains unclear. High-mobility group box 1 (HMGB1) is released from the nuclei of cells and behaves as a damage-associated molecular pattern. The aim of this study is to reveal the roles of HMGB1 and the effects of recombinant thrombomodulin (rTM) in I/R liver injury. Methods: Rats underwent partial hepatic ischemia followed by reperfusion, and changes in HMGB1 were assessed. Recombinant thrombomodulin was used as an inhibitor of HMGB1. Results: In rats with I/R injury, the HMGB1 level significantly decreased in the liver tissue and significantly increased in the serum after surgery (P < 0.001 for both). No difference in the HMGB1 level in the hepatocytes was observed between the rTM(−) group and rTM(+) group after surgery. Conversely, the serum HMGB1 level was significantly lower in the rTM(+) group than the rTM(−) group after surgery (P < 0.001). The levels of tumor necrosis factor-α and interleukin-6 in the liver tissue 24 h after surgery were significantly lower in the rTM(+) group than the rTM(−) group (P < 0.001). The plasma alanine aminotransferase level at 24 h after surgery of the rTM(+) group was significantly decreased after surgery compared with that of the rTM(−) group (P < 0.001). The necrotic area of the liver tissue 24 h after surgery was significantly smaller in the rTM(+) group than the rTM(−) group (P < 0.001). Conclusions: Recombinant thrombomodulin can serve as a treatment for I/R liver injury by inhibiting HMGB1.

    DOI: 10.1111/hepr.13005

  • Associations between antibody to hepatitis B core antigen positivity and outcomes in hepatocellular carcinoma patients undergoing hepatic resection Reviewed

    shinji itoh, Tomoharu Yoshizumi, Takahiro Tomino, Akihisa Nagatsu, Takashi Motomura, Noboru Harada, Norifumi Harimoto, Toru Ikegami, Yuji Soejima, Yoshihiko Maehara

    Hepatology Research   48 ( 3 )   E155 - E161   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.12939

  • Customization of laparoscopic gastric devascularization and splenectomy for gastric varices based on CT vascular anatomy Reviewed

    Hirofumi Kawanaka, Tomohiko Akahoshi, Yoshihiro Nagao, Nao Kinjo, Daisuke Yoshida, Yoshihiro Matsumoto, Norifumi Harimoto, shinji itoh, Tomoharu Yoshizumi, Yoshihiko Maehara

    Surgical Endoscopy   32 ( 1 )   114 - 126   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00464-017-5646-2

  • Slow Gait Speed Is a Risk Factor for Complications After Hepatic Resection Reviewed

    shinji itoh, Tomoharu Yoshizumi, Kazuhisa Sakata, Takashi Motomura, Yohei Mano, Takeo Toshima, Norifumi Harimoto, Noboru Harada, Toru Ikegami, Yuji Soejima, Ryuichi Kusaba, Takahide Kamishima, Akihiro Nishie, Yoshihiko Maehara

    Journal of Gastrointestinal Surgery   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11605-018-3993-5

  • Surgery for Hepatocellular Carcinoma in Patients with Child–Pugh B Cirrhosis Hepatic Resection Versus Living Donor Liver Transplantation Reviewed

    1 - 11   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Liver transplantation has been established as the optimal treatment for hepatocellular carcinoma in cirrhotic patients, but hepatic resection is also effective in patients with well-preserved liver function. Determining the suitable surgical treatment for patients with Child–Pugh class B cirrhosis is a more difficult challenge.Methods: We retrospectively compared the results of hepatic resection and living donor liver transplantation for hepatocellular carcinoma in 137 patients with Child–Pugh class B cirrhosis. The procedures were performed at Kyushu University Hospital from April 2014 through October 2016. Results: Patients who underwent hepatic resection were significantly older and had better liver function, larger tumor size, smaller number of tumors, and less surgical stress compared with patients who underwent living donor liver transplantation. The overall survival rate and the recurrence-free survival rate in patients with transplantation were significantly better than that in patients with resection. The multivariate analysis showed that recurrent hepatocellular carcinoma and microvascular invasion were significant prognostic factors for both overall and recurrence-free survival in the hepatic resection group. In the group with protein induced by vitamin K absence or antagonist-II ≥300 mAU/mL, both the overall survival curve and the recurrence-free survival curve in patients with living donor liver transplantation were not significantly different from those in patients with hepatic resection. Conclusions: Living donor liver transplantation for hepatocellular carcinoma in patients with Child–Pugh class B cirrhosis was favorable under the condition of protein induced by vitamin K absence or antagonist-II <300 mAU/mL in selected recipients and donors. Hepatic resection for recurrent hepatocellular carcinoma and excessive blood loss should be avoided in patients with Child–Pugh class B cirrhosis.

    DOI: 10.1007/s00268-018-4493-1

  • Hepatobiliary and Pancreatic Pregnancy induced hepatic veno-occlusive disease requiring liver transplantation Reviewed

    Norifumi Harimoto, K. Yugawa, Toru Ikegami, M. Ohira, Yohei Mano, T. Motomura, Takeo Toshima, shinji itoh, N. Harada, Yuji Soejima, Tomoharu Yoshizumi, Yoshihiko Maehara, Yoshinao Oda

    Journal of Gastroenterology and Hepatology (Australia)   33 ( 1 )   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jgh.13975

  • Living donor liver transplantation for hepatocellular carcinoma results of prospective patient selection by Kyushu University Criteria in 7 years Reviewed

    Hideaki Uchiyama, shinji itoh, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, Yuji Soejima, Noboru Harada, Kazutoyo Morita, Takeo Toshima, Takashi Motomura, Yoshihiko Maehara

    HPB   19 ( 12 )   1082 - 1090   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.hpb.2017.08.004

  • Clinical Outcomes of Living Liver Transplantation According to the Presence of Sarcopenia as Defined by Skeletal Muscle Mass, Hand Grip, and Gait Speed Reviewed

    Norifumi Harimoto, Tomoharu Yoshizumi, T. Izumi, T. Motomura, Noboru Harada, shinji itoh, Toru Ikegami, H. Uchiyama, Yuji Soejima, Akihiro Nishie, T. Kamishima, R. Kusaba, K. Shirabe, Yoshihiko Maehara

    Transplantation Proceedings   49 ( 9 )   2144 - 2152   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transproceed.2017.09.017

  • Prognostic significance of combined albumin–bilirubin and tumor–node–metastasis staging system in patients who underwent hepatic resection for hepatocellular carcinoma Reviewed

    47 ( 12 )   1289 - 1298   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: In recent years, the establishment of new staging systems for hepatocellular carcinoma (HCC) has been reported worldwide. The system combining albumin–bilirubin (ALBI) with tumor–node–metastasis stage, developed by the Liver Cancer Study Group of Japan, was called the ALBI-T score. Methods: Patient data were retrospectively collected for 357 consecutive patients who had undergone hepatic resection for HCC with curative intent between January 2004 and December 2015. The overall survival and recurrence-free survival were compared by the Kaplan–Meier method, using different staging systems: the Japan integrated staging (JIS), modified JIS, and ALBI-T. Results: Multivariate analysis identified five poor prognostic factors (higher age, poor differentiation, the presence of microvascular invasion, the presence of intrahepatic metastasis, and blood transfusion) that influenced overall survival, and four poor prognostic factors (the presence of intrahepatic metastasis, serum α-fetoprotein level, blood transfusion, and each staging system (JIS, modified JIS, and ALBI-T score)) that influenced recurrence-free survival. Patients for each these three staging system had a significantly worse prognosis regarding recurrence-free survival, but not with overall survival. The modified JIS score showed the lowest Akaike information criteria statistic value, indicating it had the best ability to predict overall survival compared with the other staging systems. Conclusions: This retrospective analysis showed that, in post-hepatectomy patients with HCC, the ALBI-T score is predictive of worse recurrence-free survival, even when adjustments are made for other known predictors. However, modified JIS is better than ALBI-T in predicting overall survival.

    DOI: 10.1111/hepr.12868

  • Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma Reviewed

    Norifumi Harimoto, Tomoharu Yoshizumi, Kazuhito Sakata, Akihisa Nagatsu, Takashi Motomura, shinji itoh, Noboru Harada, Toru Ikegami, Hideaki Uchiyama, Yuji Soejima, Yoshihiko Maehara

    World Journal of Surgery   41 ( 11 )   2805 - 2812   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00268-017-4097-1

  • p62 Promotes Amino Acid Sensitivity of mTOR Pathway and Hepatic Differentiation in Adult Liver Stem/Progenitor Cells Reviewed

    Masakazu Sugiyama, Tomoharu Yoshizumi, Yoshihiro Yoshida, Yuki Bekki, Yoshihiro Matsumoto, Shohei Yoshiya, Takeo Toshima, Toru Ikegami, shinji itoh, Norifumi Harimoto, Shinji Okano, Yuji Soejima, Ken Shirabe, Yoshihiko Maehara

    Journal of Cellular Physiology   232 ( 8 )   2112 - 2124   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/jcp.25653

  • The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer Reviewed

    Daisuke Imai, Tomoharu Yoshizumi, Shinji Okano, Hideaki Uchiyama, Toru Ikegami, Norifumi Harimoto, shinji itoh, Yuji Soejima, Shinichi Aishima, Yoshinao Oda, Yoshihiko Maehara

    Cancer Medicine   6 ( 7 )   1614 - 1626   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/cam4.1087

  • Impact and prediction of lymph node involvement in patients with intrahepatic cholangiocarcinoma after curative resection Reviewed

    Noboru Harada, Tomoharu Yoshizumi, Yo Ichi Yamashita, Yuji Soejima, Toru Ikegami, Norifumi Harimoto, shinji itoh, Yoshihiko Maehara

    Anticancer Research   37 ( 7 )   3763 - 3769   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanreS.11751

  • Hepatic stellate cells secreting WFA+-M2BP Its role in biological interactions with Kupffer cells Reviewed

    Yuki Bekki, Tomoharu Yoshizumi, Shinji Shimoda, shinji itoh, Norifumi Harimoto, Toru Ikegami, Atsushi Kuno, Hisashi Narimatsu, Ken Shirabe, Yoshihiko Maehara

    Journal of Gastroenterology and Hepatology (Australia)   32 ( 7 )   1387 - 1393   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/jgh.13708

  • Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators Reviewed

    Hirohisa Okabe, Daisuke Hashimoto, Akira Chikamoto, Morikatsu Yoshida, Katsunobu Taki, Kota Arima, Katsunori Imai, Yoshitaka Tamura, Osamu Ikeda, Takatoshi Ishiko, Hideaki Uchiyama, Toru Ikegami, Norifumi Harimoto, shinji itoh, Yo ichi Yamashita, Tomoharu Yoshizumi, Toru Beppu, Yasuyuki Yamashita, Hideo Baba, Yoshihiko Maehara

    Annals of Surgical Oncology   24 ( 5 )   1399 - 1405   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-016-5630-4

  • Surgical treatment and outcome of patients with de novo lung cancer after liver transplantation Reviewed

    Fumihiro Shoji, Gouji Toyokawa, Noboru Harada, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tatsuro Okamoto, Yuji Soejima, Tomoharu Yoshizumi, Yoshihiko Maehara

    Anticancer Research   37 ( 5 )   2619 - 2623   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11608

  • Pleural Effusion After Hepatectomy for Hepatocellular Carcinoma Risk Factor Analyses and Its Impact on Oncological Outcomes Reviewed

    Hideaki Uchiyama, Norifumi Harimoto, shinji itoh, Tomoharu Yoshizumi, Toru Ikegami, Yoshihiko Maehara

    World Journal of Surgery   41 ( 4 )   1089 - 1099   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00268-016-3826-1

  • Functional remnant liver assessment predicts liver-related morbidity after hepatic resection in patients with hepatocellular carcinoma Reviewed

    shinji itoh, Tomoharu Yoshizumi, Ken Shirabe, Koichi Kimura, Hirohisa Okabe, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Akihiro Nishie, Yoshihiko Maehara

    Hepatology Research   47 ( 5 )   398 - 404   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.12761

  • Preoperative pancreatic stiffness by real-time tissue elastography to predict pancreatic fistula after pancreaticoduodenectomy Reviewed

    Noboru Harada, Tomoharu Yoshizumi, Takashi Maeda, Hiroto Kayashima, Toru Ikegami, Norifumi Harimoto, shinji itoh, Yoshihiko Maehara

    Anticancer Research   37 ( 4 )   1909 - 1915   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11529

  • Post-hepatectomy refractory ascites in cirrhotic patients with hepatocellular carcinoma Risk factor analysis to overcome this problematic complication Reviewed

    shinji itoh, Hideaki Uchiyama, Yasuharu Ikeda, Kazutoyo Morita, Noboru Harada, Keishi Sugimachi, Hirofumi Kawanaka, Daisuke Korenaga, Tomoharu Yoshizumi, Kenji Takenaka, Yoshihiko Maehara

    Anticancer Research   37 ( 3 )   1381 - 1385   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11459

  • Surgical resection for lymph node metastasis after liver transplantation for hepatocellular carcinoma Reviewed

    Toru Ikegami, Tomoharu Yoshizumi, Jyunji Kawasaki, Akihisa Nagatsu, Hideaki Uchiyama, Noboru Harada, Norifumi Harimoto, shinji itoh, Takashi Motomura, Yuji Soejima, Yoshihiko Maehara

    Anticancer Research   37 ( 2 )   891 - 896   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11395

  • Eversion technique to prevent biliary stricture after living donor liver transplantation in the universal minimal hilar dissection era Reviewed

    Toru Ikegami, Tomonari Shimagaki, Junji Kawasaki, Tomoharu Yoshizumi, Hideaki Uchiyama, Noboru Harada, Norifumi Harimoto, shinji itoh, Yuji Soejima, Yoshihiko Maehara

    Transplantation   101 ( 1 )   e20 - e25   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/TP.0000000000001533

  • Surgical resection of giant pheochromocytomas arising behind the retrohepatic inferior vena cava Reviewed

    Yuji Soejima, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, shinji itoh, Noboru Harada, Takashi Motomura, Akihisa Nagatsu, Tetsuo Ikeda, Yoshihiko Maehara

    Anticancer Research   37 ( 1 )   277 - 280   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11318

  • Role of autophagy in liver regeneration

    Takeo Toshima, Ken Shirabe, Yoshihiro Matsumoto, Shinji Itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Yoshihiko Maehara

    Autophagy Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging Volume 12   451 - 461   2017.1

     More details

    Language:English  

    DOI: 10.1016/B978-0-12-812146-7.00023-8

  • Use of internal jugular vein grafts in reconstructing multiple venous orifices of right hepatic grafts without the middle hepatic vein trunk Reviewed

    Hideaki Uchiyama, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, shinji itoh, Hirohisa Okabe, Yuji Soejima, Yoshihiko Maehara

    Liver Transplantation   23 ( 1 )   110 - 116   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.24644

  • Left lobe living donor liver transplantation in adults What is the safety limit? Reviewed

    Toru Ikegami, Tomoharu Yoshizumi, Kazuhito Sakata, Hideaki Uchiyama, Norifumi Harimoto, Noboru Harada, shinji itoh, Akihisa Nagatsu, Yuji Soejima, Yoshihiko Maehara

    Liver Transplantation   22 ( 12 )   1666 - 1675   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.24611

  • The learning curves in living donor hemiliver graft procurement using small upper midline incision Reviewed

    Toru Ikegami, Norifumi Harimoto, Masahiro Shimokawa, Tomoharu Yoshizumi, Hideaki Uchiyama, shinji itoh, Norihisa Okabe, Kazuhito Sakata, Akihisa Nagatsu, Yuji Soejima, Yoshihiko Maehara

    Clinical Transplantation   30 ( 12 )   1532 - 1537   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ctr.12850

  • Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma Reviewed

    46 ( 12 )   1247 - 1255   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aim: The present study investigated the effect of sarcopenia on short- and long-term surgical outcomes and identified potential prognostic factors for hepatocellular carcinoma (HCC) following hepatectomy among patients 70 years of age and older. Methods: Patient data were retrospectively collected for 296 consecutive patients who underwent hepatectomy for HCC with curative intent. Patients were assigned to two groups according to age (younger than 70 years, and 70 years and older), and the presence of sarcopenia. The clinicopathological, surgical outcome, and long-term survival data were analyzed. Results: Sarcopenia was present in 112 of 296 (37.8%) patients with HCC, and 35% of patients aged 70 years and older. Elderly patients had significantly lower serum albumin levels, prognostic nutrition index, percentage of liver cirrhosis, and histological intrahepatic metastasis compared with patients younger than 70 years. Overall survival and disease-free survival rates in patients with sarcopenia correlated with significantly poor prognosis in the group aged 70 years and older. Multivariate analysis revealed that sarcopenia was predictive of an unfavorable prognosis. Conclusion: This retrospective analysis revealed that sarcopenia was predictive of worse overall survival and recurrence-free survival after hepatectomy in patients 70 years of age and older with HCC.

    DOI: 10.1111/hepr.12674

  • Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma Reviewed

    Norifumi Harimoto, Tomoharu Yoshizumi, Tomonari Shimagaki, Akihisa Nagatsu, Takashi Motomura, Noboru Harada, Hirohisa Okabe, shinji itoh, Toru Ikegami, Hideaki Uchiyama, Yuji Soejima, Yoshihiko Maehara

    Anticancer Research   36 ( 10 )   5537 - 5542   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.11137

  • The use of left grafts with a replaced or accessory left hepatic artery in adult-to-adult living donor liver transplantation analyses of donor and recipient outcomes Reviewed

    Hideaki Uchiyama, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, shinji itoh, Hirohisa Okabe, Koichi Kimura, Yoshihiko Maehara

    Clinical Transplantation   30 ( 9 )   1021 - 1027   2016.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ctr.12783

  • Validity of hepatic or pancreatic resection for elderly patients aged 85 years or older at a single community hospital in Japan Reviewed

    shinji itoh, Shunji Kohnoe, Ken Shirabe, Daisuke Yoshida, Hirofumi Kawanaka, Tomoharu Yoshizumi, Toru Ikegami, Yo Ichi Yamashita, Takeshi Kurihara, Yoshihiko Maehara

    Anticancer Research   36 ( 8 )   4289 - 4292   2016.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Graft selection strategy in adult-to-adult living donor liver transplantation When both hemiliver grafts meet volumetric criteria Reviewed

    Takeshi Kurihara, Tomoharu Yoshizumi, Yoshihiro Yoshida, Toru Ikegami, shinji itoh, Norifumi Harimoto, Mizuki Ninomiya, Hideaki Uchiyama, Hirohisa Okabe, Koichi Kimura, Hirofumi Kawanaka, Ken Shirabe, Yoshihiko Maehara

    Liver Transplantation   22 ( 7 )   914 - 922   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.24431

  • Inquiries About Biomarkers of Acute Liver Failure in Patients Who Underwent Living Donor Liver Transplantation Using a Protein Chip Array Reviewed

    Yo ichi Yamashita, Tomoharu Yoshizumi, Toru Ikegami, Hideaki Uchiyama, Eiji Tsujita, shinji itoh, Norifumi Harimoto, Yuji Soejima, Akinobu Taketomi, Hideo Baba, Yoshihiko Maehara

    Fukuoka Acta Medica   107 ( 7 )   131 - 135   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Effect of sarcopenic obesity on outcomes of living-donor liver transplantation for hepatocellular carcinoma Reviewed

    shinji itoh, Tomoharu Yoshizumi, Koichi Kimura, Hirohisa Okabe, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Ken Shirabe, Akihiro Nishie, Yoshihiko Maehara

    Anticancer Research   36 ( 6 )   3029 - 3034   2016.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation Reviewed

    Kazutoyo Morita, Ken Shirabe, Akinobu Taketomi, Yuji Soejima, Tomoharu Yoshizumi, Hideaki Uchiyama, Toru Ikegami, Yo Ichi Yamashita, Keishi Sugimachi, Norifumi Harimoto, shinji itoh, Tetsuo Ikeda, Yoshihiko Maehara

    Liver Transplantation   22 ( 5 )   665 - 676   2016.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.24400

  • CURRENT STATUS OF HEPATOBILIARY PANCREATIC SURGERY FOR ELDERLY PATIENTS Reviewed

    Tomoharu Yoshizumi, Norifumi Harimoto, shinji itoh, Toru Ikegami, Hideaki Uchiyama, Tetsuo Ikeda, Yoshihiko Maehara

    Nihon Geka Gakkai zasshi   117 ( 3 )   174 - 181   2016.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Diverse basis of β-catenin activation in human hepatocellular carcinoma Implications in biology and prognosis Reviewed

    11 ( 4 )   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aim: β-catenin signaling is a major oncogenic pathway in hepatocellular carcinoma (HCC). Since β-catenin phosphorylation by glycogen synthase kinase 3β (GSK3β) and casein kinase 1ϵ (CK1ϵ) results in its degradation, mutations affecting these phosphorylation sites cause β-catenin stabilization. However, the relevance of missense mutations in non-phosphorylation sites in exon 3 remains unclear. The current study explores significance of such mutations in addition to addressing the clinical and biological implications of β-catenin activation in human HCC. Methods: Gene alteration in exon3 of CTNNB1, gene expression of β-catenin targets such as glutamate synthetase (GS), axin2, lect2 and regucalcin (RGN), and protein expression of β-catenin were examined in 125 human HCC tissues. Results: Sixteen patients (12.8%) showed conventional missense mutations affecting codons 33, 37, 41, and 45. Fifteen additional patients (12.0%) had other missense mutations in codon 32, 34, and 35. Induction of exon3 mutation caused described β-catenin target gene upregulation in HCC cell line. Interestingly, conventional and non-phosphorylation site mutations were equally associated with upregulation of β-catenin target genes. Nuclear localization of β-catenin was associated with poor overall survival (p = 0.0461). Of these patients with nuclear β-catenin localization, loss of described β-catenin target gene upregulation showed significant poorer overall survival than others (p = 0.0001). Conclusion: This study suggests that both conventional and other missense mutations in exon 3 of CTNNB1 lead to β-catenin activation in human HCC. Additionally, the mechanism of nuclear β-catenin localization without upregulation of described β-catenin target genes might be of clinical importance depending on distinct mechanism.

    DOI: 10.1371/journal.pone.0152695

  • Skeletal muscle mass assessed by computed tomography correlates to muscle strength and physical performance at a liver-related hospital experience Reviewed

    shinji itoh, Ken Shirabe, Tomoharu Yoshizumi, Kazuki Takeishi, Norifumi Harimoto, Toru Ikegami, Hirofumi Kawanaka, Akihiro Nishie, Takahide Kamishima, Yoshihiko Maehara

    Hepatology Research   46 ( 4 )   292 - 297   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.12537

  • Living donor liver transplantation for intrahepatic arteriovenous fistula with hepatic artery reconstruction using the right gastroepiploic artery Reviewed

    Hideaki Uchiyama, Ken Shirabe, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, shinji itoh, Koichi Kimura, Hirohisa Okabe, Yoshihiko Maehara

    Liver Transplantation   22 ( 4 )   552 - 556   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.24377

  • Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation Reviewed

    Toru Ikegami, Tomoharu Yoshizumi, Yoshihro Yoshida, Takeshi Kurihara, Norifumi Harimoto, shinji itoh, Masahiro Shimokawa, Takasuke Fukuhara, Ken Shirabe, Yoshihiko Maehara

    Hepatology Research   46 ( 3 )   E136 - E145   2016.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.12546

  • A Cohort Study for Derivation and Validation of Early Detection of Pancreatic Fistula After Pancreaticoduodenectomy Reviewed

    Kazuki Takeishi, Takashi Maeda, Yo ichi Yamashita, Eiji Tsujita, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Ken Shirabe, Yoshihiko Maehara

    Journal of Gastrointestinal Surgery   20 ( 2 )   385 - 391   2016.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11605-015-3030-x

  • Predictors of Benign Status in Liver Tumors Under 3 cm in Diameter Misdiagnosed as Hepatocellular Carcinoma Reviewed

    Koichi Kimura, shinji itoh, Takeshi Kurihara, Yoshihiro Yoshida, Huanlin Wang, Norifumi Harimoto, Akihiro Nishie, Ken Shirabe, Yoshinao Oda, Yoshihiko Maehara

    Anticancer Research   36 ( 2 )   793 - 797   2016.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Impact of recombinant human soluble thrombomodulin for disseminated intravascular coagulation Reviewed

    shinji itoh, Ken Shirabe, Shunji Kohnoe, Noriaki Sadanaga, Kiyoshi Kajiyama, Motoyuki Yamagata, Hideaki Anai, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Yoshihiko Maehara

    Anticancer Research   36 ( 5 )   2493 - 2496   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Surgical results of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma A multi-institutional retrospective study of 174 patients Reviewed

    Yo Ichi Yamashita, Tomoharu Yoshizumi, Kengo Fukuzawa, Takashi Nishizaki, Eiji Tsujita, Kiyoshi Kajiyama, Yuji Soejima, Motoyuki Yamagata, Kazuharu Yamamoto, Eisuke Adachi, Keishi Sugimachi, Yasuharu Ikeda, Hideaki Uchiyama, Takashi Maeda, shinji itoh, Norifumi Harimoto, Toru Ikegami, Yoshihiko Maehara

    Anticancer Research   36 ( 5 )   2407 - 2412   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Living Donor Liver Transplantation for Hepatocellular Carcinoma within Milan Criteria in the Present Era Reviewed

    Tomoharu Yoshizumi, Norifumi Harimoto, shinji itoh, Hirohisa Okabe, Koichi Kimura, Hideaki Uchiyama, Toru Ikegami, Tetsuo Ikeda, Yoshihiko Maehara

    Anticancer Research   36 ( 1 )   439 - 445   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Ischemia-reperfusion injury in fatty liver is mediated by activated NADPH oxidase 2 in rats Reviewed

    Koichi Kimura, Ken Shirabe, Tomoharu Yoshizumi, Kazuki Takeishi, shinji itoh, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Shinji Okano, Yoshihiko Maehara

    Transplantation   100 ( 4 )   791 - 800   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/TP.0000000000001130

  • Impact of recombinant human soluble thrombomodulin for disseminated intravascular coagulation Reviewed

    shinji itoh, Ken Shirabe, Shunji Kohnoe, Noriaki Sadanaga, Kiyoshi Kajiyama, Motoyuki Yamagata, Hideaki Anai, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Yoshihiko Maehara

    Anticancer Research   36 ( 5 )   2493 - 2496   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Favorable Outcomes of Hepatectomy for Ruptured Hepatocellular Carcinoma Retrospective Analysis of Primary R0-Hepatectomized Patients Reviewed

    Hideaki Uchiyama, Ryosuke Minagawa, shinji itoh, Kiyoshi Kajiyama, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Ken Shirabe, Kenji Takenaka, Yoshihiko Maehara

    Anticancer Research   36 ( 1 )   379 - 385   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Surgical results of pancreaticoduodenectomy for pancreatic ductal adenocarcinoma A multi-institutional retrospective study of 174 patients Reviewed

    Yo Ichi Yamashita, Tomoharu Yoshizumi, Kengo Fukuzawa, Takashi Nishizaki, Eiji Tsujita, Kiyoshi Kajiyama, Yuji Soejima, Motoyuki Yamagata, Kazuharu Yamamoto, Eisuke Adachi, Keishi Sugimachi, Yasuharu Ikeda, Hideaki Uchiyama, Takashi Maeda, shinji itoh, Norifumi Harimoto, Toru Ikegami, Yoshihiko Maehara

    Anticancer Research   36 ( 5 )   2407 - 2412   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Living Donor Liver Transplantation for Hepatocellular Carcinoma within Milan Criteria in the Present Era Reviewed

    Tomoharu Yoshizumi, Norifumi Harimoto, shinji itoh, Hirohisa Okabe, Koichi Kimura, Hideaki Uchiyama, Toru Ikegami, Tetsuo Ikeda, Yoshihiko Maehara

    Anticancer Research   36 ( 1 )   439 - 445   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Ischemia-reperfusion injury in fatty liver is mediated by activated NADPH oxidase 2 in rats Reviewed

    Koichi Kimura, Ken Shirabe, Tomoharu Yoshizumi, Kazuki Takeishi, shinji itoh, Norifumi Harimoto, Toru Ikegami, Hideaki Uchiyama, Shinji Okano, Yoshihiko Maehara

    Transplantation   100 ( 4 )   791 - 800   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/TP.0000000000001130

  • Clinicopathologic Features and Outcomes of Non-B, Non-C Hepatocellular Carcinoma After Hepatectomy Reviewed

    Kazuki Takeishi, Takashi Maeda, Ken Shirabe, Eiji Tsujita, Yo ichi Yamashita, Norifumi Harimoto, shinji itoh, Toru Ikegami, Tomoharu Yoshizumi, Yoshihiko Maehara

    Annals of Surgical Oncology   22   1116 - 1124   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-015-4728-4

  • Risk factors for hepatitis B virus recurrence after living donor liver transplantation A 17-year experience at a single center Reviewed

    Sung Kwan Bae, Shinji Shimoda, Toru Ikegami, Tomoharu Yoshizumi, Norifumi Harimoto, shinji itoh, Yuji Soejima, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara

    Hepatology Research   45 ( 12 )   1203 - 1210   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.12489

  • Profile of plasma amino acids values as a predictor of sepsis in patients following living donor liver transplantation Special reference to sarcopenia and postoperative early nutrition Reviewed

    Takeo Toshima, Ken Shirabe, Takeshi Kurihara, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Hirofumi Kawanaka, Tetsuo Ikeda, Yoshihiko Maehara

    Hepatology Research   45 ( 12 )   1170 - 1177   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hepr.12484

  • Pancreatic Transection Using Tape Sling and Ultrasonic Aspirator Dissection Technique in Pancreaticoduodenectomy and Distal Pancreatectomy Reviewed

    Hideaki Uchiyama, Kazutoyo Morita, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Ken Shirabe, Kenji Takenaka, Yoshihiko Maehara

    Journal of the American College of Surgeons   221 ( 5 )   e91 - e95   2015.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2015.08.005

  • Predictors of the Effectiveness of Prophylactic Drains after Hepatic Resection Reviewed

    Yuki Bekki, Yo Ichi Yamashita, shinji itoh, Norifumi Harimoto, Ken Shirabe, Yoshihiko Maehara

    World Journal of Surgery   39 ( 10 )   2543 - 2549   2015.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00268-015-3116-3

  • Indocyanine Green Fluorescent Imaging for Hepatic Resection of the Right Hepatic Vein Drainage Area Reviewed

    Takeshi Kurihara, Yo Ichi Yamashita, Yoshihiro Yoshida, Kazuki Takeishi, shinji itoh, Norifumi Harimoto, Tomoharu Yoshizumi, Ken Shirabe, Tetsuo Ikeda, Yoshihiko Maehara

    Journal of the American College of Surgeons   221 ( 3 )   e49 - e53   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2015.05.009

  • The changes in treatment strategies in ABOi living donor liver transplantation for acute liver failure Reviewed

    Mitsuhiro Yasuda, Toru Ikegami, Daisuke Imai, Huanlin Wang, Yuki Bekki, shinji itoh, Tomoharu Yoshizumi, Yuji Soejima, Ken Shirabe, Yoshihiko Maehara

    Journal of Medical Investigation   62 ( 3 )   184 - 187   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2152/jmi.62.184

  • Optimal changes in portal hemodynamics induced by splenectomy during living donor liver transplantation Reviewed

    Huanlin Wang, Toru Ikegami, Noboru Harada, Tomoharu Yoshizumi, Yuji Soejima, Hideaki Uchiyama, Yo Ichi Yamashita, shinji itoh, Norifumi Harimoto, Hirofumi Kawanaka, Ken Shirabe, Yoshihiko Maehara

    Surgery Today   45 ( 8 )   979 - 985   2015.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00595-014-0999-9

  • Surgical results for recurrent hepatocellular carcinoma after curative hepatectomy Repeat hepatectomy versus salvage living donor liver transplantation Reviewed

    Yo Ichi Yamashita, Yoshihiro Yoshida, Takeshi Kurihara, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara

    Liver Transplantation   21 ( 7 )   961 - 968   2015.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/lt.24111

  • Impact of platelets and serotonin on liver regeneration after living donor hepatectomy Reviewed

    Tomoharu Yoshizumi, shinji itoh, D. Imai, Toru Ikegami, M. Ninomiya, T. Iguchi, Norifumi Harimoto, K. Takeishi, Y. Kimura, H. Uchiyama, Yuji Soejima, Tetsuo Ikeda, H. Kawanaka, K. Shirabe, Yoshihiko Maehara

    Transplantation Proceedings   47 ( 3 )   683 - 685   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transproceed.2014.11.050

  • Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation A single-center experience Reviewed

    Toru Ikegami, Tomoharu Yoshizumi, Yuji Soejima, Norifumi Harimoto, shinji itoh, K. Takeishi, H. Uchiyama, H. Kawanaka, Y. I. Yamashita, E. Tsujita, Noboru Harada, Eiji Oki, Hiroshi Saeki, Y. Kimura, K. Shirabe, Yoshihiko Maehara

    Transplantation Proceedings   47 ( 3 )   730 - 732   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.transproceed.2014.10.058

  • Right paraduodenal hernia successfully treated with laparoscopic surgery Reviewed

    Takahiro Tomino, shinji itoh, Daisuke Yoshida, Takahiro Nishida, Hirofumi Kawanaka, Tetsuo Ikeda, Shunji Kohnoe, Ken Shirabe, Yoshihiko Maehara

    Asian journal of endoscopic surgery   8 ( 1 )   87 - 90   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ases.12139

  • BiClamp-Fracture Method in Pure Laparoscopic Hepatectomy Verifying its Efficacy Irrespective of Liver Stiffness Reviewed

    Hideaki Uchiyama, Kazutoyo Morita, shinji itoh, Kenji Takenaka, Yoshihiko Maehara

    Surgical Laparoscopy, Endoscopy and Percutaneous Techniques   25 ( 4 )   e113 - e116   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/SLE.0000000000000172

  • Prognostic impact of Des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma Reviewed

    47 ( 3 )   703 - 704   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background Although the Milan criteria are widely accepted for liver transplantation (LT) in patients for hepatocellular carcinoma (HCC), they have not been fully evaluated for salvage LT in patients with recurrent HCC. We have previously reported outcomes of living-donor LT (LDLT) for HCC and identified 2 risk factors affecting recurrence-free survival (RFS): tumor size >5 cm and des-γ-carboxyl prothrombin (DCP) concentration >300 mAU/mL (Kyushu University criteria). This study was designed to clarify risk factors for tumor recurrence after LDLT in patients with recurrent HCC. Methods Outcomes in 114 patients who underwent LDLT for recurrent HCC were analyzed retrospectively. RFS rates after LDLT were calculated, and risk factors for tumor recurrence were identified. Results The 1-, 3-, and 5-year RFS rates after LDLT were 90.6%, 80.4%, and 78.8%, respectively. Univariate analysis showed that tumor recurrence was associated with alpha-fetoprotein concentration ≥300 ng/mL, DCP concentration ≥300 mAU/mL, tumor number ≥4, tumor size ≥5 cm, transarterial chemotherapy before LDLT, duration of last treatment of HCC to LDLT <3 months, bilobar distribution, exceeding Milan criteria, exceeding Kyushu University criteria, poor differentiation, and histologic vascular invasion. Multivariate analysis showed that DCP ≥300 mAU/mL (P =.03) and duration from last treatment to LDLT <3 months (P =.01) were independent predictors of RFS. Conclusions DCP concentration and time between last treatment and LDLT are prognostic of RFS in patients undergoing LDLT for HCC.

    DOI: 10.1016/j.transproceed.2014.09.178

  • Predictors of intrahepatic multiple recurrences after curative hepatectomy for hepatocellular carcinoma Reviewed

    Kazuki Takeishi, Takashi Maeda, Eiji Tsujita, Yo Ichi Yamashita, Noboru Harada, shinji itoh, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, Ken Shirabe, Yoshihiko Maehara

    Anticancer Research   35 ( 5 )   3061 - 3066   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Outcomes after laparoscopic hepatectomy in the semi-prone position for hepatocellular carcinoma located in segment 6,7, or 8 Reviewed

    Norifumi Harimoto, Tetsuo Ikeda, Kazuki Takeishi, shinji itoh, Yo Ichi Yamashita, Toru Ikegami, Tomoharu Yoshizumi, Hirofumi Kawanaka, Ken Shirabe, Yoshihiko Maehara

    Anticancer Research   35 ( 7 )   4167 - 4170   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Long-term outcome of living-donor liver transplantation for combined hepatocellular-cholangiocarcinoma Reviewed

    shinji itoh, Toru Ikegami, Tomoharu Yoshizumi, Huanlin Wang, Kazuki Takeishi, Norifumi Harimoto, Yo Ichi Yamashita, Hirofumi Kawanaka, Shinichi Aishima, Ken Shirabe, Yoshihiko Maehara

    Anticancer Research   35 ( 4 )   2475 - 2476   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Laparoscopic Splenectomy with Technical Standardization and Selection Criteria for Standard or Hand-Assisted Approach in 390 Patients with Liver Cirrhosis and Portal Hypertension Reviewed

    Hirofumi Kawanaka, Tomohiko Akahoshi, Nao Kinjo, Norifumi Harimoto, shinji itoh, Norifumi Tsutsumi, Yoshihiro Matsumoto, Tomoharu Yoshizumi, Ken Shirabe, Yoshihiko Maehara

    Journal of the American College of Surgeons   221 ( 2 )   354 - 366   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2015.04.011

  • Correlation between portal vein anatomy and bile duct variation in 407 living liver donors Reviewed

    K. Takeishi, K. Shirabe, Y. Yoshida, Y. Tsutsui, T. Kurihara, K. Kimura, shinji itoh, Norifumi Harimoto, Y. I. Yamashita, Toru Ikegami, Tomoharu Yoshizumi, Akihiro Nishie, Yoshihiko Maehara

    American Journal of Transplantation   15 ( 1 )   155 - 160   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/ajt.12965

  • Transdisciplinary Approach for Sarcopenia. Clinical significance of sarcopenia in the patients with chronic liver disease Reviewed

    Ken Shirabe, Norifumi Harimoto, Toru Ikegami, Tomoharu Yoshizumi, shinji itoh, Kazuki Takeishi, Takeo Toshima, Kohichi Kimura, Yoshihiro Matsumoto, Yuki Bekki, Daisuke Imai, Yoichi Yamashita, Hirofumi Kawanaka, Yoshihiko Maehara

    Clinical calcium   24 ( 10 )   1493 - 1499   2014.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Characteristic risk factors in cirrhotic patients for posthepatectomy complications Comparison with noncirrhotic patients Reviewed

    shinji itoh, Hideaki Uchiyama, Hirofumi Kawanaka, Takahiro Higashi, Akinori Egashira, Daihiko Eguchi, Toshiro Okuyama, Masahiro Tateishi, Daisuke Korenaga, Kenji Takenaka

    American Surgeon   80 ( 2 )   166 - 170   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma Reviewed

    shinji itoh, Ken Shirabe, Yoshihiro Matsumoto, Shohei Yoshiya, Jun Muto, Norifumi Harimoto, Yo Ichi Yamashita, Toru Ikegami, Tomoharu Yoshizumi, Akihiro Nishie, Yoshihiko Maehara

    Annals of Surgical Oncology   21 ( 9 )   3063 - 3068   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1245/s10434-014-3686-6

  • [Experience of 2013 Japan Exchange Fellow of the Japan Surgical Society and the American College of Surgeons]. Reviewed

    shinji itoh

    Nihon Geka Gakkai zasshi   115 ( 2 )   113 - 115   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Tape-guided pure laparoscopic hepatectomy for laterally located tumors A technique to yield an appropriate tumor-free surgical margin and to make parenchymal transection easier Reviewed

    Hideaki Uchiyama, Kazutoyo Morita, shinji itoh, Kenji Takenaka

    Journal of the American College of Surgeons   219 ( 3 )   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2014.03.059

  • Small upper midline incision for living donor hemi-liver graft procurement in adults Reviewed

    Toru Ikegami, Ken Shirabe, Yo Ichi Yamashita, Tomoharu Yoshizumi, Norifumi Harimoto, Kazuki Takeishi, Eiji Tsujita, shinji itoh, Yoshihiko Maehara

    Journal of the American College of Surgeons   219 ( 3 )   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2014.04.021

  • Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation Reviewed

    Daisuke Imai, Toru Ikegami, Takeo Toshima, Tomoharu Yoshizumi, Yo Ichi Yamashita, Mizuki Ninomiya, Norifumi Harimoto, shinji itoh, Hideaki Uchiyama, Ken Shirabe, Yoshihiko Maehara

    Journal of the American College of Surgeons   219 ( 6 )   1134 - 1142.e2   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2014.09.006

  • Optimizing risk stratification in portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension Reviewed

    Hirofumi Kawanaka, Tomohiko Akahoshi, shinji itoh, Tomohiro Iguchi, Norifumi Harimoto, Hideaki Uchiyama, Tomoharu Yoshizumi, Ken Shirabe, Kenji Takenaka, Yoshihiko Maehara

    Journal of the American College of Surgeons   219 ( 5 )   865 - 874   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2014.07.939

  • Long-term favorable surgical results of laparoscopic hepatic resection for hepatocellular carcinoma in patients with cirrhosis A single-center experience over a 10-year periods Reviewed

    Yo Ichi Yamashita, Tetsuo Ikeda, Takeshi Kurihara, Yoshihiro Yoshida, Kazuki Takeishi, shinji itoh, Norifumi Harimoto, Hirofumi Kawanaka, Ken Shirabe, Yoshihiko Maehara

    Journal of the American College of Surgeons   219 ( 6 )   1117 - 1123   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jamcollsurg.2014.09.003

  • Outcomes of emergency surgery for acute abdomen in dialysis patients Experience of a single community hospital Reviewed

    Takahiro Tomino, Hideaki Uchiyama, shinji itoh, Takahiro Higashi, Ai Edagawa, Akinori Egashira, Daihiko Eguchi, Hirofumi Kawanaka, Toshiroh Okuyama, Masahiro Tateishi, Daisuke Korenaga, Kenji Takenaka

    Surgery Today   44 ( 4 )   690 - 695   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00595-013-0673-7

  • Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation Reviewed

    Toru Ikegami, Tomoharu Yoshizumi, Masaki Kato, Satomi Yamamoto, Takasuke Fukuhara, Yoshiharu Matsuura, Shota Nakamura, shinji itoh, Ken Shirabe, Yoshihiko Maehara

    Transplantation   98 ( 9 )   994 - 999   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/TP.0000000000000166

  • Pure laparoscopic partial hepatectomy using a newly developed vessel sealing device, BiClamp Reviewed

    Hideaki Uchiyama, shinji itoh, Takahiro Higashi, Daisuke Korenaga, Kenji Takenaka

    Surgical Laparoscopy, Endoscopy and Percutaneous Techniques   23 ( 3 )   2013.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/SLE.0b013e3182806535

▼display all

Presentations

▼display all

MISC

  • Is preoperative weight reduction of living-donor liver transplant recipients and donors harmful to postoperative outcomes? Reviewed International journal

    Yoshiya, S; Itoh, S; Toshima, T; Bekki, Y; Izumi, T; Iseda, N; Toshida, K; Nakayama, Y; Ishikawa, T; Yoshizumi, T

    TRANSPLANTATION   108 ( 9 )   629 - 629   2024.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • Up-regulated LRRN2 expression is effective as a marker for graft quality in living donor liver transplantation Reviewed International journal

    Tomiyama, T; Yoshizumi, T; Itoh, S; Toshima, T; Yoshiya, S; Bekki, Y; Izumi, T; Iseda, N; Toshida, K

    TRANSPLANTATION   108 ( 9 )   239 - 240   2024.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • 【肝細胞癌診療におけるunmet needs】肝移植後の肝細胞癌再発

    伊藤 心二, 戸島 剛男, 吉住 朋晴

    日本消化器病学会雑誌   121 ( 9 )   729 - 736   2024.9   ISSN:0446-6586

     More details

    Authorship:Corresponding author   Language:Japanese   Publisher:(一財)日本消化器病学会  

    肝細胞癌に対する肝移植の保険適用は5-5-500基準内もしくはミラノ基準内であり,肝細胞癌治療アルゴリズムではChild-Pugh分類C症例に推奨されている.肝移植は良好な治療成績をあげているが,一定数の再発を認める.術前因子や病理学的因子を用いた再発予測の検討や,ダウンステージの有用性が報告されている.肝移植後再発症例の予後不良因子として移植後早期再発,AFP高値,根治治療不能が報告されており,mTOR阻害剤を用いた免疫抑制剤の調節,可能な場合における積極的外科治療や局所療法の介入,マルチキナーゼ阻害剤を中心とした薬物療法のシークエンス治療が,肝移植後再発の治療において重要となる.(著者抄録)

  • 【慢性肝疾患患者の周術期管理-出血の予防と対策を中心に】観血的手技における出血予防 部分的脾動脈塞栓(PSE),脾臓摘出

    泉 琢磨, 伊藤 心二, 長尾 吉泰, 吉住 朋晴

    Thrombosis Medicine   14 ( Suppl.1 )   26 - 30   2024.5   ISSN:2186-0327

     More details

    Language:Japanese   Publisher:(株)先端医学社  

    慢性肝疾患患者では,門脈の血流が障害されることにより門脈圧亢進症を発症しやすく,食道・胃静脈瘤の発生や,脾機能亢進症・脾腫を伴うことで血小板数が低下し出血リスクが高まる.慢性肝疾患患者において,静脈瘤などからの出血予防は生命予後の改善に大きく寄与することから,これらの病態に対する治療として脾臓摘出術や部分的脾動脈塞栓(PSE)が発展してきた.治療機器の開発や手技の工夫により両治療法の治療成績は向上し,安全に施行することが可能となっている.しかし,治療侵襲や合併症を伴うのも事実であるため,患者の状態,施設の特色などから総合的に判断して治療法を選択する必要がある.(著者抄録)

  • 【微小環境から読み解く肝癌】肝癌進展機序とマクロファージ機能

    利田 賢哉, 伊藤 心二, 吉住 朋晴

    肝胆膵   88 ( 4 )   439 - 443   2024.4   ISSN:0389-4991

     More details

    Authorship:Corresponding author   Language:Japanese   Publisher:(株)アークメディア  

  • 【肝細胞癌の集学的治療】肝細胞癌治療の実際 肝移植

    吉住 朋晴, 戸島 剛男, 伊藤 心二

    臨床消化器内科   39 ( 5 )   581 - 588   2024.4   ISSN:0911-601X

     More details

    Language:Japanese   Publisher:(株)日本メディカルセンター  

    <文献概要>本邦の肝細胞癌(HCC)に対する肝移植の保険適用(5-5-500基準内あるいはミラノ基準内)は欧米で用いられている基準と比較しても広い基準である.肝細胞癌治療アルゴリズムでは,肝移植はChild-Pugh C症例で同基準内に留まっているものに推奨されている.肝移植後の成績は大変良好であるにもかかわらず,肝予備能が許容されるかぎり,肝切除,焼灼療法,塞栓療法,肝動注,薬物療法などが行われ,肝機能不良となった症例に肝移植が施行される.HCCに対してチロシンキナーゼ阻害剤や免疫チェックポイント阻害剤が使用可能となり,肝移植前のdown stageあるいは移植後再発病変の治療にこれらの薬物療法を使用した報告が見られるようになった.これらの報告とわれわれの経験を概説する.

  • 【必携 消化器・一般外科医のための外科解剖アトラス】肝胆膵 左肝切除に必要な局所解剖

    戸島 剛男, 伊藤 心二, 吉住 朋晴

    手術   78 ( 4 )   475 - 485   2024.3   ISSN:0037-4423

     More details

    Language:Japanese   Publisher:金原出版(株)  

  • Comprehensive clinico-molecular profile and efficacy of anti-HER2 therapy for <i>HER2</i>-amplified biliary tract cancer. Reviewed International coauthorship International journal

    Inoue, K; Nakamura, Y; Caughey, B; Zheng-Lin, B; Ueno, M; Furukawa, M; Kawamoto, Y; Itoh, S; Umemoto, K; Sudo, K; Satoh, T; Mizuno, N; Kajiwara, T; Fujisawa, T; Bando, H; Yoshino, T; Strickler, JH; Bekaii-Saab, TS; Morizane, C; Ikeda, M

    JOURNAL OF CLINICAL ONCOLOGY   42 ( 3_SUPPL )   544 - 544   2024.1   ISSN:0732-183X eISSN:1527-7755

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    DOI: 10.1200/JCO.2024.42.3_suppl.544

    Web of Science

  • Prognostic effects of co-occurring <i>TP53</i> and <i>KRAS</i> aberrations in patients with advanced biliary tract cancer. Reviewed International coauthorship International journal

    Shibuki, T; Nakamura, Y; Ueno, M; Furukawa, M; Kawamoto, Y; Itoh, S; Umemoto, K; Sudo, K; Satoh, T; Mizuno, N; Asagi, A; Okano, N; Shimizu, S; Bekaii-Saab, TS; Strickler, JH; Fujisawa, T; Bando, H; Yoshino, T; Morizane, C; Ikeda, M

    JOURNAL OF CLINICAL ONCOLOGY   42 ( 3_SUPPL )   538 - 538   2024.1   ISSN:0732-183X eISSN:1527-7755

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    DOI: 10.1200/JCO.2024.42.3_suppl.538

    Web of Science

  • 【チーム医療で取り組む肝胆膵疾患の栄養マネジメント】肝移植・肝切除における周術期栄養管理

    筒井 由梨子, 伊藤 心二, 吉住 朋晴

    肝胆膵   88 ( 1 )   79 - 84   2024.1   ISSN:0389-4991

     More details

    Language:Japanese   Publisher:(株)アークメディア  

  • 【外科医の働き方改革を考える】働き方改革実現に向けた具体的な取り組み チーム制 九州大学病院肝臓・脾臓・門脈・肝臓移植外科での取り組み

    吉屋 匠平, 伊藤 心二, 戸島 剛男, 吉住 朋晴

    手術   78 ( 1 )   27 - 31   2024.1   ISSN:0037-4423

     More details

    Language:Japanese   Publisher:金原出版(株)  

  • 消化器外科手術アトラス 肝移植レシピエント手術

    戸島 剛男, 伊藤 心二, 吉住 朋晴

    消化器外科   47 ( 1 )   1 - 10   2024.1   ISSN:0387-2645

     More details

    Language:Japanese   Publisher:(株)へるす出版  

  • Robot-assisted liver resection Reviewed

    Itoh Shinji, Yoshizumi Tomoharu

    Kanzo   64 ( 12 )   595 - 602   2023.12   ISSN:04514203 eISSN:18813593

     More details

    Language:Japanese   Publisher:The Japan Society of Hepatology  

    <p>Since April 2022, robot-assisted liver resection has been covered by insurance, and strict institutional standards and guidelines from the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Society of Endoscopic Surgery have been proposed for its safe introduction, setting forth the criteria for proctors certified by the societies. Robotic precision surgical techniques are expected to enable safer liver resection. However, several issues must be addressed for widespread use of robot-assisted liver resection, such as overcoming the learning curve of the robotic technique and establishing evidence through prospective case registries in terms of short- and long-term outcomes.</p>

    DOI: 10.2957/kanzo.64.595

    Scopus

    CiNii Research

  • ロボット支援下肝切除の現状 Reviewed

    伊藤心二、吉住朋晴

    肝臓   2023.12

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

  • ASO Author Reflections: Association of Ferroptosis with Transferrin Receptor in Hepatocellular Carcinoma Invited Reviewed International journal

    Itoh, S; Toshida, K; Hiromatsu, M; Yoshizumi, T

    ANNALS OF SURGICAL ONCOLOGY   30 ( 13 )   8007 - 8008   2023.12   ISSN:1068-9265 eISSN:1534-4681

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:Annals of Surgical Oncology  

    DOI: 10.1245/s10434-023-14054-6

    Web of Science

    Scopus

    PubMed

  • ASO Visual Abstract: Transferrin Receptor is Associated with Sensitivity to Ferroptosis Inducers in Hepatocellular Carcinoma Invited Reviewed International journal

    Itoh, S; Hiromatsu, M; Toshida, K; Oda, Y; Yoshizumi, T

    ANNALS OF SURGICAL ONCOLOGY   30 ( 13 )   8018 - 8018   2023.12   ISSN:1068-9265 eISSN:1534-4681

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)  

    DOI: 10.1245/s10434-023-14202-y

    Web of Science

    PubMed

  • 【Stenting Bible~Renewal~ステントと挿入・留置手技にこだわる!!】炎症・液体貯留に対するStenting Strategy 術後膵液瘻に対するStenting Strategy

    藤森 尚, 小森 康寛, 末永 顕彦, 梯 祥太郎, 大野 彰久, 松本 一秀, 村上 正俊, 寺松 克人, 植田 圭二郎, 伊藤 心二, 吉住 朋晴, 池永 直樹, 仲田 興平, 中村 雅史, 小川 佳宏

    胆と膵   44 ( 臨増特大 )   1215 - 1221   2023.10   ISSN:0388-9408

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    術後膵液瘻(postoperative pancreatic fistula:POPF)は発生頻度の高い膵切除術後合併症であり,適切なタイミングでドレナージを行う必要がある。従来は経皮的ドレナージが主流であったが,近年では内視鏡治療,とくにEUSガイド下経消化管ドレナージ(EUS-guided transluminal drainage:EUS-TD)の報告が増えている。EUS-TDで用いるステントとして,主に経鼻胆道ドレナージチューブ,ダブルピッグテイル型プラスチックステント,lumen-apposing metal stent,などがあり,POPFの部位,大きさ,性状に応じて,適切なステント選択を心がける必要がある。事前に外科医と情報共有のうえで,内視鏡治療にあたることが重要である。(著者抄録)

  • Treatment strategy for hepatocellular carcinoma recurrence in the transplant era: focusing on the Japan criteria Reviewed International journal

    Yoshiya, S; Harada, N; Toshima, T; Toshida, K; Kosai-Fujimoto, Y; Tomino, T; Nagao, Y; Kayashima, H; Itoh, S; Yoshizumi, T

    TRANSPLANTATION   107 ( 9 )   264 - 264   2023.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • What are risk factors for graft mortality in patients who underwent simultaneous splenectomy during living-donor liver transplantation? Reviewed International journal

    Toshima, T; Harada, N; Nakayama, Y; Toshida, K; Tomiyama, T; Kosai-Fujimoto, Y; Tomino, T; Yoshiya, S; Nagao, Y; Itoh, S; Yoshizumi, T

    TRANSPLANTATION   107 ( 9 )   143 - 144   2023.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • Up-regulated LRRN2 expression as a marker for graft quality in living donor liver transplantation Reviewed International journal

    Tomiyama, T; Toshima, T; Harada, N; Itoh, S; Takeishi, K; Nagao, Y; Yoshiya, S; Tomino, T; Kosai-Fujimoto, Y; Toshida, K; Tsutsui, Y; Nakayama, Y; Yoshizumi, T

    TRANSPLANTATION   107 ( 9 )   208 - 208   2023.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • 【肝胆膵外科手術における術中トラブルシューティング】肝臓 開腹肝切除術における肝静脈・下大静脈出血への対処法

    吉屋 匠平, 原田 昇, 伊藤 心二, 戸島 剛男, 吉住 朋晴

    外科   85 ( 8 )   863 - 867   2023.7   ISSN:0016-593X

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>開腹肝切除術を安全に施行するためには下大静脈,肝静脈出血を避けることが重要である.出血を低減する備えとして,低中心静脈圧麻酔などの呼吸循環管理や肝流入血遮断が有用である.術中操作として,短肝静脈の引き抜き損傷や肝静脈分枝の股裂損傷を避ける操作が第一である.万一の出血時には,闇雲な熱凝固ではなく,出血点を十分に評価し適切な方法で止血を行うことが重要である.

  • Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study Reviewed International journal

    Ueshima, K; Kudo, M; Tsuchiya, K; Kato, N; Yamashita, T; Shimose, S; Numata, K; Kodama, Y; Tanaka, Y; Kuroda, H; Itoh, S; Aikata, H; Hiraoka, A; Moriguchi, M; Wada, Y; Nakao, K; Tateishi, R; Ogasawara, S; Yamamoto, K; Ikeda, M

    JOURNAL OF CLINICAL ONCOLOGY   41 ( 16 )   2023.6   ISSN:0732-183X eISSN:1527-7755

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • ASO Visual Abstract: Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Hepatocellular Carcinoma Invited Reviewed International journal

    Tomiyama, T; Itoh, S; Iseda, N; Toshida, K; Kosai-Fujimoto, Y; Tomino, T; Kurihara, T; Nagao, Y; Morita, K; Harada, N; Liu, YC; Okuzaki, D; Kohashi, K; Oda, Y; Mori, M; Yoshizumi, T

    ANNALS OF SURGICAL ONCOLOGY   30 ( 6 )   3390 - 3391   2023.6   ISSN:1068-9265 eISSN:1534-4681

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)  

    DOI: 10.1245/s10434-023-13182-3

    Web of Science

    PubMed

  • 【外科手術と感染症】総論 肝移植後の免疫抑制下における感染症対策

    吉屋 匠平, 原田 昇, 戸島 剛男, 伊藤 心二, 吉住 朋晴

    外科   85 ( 5 )   489 - 494   2023.4   ISSN:0016-593X

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>臓器移植において免疫抑制は必須であり,易感染性の宿主に対して,免疫抑制下の感染症対策が非常に重要である.本稿では,肝移植後の免疫抑制下における感染症対策について,細菌性感染症,ウイルス性感染症,真菌性感染症に関してそれぞれ概説した.

  • Interim analysis results of gut microbiota in patients with unresectable cholangiopancreatic cancer: SCRUM-Japan MONSTAR-SCREEN. Reviewed International journal

    Tezuka, S; Sakai, S; Yamashita, R; Horasawa, S; Fujisawa, T; Sawada, K; Yoshikawa, A; Nakamura, Y; Umemoto, K; Shibata, N; Ohtsubo, K; Itoh, S; Todaka, A; Sudo, K; Furukawa, M; Ikeda, M; Morizane, C; Ueno, M; Yoshino, T

    JOURNAL OF CLINICAL ONCOLOGY   41   733 - 733   2023.2   ISSN:0732-183X eISSN:1527-7755

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • Real-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM study. Reviewed International journal

    Ikeda, M; Itoh, S; Tateishi, R; Yamashita, T; Okusaka, T; Kato, N; Furuse, J; Kudo, M

    JOURNAL OF CLINICAL ONCOLOGY   41   566 - 566   2023.2   ISSN:0732-183X eISSN:1527-7755

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • 【肝移植手術を再考する】レシピエント手術における血行再建

    原田 昇, 戸島 剛男, 伊藤 心二, 松浦 俊治, 吉住 朋晴

    手術   77 ( 1 )   67 - 76   2023.1   ISSN:0037-4423

     More details

    Language:Japanese   Publisher:金原出版(株)  

  • Machine Perfusion and normothermic regional perfusion can Improve Both Utilization and Outcomes in Liver Transplantation Reviewed

    Yuki Bekki, Itoh Shinji, Toshima Takeo, Yoshiya Shohei, Izumi Takuma, Iseda Norifumi, Tsutsui Yuriko, Toshida Katsuya, Nakayama Yuuki, Ishikawa Takuma, Ninomiya Miuzki, Yoshizumi Tomoharu

    Japanese Journal of Transplantation   58 ( Supplement )   s127_1 - s127_1   2023   ISSN:05787947 eISSN:21880034

     More details

    Language:English   Publishing type:Research paper, summary (national, other academic conference)   Publisher:The Japan Society for Transplantation  

    <p>The aim of this study was to examine the influence of machine perfusion (MP) and normothermic regional perfusion (NRP) on the utilization and outcomes of liver transplantation (LT). Using US national data, 4642 donation after circulatory death (DCD) donors between 2016 and 2021 were analyzed. 4542 were with static cold storage(SCS), 79 were with MP(1.7%), and 21 were with NRP(0.5%).The utilization rates of liver in DCD with MP or NRP were significantly higher (P=0.001; 92.4% or 95.2% vs 70.4%). There were no graft failure with primary nonfunction or ischemic cholangiopathy after LT with MP or NRP. MP or NRP significantly increased the utilization rate of livers with favorable outcomes after LT. Increasing use of MP or NRP should be considered in low utilization donors to expand donor pool.</p>

    DOI: 10.11386/jst.58.supplement_s127_1

    CiNii Research

  • 【病態に応じた栄養療法の重要性】肝硬変を伴う肝癌患者の術前栄養状態の評価と栄養療法の実際

    冨野 高広, 伊藤 心二, 原田 昇, 吉住 朋晴

    外科   84 ( 13 )   1362 - 1367   2022.12   ISSN:0016-593X

     More details

    Language:Japanese   Publisher:(株)南江堂  

    <文献概要>肝硬変を伴う肝癌患者は,蛋白質・エネルギー栄養障害を合併するため周術期合併症発生リスクが高く,術前栄養評価を行うことがきわめて重要である.新たな評価法として血液細胞成分や炎症反応指標,サルコペニアによる評価の有用性が近年明らかとなった.従来の栄養療法に加えてL-カルニチンやω-3脂肪酸を併用して栄養状態の改善を図ることで,術後合併症の予防,さらには予後の改善が期待できる.

  • Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma Invited Reviewed International journal

    Itoh, S; Ikeda, M

    HEPATOBILIARY SURGERY AND NUTRITION   11 ( 6 )   876 - 878   2022.10   ISSN:2304-3881 eISSN:2304-389X

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

    DOI: 10.21037/hbsn-22-432

    Web of Science

    PubMed

  • Osteopenia Predicts Posttransplant Survival Among Livingdonor Liver Transplant Recipients Reviewed

    Toshima, T; Harada, N; Itoh, S; Morita, K; Nagao, Y; Kurihara, T; Tomino, T; Kosai-Fujimoto, Y; Morinaga, A; Tomiyama, T; Toshida, K; Yoshizumi, T

    TRANSPLANTATION   106 ( 9 )   S278 - S278   2022.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Publishing type:Research paper, summary (national, other academic conference)  

    Web of Science

  • Up-Regulated LRRN2 Expression as a Marker for Graft Quality in Living Donor Liver Reviewed International journal

    Tomiyama, T; Yoshizumi, T; Itoh, S; Morita, K; Toshima, T; Nagao, Y; Kurihara, T; Tomino, T; Kosai-Fujimoto, Y; Morinaga, A; Toshida, K; Harada, N

    TRANSPLANTATION   106 ( 9 )   S282 - S282   2022.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • What Is the Risk Factor of Graft Mortality in Patients Who Underwent Simultaneous Splenectomy During Living Donor Liver Transplantation? Reviewed International journal

    Yoshizumi, T; Harada, N; Toshima, T; Takeishi, K; Morita, K; Nagao, Y; Yoshiya, S; Itoh, S

    TRANSPLANTATION   106 ( 9 )   S208 - S209   2022.9   ISSN:0041-1337 eISSN:1534-6080

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

  • 増大号特集 肝臓外科におけるスタンダード肝切除 Ⅱ.各論 13)再肝切除における手技と注意点

    原田 昇, 吉住 朋晴, 伊藤 心二, 森田 和豊, 冨野 高広, 栗原 健

    手術   76 ( 8 )   1269 - 1275   2022.7   ISSN:00374423

     More details

    Publisher:金原出版  

    DOI: 10.18888/op.0000002887

    CiNii Research

  • 【肝臓外科におけるスタンダード肝切除】再肝切除における手技と注意点

    原田 昇, 吉住 朋晴, 伊藤 心二, 森田 和豊, 冨野 高広, 栗原 健

    手術   76 ( 8 )   1269 - 1275   2022.7   ISSN:0037-4423

     More details

    Language:Japanese   Publisher:金原出版(株)  

  • 【肝細胞癌に対する最新の薬物療法時代における各種治療法の現況と展望】最新の薬物療法時代における肝細胞癌に対する肝移植

    吉住 朋晴, 原田 昇, 伊藤 心二

    日本消化器病学会雑誌   119 ( 5 )   432 - 437   2022.5   ISSN:0446-6586

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    肝細胞癌に対する肝移植の保険適用が新日本基準(5-5-500基準内あるいはミラノ基準内)に拡大された.本邦の肝細胞癌治療アルゴリズムでは,肝移植はChild-Pugh C症例で新基準内に留まっているものに推奨されている.このため肝予備能が許容される限り,肝切除,焼灼療法,塞栓療法,肝動注,薬物療法などが行われ,肝機能不良となった症例に肝移植が施行される.肝細胞癌に対してチロシンキナーゼ阻害剤や免疫チェックポイント阻害剤が使用可能となり,肝移植前のdown stageあるいは移植後の補助療法・再発後の治療に,これらの薬物療法を使用した報告が見られるようになった.これらの報告とわれわれの経験を概説する.(著者抄録)

  • 【鉄と肝がん:肝胆相照らす】鉄からみた肝発癌機構と治療標的 肝細胞癌治療としての分子標的治療薬とフェロトーシス

    伊藤 心二, 伊勢田 憲史, 利田 賢哉, 森永 哲成, 冨山 貴央, 小斉 侑希子, 冨野 高広, 栗原 健, 長尾 吉泰, 森田 和豊, 原田 昇, 森 正樹, 吉住 朋晴

    肝胆膵   84 ( 4 )   497 - 502   2022.4   ISSN:0389-4991

     More details

    Authorship:Corresponding author   Language:Japanese   Publisher:(株)アークメディア  

  • Ferroptosis is induced by lenvatinib through FGFR4 inhibition and play a key role in the suppression of HCC Reviewed International journal

    Itoh, S; Yoshizumi, T; Iseda, N; Harada, N; Mori, M

    CANCER SCIENCE   113   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper, summary (national, other academic conference)  

    Web of Science

▼display all

Professional Memberships

  • 日本腹部救急医学会

  • 日本外科感染症学会

  • 日本消化器癌発生学会

  • 日本臨床外科学会

  • 日本がん転移学会

  • 日本がん分子標的治療学会

  • 日本内視鏡外科学会

  • 日本癌学会

  • 日本癌治療学会

  • 日本消化器病学会

  • 日本移植学会

  • 日本膵臓学会

  • 日本胆道学会

  • 日本肝臓学会

  • 日本肝胆膵外科学会

  • 日本消化器外科学会

  • 日本外科学会

  • American College of Surgeons

  • 日本酸化ストレス学会

  • 九州内視鏡・ロボット外科手術研究会

  • 九州外科学会

  • 日本肝癌研究会

  • 日本肝がん分子標的治療研究会

  • 日本バイオセラピィ学会

  • 日本肝移植学会

  • 日本門脈圧亢進症学会

▼display all

Committee Memberships

  • Councilor   Domestic

    2023.11 - Present   

  • Councilor   Domestic

    2023.9 - Present   

  • Councilor   Domestic

    2023.9 - Present   

  • Steering committee member   Domestic

    2022.7 - Present   

  • 日本肝臓学会   治験支援委員会委員   Domestic

    2022.7 - Present   

  • Councilor   Domestic

    2022.5 - Present   

  • Councilor   Domestic

    2022.4 - Present   

  • Councilor   Domestic

    2022.3 - Present   

  • Councilor   Domestic

    2022.1 - Present   

  • Councilor   Domestic

    2021.1 - Present   

  • 日本肝がん分子標的治療研究会   世話人   Domestic

    2021.1 - Present   

  • Councilor   Domestic

    2020.6 - Present   

  • Councilor   Domestic

    2019.6 - Present   

  • Councilor   Domestic

    2019.1 - Present   

  • 日本肝臓学会   西部支部評議員   Domestic

    2017.11 - Present   

  • 日本消化器病学会   九州支部評議員   Domestic

    2017.6 - Present   

  • Steering committee member   Domestic

    2013.11 - Present   

  • 日本消化器癌発生学会   財務委員   Domestic

    2013.11 - Present   

  • Councilor   Domestic

    2011.11 - Present   

  • Councilor   Domestic

    2009.6 - Present   

▼display all

Academic Activities

  • Screening of academic papers

    Role(s): Peer review

    2023

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:58

    Number of peer-reviewed articles in Japanese journals:2

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:9

  • Screening of academic papers

    Role(s): Peer review

    2022

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:61

    Number of peer-reviewed articles in Japanese journals:1

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:0

  • Screening of academic papers

    Role(s): Peer review

    2021

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:49

    Number of peer-reviewed articles in Japanese journals:1

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:0

  • Screening of academic papers

    Role(s): Peer review

    2020

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:41

    Number of peer-reviewed articles in Japanese journals:0

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:0

  • Screening of academic papers

    Role(s): Peer review

    2019

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:18

    Number of peer-reviewed articles in Japanese journals:0

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:0

  • Screening of academic papers

    Role(s): Peer review

    2018

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:9

    Number of peer-reviewed articles in Japanese journals:0

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:0

  • Screening of academic papers

    Role(s): Peer review

    2017

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:3

    Number of peer-reviewed articles in Japanese journals:0

    Proceedings of International Conference Number of peer-reviewed papers:0

    Proceedings of domestic conference Number of peer-reviewed papers:0

▼display all

Research Projects

  • 老化に伴う形質的変化に着目した生体肝移植成績の革新的向上戦略

    Grant number:23K08092  2024.2 - 2027.3

    科学研究費助成事業  基盤研究(C)

    三浦 奈央子, 吉住 朋晴, 原田 昇, 冨山 貴央, 伊藤 心二

      More details

    Grant type:Scientific research funding

    ①ヒトドナー肝組織を用いRNA sequenceによる若年/高齢ドナーグラフトの質的変化を網羅的に評価し、質的変化の原因遺伝子やシグナルを同定。②ヒト由来iPS-Hepsを用い①の候補遺伝子やシグナルをdCas9を用いて活性化。候補遺伝子非活性化iPS-Heps(若年モデルiPS-Heps)と活性化iPS-Heps(高齢モデルiPS-Heps)で増殖能やアポトーシスを評価。③70%肝切除肝不全モデルラットに若年モデルiPS-Hepsと高齢モデルiPS-Hepsを移植し、ラットの救命率を比較。④高齢モデルiPS-Heps移植・肝不全モデルラットに活性化している遺伝子やシグナルを抑制する試薬を投与し、救命率が向上するかを検討。

    CiNii Research

  • IMPACT試験

    2023.7

      More details

    Authorship:Coinvestigator(s) 

  • LEOPARD-Neo試験

    2023.6

      More details

    Authorship:Coinvestigator(s) 

  • Elucidation of the mechanism of metastasis and acquisition of malignancy in postoperative recurrence of hepatocellular carcinoma and construction of an innovative treatment strategy

    Grant number:23K08214  2023.4 - 2026.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • 生体肝移植後長期予後を目指した革新的なグラフト質的評価法の樹立

    Grant number:23K08174  2023.4 - 2026.3

    科学研究費助成事業  基盤研究(C)

    萱島 寛人, 吉屋 匠平, 戸島 剛男, 長尾 吉泰, 吉住 朋晴, 原田 昇, 伊藤 心二

      More details

    Grant type:Scientific research funding

    非代償性肝硬変の唯一の治療法は肝移植であるが、本邦では健常人ドナーから部分的に摘出した肝臓(グラフト)を用いた生体肝移植が主体である。生体肝移植においてはドナーの安全性が最重要であり、摘出するグラフトは最小限にすることが望ましいが、レシピエントには十分に機能する最大限のグラフトが必要である。この矛盾を解消するためには、グラフトの量のみならず、質の評価が必要である。本研究は今までドナーの実年齢以外に明らかとされてこなかった生体肝移植のグラフトの質の評価に着目した研究であり、低侵襲で精度の高い革新的なグラフトの質的評価方法を確立し、本邦における生体肝移植の治療成績向上を目指すことが目的である。

    CiNii Research

  • Development of medical equipment for minimally invasive diagnosis of steatohepatitis or carcinogenesis

    Grant number:23K11920  2023.4 - 2026.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • GAIA試験

    2023.4

      More details

    Authorship:Coinvestigator(s) 

  • 肝癌微小環境における薬物療法耐性機序解明と新規治療法の開発

    Grant number:23K08133  2023 - 2025

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • PRISM-Bio試験

    2022.7

      More details

    Authorship:Coinvestigator(s) 

  • New treatment methods for liver failure by human iPS cells

    Grant number:22K08735  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • Cas9発現iPS細胞を用いた機能特化型肝再生による、革新的肝不全治療の開発

    Grant number:22K08716  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    森田 和豊, 吉住 朋晴, 原田 昇, 伊藤 心二, 栗原 健

      More details

    Authorship:Coinvestigator(s)  Grant type:Scientific research funding

    ①iPSCs-Cas9を肝細胞(iHeps-dCas9) に分化させ、遺伝子の発現を調べ、iHeps-Cas9において発現が低い遺伝子をリストアップする。
    ②標的遺伝子に対するガイドRNAを導入して、遺伝子を活性化する。
    ③活性化したiHepsを免疫不全動物モデルに移植し、機能を解析する。
    ④活性化したiHepsを血管内皮細胞などと共培養し、ミニ肝組織を作成する。

    CiNii Research

  • COSMOS試験

    2021.5

      More details

    Authorship:Coinvestigator(s) 

    肝細胞癌患者の血液循環腫瘍DNAのゲノム・エピゲノム統合解析を行う

  • 高分子薬の有効化に寄与する癌微小環境改善薬の開発

    Grant number:21H04831  2021.4 - 2024.3

    科学研究費助成事業  基盤研究(A)

    山本 浩文, 安藤 幸滋, 中川 貴之, 赤井 周司, 横山 雄起, 森 正樹, 伊藤 心二, 江口 英利

      More details

    Grant type:Scientific research funding

    日本人の死因のトップは癌であり、膵癌の5年生存率は6-7% しかない。最新医療の免疫チェックポイント阻害剤「オプジーボ」の奏効率は20%に留まり、CAR-T細胞療法「キムリア」は急性白血病や悪性リンパ腫に対しては著効するが、固形癌に対する効果は乏しい。固形癌の治療を困難にしているのは、癌細胞を取り巻く堅固な間質のバリアによって投与された薬の一部しか腫瘍細胞に到達しないという問題である。本研究課題では、これまでに開発してきたドラッグデリバリー技術を更に進化させ、癌の微小環境を改善する核酸医薬を確立する。その結果、抗体医薬、核酸医薬、細胞療法、ポリマー型抗癌剤 などの新しい医療の効果を高める。

    CiNii Research

  • Development of the innovative treatment using self iPS cell for acute liver failure

    Grant number:21K08685  2021.4 - 2024.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • シングルセル解析を駆使した癌幹細胞の捕捉と新規治療法の開発

    Grant number:21H03001  2021.4 - 2024.3

    科学研究費助成事業  基盤研究(B)

    Shamma A.A.Awad, 奥崎 大介, 安藤 幸滋, 山本 浩文, 横山 雄起, 伊藤 心二, 江口 英利

      More details

    Grant type:Scientific research funding

    自己複製能や多分化能を有し、子孫の細胞を作り続ける少数の癌幹細胞(CSC:cancer stem cell) は治療抵抗性で再発の原因となるので、これを駆除することが重要である。本研究では多角的にCSCを追い詰める。すなわち、CD44v9などの既存のCSCマーカーを用いたアプローチと、特定のマーカーに依らない患者検体からのアプローチの両面からCSCを捉える。臨床検体を用いた研究ではCSC独自の特性を利用して、シングルセル解析を駆使し、細胞株・マウスから得た分子ネットワーク情報を加味して、CSCとそのdriver遺伝子群の全貌を明らかとする。

    CiNii Research

  • REPLACEMENT試験

    2020.12

      More details

    Authorship:Coinvestigator(s) 

    BCLC-B(up to 7)の肝細胞癌に対するアテゾリズマブ+ベバシズマブ療法の有効性と安全性を検討する多施設共同第2相試験

  • PRISM試験

    2020.6

      More details

    Authorship:Coinvestigator(s) 

    切除不能肝細胞癌に対する薬物療法によるシークエンシャル治療の実態を明らかにする。切除不能肝細胞癌に対する全身薬物療法を開始する症例を前向きに登録し、各治療ラインにおけるそれぞれの治療レジメンの治療効果を検討する。

  • HAMRET試験

    2020.2

    KSCC(日本) 

      More details

    Authorship:Coinvestigator(s) 

    切除不能肝細胞癌に対する薬物療法によるシークエンシャル治療の実態を明らかにする。切除不能肝細胞癌に対する全身薬物療法(ソラフェニブ、レンバチニブ)を開始する症例を前向きに登録し、一次治療を含めた各治療ラインにおけるそれぞれの治療レジメンの治療効果を検討する。

  • 肝癌における新規細胞死フェロトーシス機序解明と革新的治療法への開発

    Grant number:19K09198  2019 - 2021

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • ストレス応答性転写因子による代謝リプログラミングを標的とした肝癌への革新的治療

    Grant number:16K10576  2016 - 2018

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 治療抵抗性肝細胞癌おけるマイクロRNAの機能解析と新規治療への展開

    Grant number:26893191  2014 - 2015

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • エピジェネティック年齢解析に基づく肝切除、肝移植における安全性の追求

    Grant number:19K09149 

    内山 秀昭, 副島 雄二, 吉住 朋晴, 原田 昇, 池上 徹, 伊藤 心二

      More details

    Grant type:Scientific research funding

    近年、暦年齢とは別の、細胞や組織の老化を表す生物学的年齢(epigenetic aging clock)が注目されている。この生物学的年齢はDNA上のCpGサイトのメチル化レベルを解析することにより測定される。肝切除、肝移植におけるエピジェネティックな生物学的年齢の解析はまだ報告がなく、本研究では肝切除、肝移植の安全性を高めるために、肝移植ドナー、大量肝切除を受けた患者、および肝移植レシピエントの、肝臓、そ